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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Motivation and objectives 
The goal of this PhD is to correlate the changes that occur in the colon 
as part of inflammatory bowel disease to differences seen in Rama spectra. This 
work demonstrates that the sensitivity of Raman spectroscopy (RS) to colon 
changes can be used to detect and characterize inflammatory bowel disease in 
humans and experimental colitis in mice. 
In 2015, inflammatory bowel disease (IBD), including ulcerative colitis 
(UC) and Crohn’s colitis (CC), was estimated to affect nearly 1.5 million 
Americans and 2.2 million Europeans, and the incidence is increasing 
worldwide.1-3 Despite advances in therapy, hospitalization rates for IBD, 
particularly CC, have shown significant increase, incurring a substantial rise in 
inflation-adjusted economic burden.4 Ulcerative and Crohn’s colitis are two 
distinct forms of IBD and require different medical and surgical management 
despite significant overlap in clinical presentation, symptoms, and disease 
progression. Currently, the distinction between UC and CC is made based on 
inexact clinical, radiologic, endoscopic, and pathologic features,5-8 such that in 
up to 15% IBD cases, indeterminate colitis (IC, or IBD unspecified) is 
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diagnosed because of the difficulty in distinguishing between UC and CC.3,9 In 
these patients, diagnosis ultimately relies on long term follow up based on 
success or failure of existing treatment and recurrence of disease. Therefore, 
accurate diagnosis of IBD is of paramount importance for appropriate medical 
and surgical care, intervention, and prognosis.  
Development of new technologies that can improve understanding of 
IBD and aide objective diagnosis is urgently needed. One of the objectives of 
this research is to apply RS, an optical technique, as a novel tool to characterize 
IBD in vivo during colonoscopy. In order to develop robust techniques that can 
effectively evaluate tissue changes several steps must be undertaken including 
optimization of instrumentation for this application, characterization of the 
effects of colon variability and disease severity, and evaluate a clinical 
population to demonstrate feasibility of this technique for further application. 
Therefore, the overall objective of this doctoral research is to 
characterize the effects that IBD related changes in the colon have on Raman 
spectra in order to develop a viable optical tool for studying IBD and provide 
and accurate, objective aide for diagnosis and monitoring. 
 
1.2 Specific aims 
 Aim 1: Develop a multimodal probabilistic Monte Carlo model 
incorporating absorption, elastic scattering, Raman scattering and 
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fluorescence to evaluate fiber optic probe designs used for Raman 
spectroscopy. Fiber optic probes are the primary interface between most 
Raman instruments and the target samples. Numerous designs have been 
implemented for in vivo applications for soft tissues however most have been 
optimized based on theoretical performance in low or non-scattering scenarios 
that are not representative of biomedical applications. In this aim, a 
probabilistic model incorporating all of the competing optical phenomena 
detected by fiber optic Raman spectroscopy probes was implemented and 
experimentally validated in both biological and synthetic phantoms to compare 
four distinct volume integrating probe designs. Modelling results were 
evaluated between probe designs relative to experimental results and theoretical 
design parameters for each probe, such as excitation and collection cone 
overlap, surface area for detection, and fiber optic collection angle. 
 Aim 2: Characterize IBD and normal signals in vivo during 
colonoscopy and assess influential patient variables that impact disease 
discrimination. Previous studies have demonstrated promising disease 
discrimination for ex vivo IBD tissue biopsies based on Raman spectra. To 
evaluate the performance of Raman spectroscopy in vivo, patients undergoing 
colonoscopy in the VUMC were recruited and measured under this aim. Raman 
spectra were collected from multiple locations in each segment of the colon and 
compared with endoscopic findings and tissue biopsies obtained from each 
measurement site as determined by the clinician. Spectral classification was 
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implemented using statistical multivariate analysis relative to established 
diagnosis which served as the gold standard. Subsequent discrimination based 
on stratification of colon segment and disease severity was implemented to 
demonstrate potential for improved performance when accounting for relevant 
patient and disease variables. 
 Aim 3: Characterize the effects of IBD disease presentation on 
Raman spectra acquired from the colon in (A) human colectomy specimens 
and (B) a murine model of experimental colitis. In this aim, Raman spectra 
were acquired from excised colon tissues to more fully characterize the 
complex disease presentation as a function of inter-anatomical variability and 
disease severity. To thoroughly assess the impact of colon segment and 
histological markers of chronic and acute disease severity, total or partial colon 
resection samples were collected from patients undergoing colectomy 
procedures at VUMC. Gross mapping of the tissue with a Raman fiber optic 
probe was correlated with histologically scored tissue biopsies to establish 
factors that significantly impact the Raman spectral measurements of 
inflammatory disease in the colon. To assess the impact of active inflammation 
on acquired spectra with relative control over disease severity, a murine model 
of experimental colitis was be evaluated with ex vivo Raman 
microspectroscopic mapping and correlated with clinical disease indicators and 
histologic scoring of epithelial injury and inflammation. Hypothesis: The 
degree of active inflammation will impact acquired spectra and controlled 
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murine models of IBD will yield information to improve classification accuracy 
in vivo. 
 In Appendix 1, an evaluation of several user, instrument, and 
physiological factors that influence Raman spectra collected from in vivo 
tissues are discussed. Multiple identical clinical fiber optic probe based Raman 
spectroscopy systems were used to measure the skin from multiple anatomical 
sites across a pilot cohort of subjects. This work supports prior reports of intra-
anatomical and inter-patient variability sources as influential factors for in vivo 
Raman spectra, as well as provides guidelines for mitigating the impact of non-
physiological sources of spectral variability. 
 The combination of these three Aims and Appendix 1 serves to establish 
the potential for in vivo Raman spectroscopy as a clinical adjunct for disease 
discrimination and evaluation of inflammatory bowel disease. Further, this 
work establishes new methods for evaluating instrumentation and provides a 
characterization of several influential variables from patients and models of 
inflammatory disease that impact Raman spectral measurements. The 
completion of this project demonstrates the sensitivity of Raman scattering to 
subtle biochemical changes in colon tissues associated with anatomic variation 
and disease presentation. Understanding these influential factors resulted in 
improved classification of disease type based on decoupling the complex 
interplay of disease and natural variations in the colon.  
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1.3 Summary of chapters 
Following this introductory chapter, Chapter 2 contains relevant 
background information on the biology and anatomy of the colon, 
inflammatory bowel disease, as well as a review of developments for clinical 
instrumentation and applications of Raman spectroscopy. 
In Chapter 3, an assessment of the instrumentation designs utilized for 
fiber optic probe based Raman spectroscopy in vivo is undertaken based on a 
comparison of results generated from a new multimodal optical model and 
experimental results from both biological and synthetic phantoms. 
Chapter 4 provides the first report on the sensitivity of in vivo RS from 
this research, or any other peer-reviewed work, specifically addressing 
differences between disease classes, colon segments, and disease severity in 
measurements obtained during colonoscopy from healthy control, Crohn’s 
disease, or ulcerative colitis patients. 
Chapter 5 details the effects of colon tissue variability on Raman spectra 
obtained from unique locations and disease presentations in colectomy tissues 
to decouple the interactions of disease and tissue variability effects based on 
histopathological scoring. 
Chapter 6 presents the results of Raman microspectroscopic evaluation 
of a controlled experimental colitis model to interrogate the effects of disease 
severity and active inflammation in the colon wall compared with both clinical 
and histopathological indicators of disease. 
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Chapter 7 comprises a summary of the major results presented in this 
dissertation and potential avenues for future directions for this project. It also 
provides information about the impact of this research on the larger scientific 
field and society. 
Appendix I entails a characterization of sources of variability associated 
with in vivo Raman spectroscopy. This chapter identifies and isolates the 
contributions from user, instrumentation, and physiology induced sources of 
variation, and presents guidelines for minimizing these effects for clinical 
applications of Raman spectroscopy. 
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CHAPTER 2 
 
BACKGROUND 
 
2.1 Physiology of the normal colon and rectum 
 
 
Figure 2.1. Anatomy of healthy human colon (courtesy of Johns Hopkins 
Gastroenterology and Hepatology). 
 
The colon is the organ in the gastrointestinal (GI) tract responsible for 
concentrating waste through water and electrolyte absorption, storing and 
controlled evacuation of waste, and digestion and absorption of undigested 
food.1,2 Extracting water, salt, and some fat soluble vitamins from the chyme 
deposited from the small intestine, the colon stores and transports feces prior to 
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elimination from the body. The colon is generally divided in to three segments, 
the right (cecum and ascending colon), transverse, and left (descending and 
sigmoid colon) colon which connects to the rectum. The outside of the colon is 
connected to the abdominal wall by folds of peritoneum (mesentery), in 
ascending, transverse, descending, and sigmoid colon segments.3,4 As depicted 
in Figure 2.1, the colon is a muscular organ composed four layers found in other 
hollow GI organs: the mucosa, submucosa, circular muscle and longitudinal 
muscle layers. Unlike the small intestine which has a villous projections, the 
colon mucosa is relatively smooth with crypt invaginations. This mucosal layer, 
lining the inner lumen is composed of simple (non-ciliated) columnar epithelial 
cells and mucous secreting goblet cells to promote waste transport.3,4 Haustral 
folds are a constantly changing anatomic factor caused by circular muscle 
contractions that last for hours. The outer longitudinal muscles, called tenia 
coli, are three equidistantly spaced bands that extend from the cecum to the 
rectum where they fuse to form a continuous muscular layer. The muscular 
contractions in the right colon cause mixing to facilitate water absorption, while 
feces is slowly moved in the left colon prior to reflexes that activate 
contractions to evacuate stool.2 Due to the slow movement of waste through 
this organ, the colon also has a large population of commensal bacteria which 
are typically harmless and compete with potentially pathogenic microbes, 
promote motility, help maintain mucosal integrity, and make nutritional 
contributions. 
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2.2 Inflammatory bowel disease 
 Inflammatory bowel disease (IBD) describes a group of disorders in 
which the inner lining of the GI tract become inflamed. IBD affects nearly 1.5 
million people in the United States and 2.2 million in Europe, with increasing 
incidence worldwide.5-8 It has recently been cited that IBD is one of the five 
most prevalent gastrointestinal disease burdens in the US, with an annual 
overall health care cost of more than $1.7 billion.9,10 The two major types of 
IBD are ulcerative colitis (UC) and Crohn's disease (CD), with different causes 
and discrete mechanisms of tissue damage.11 Ulcerative colitis is limited to the 
colon whereas CD can rise in any part of the GI tract, although it often manifests 
itself in the colon. IBD contributes to significant morbidity and reduced quality 
of life; the estimated incidence and prevalence of 7-9 and 210-240 per 100,000 
and 6-8 and 130-200 per 100,000, for UC and CD respectively.12,13 Patients 
with IBD are at increased risk of developing colon cancer.14,15 They also have 
an higher risk of endothelial dysfunction and coronary artery disease.16 Despite 
advances in therapy, hospitalization and surgery rates for IBD in the United 
States have increased since 1990.17,18 With the high drug costs, and up to 75% 
of CC and 25-33% of UC patients that require surgery in the long-term, IBD is 
one of the most costly conditions on a per year basis in the US, with expenses 
for CC surpassing diabetes, coronary artery disease, and chronic obstructive 
pulmonary disorder.19,20 This reinforces the need to improve the current 
diagnostic and therapeutic strategies for IBD. 
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2.3 Crohn’s disease 
Crohn’s disease is a chronic inflammatory disorder that can affect the 
entire GI tract. The key pathological feature is an inflammatory process that 
extends through all layers of the bowel wall. Microscopic examination of 
tissues from CD reveals lymphoid hyperplasia, diffuse granuloma infiltration, 
discrete noncaseating granulomas in the submucosa and lamina propria, diffuse 
edema, and monocytic infiltration in lymph nodules.2 Aphthous ulcers, small 
superficial ulcerations, are the earliest mucosal lesion in CD. As disease 
progresses, these tiny lesions enlarge and coalesce to form longitudinal and 
transverse ulcers and have a characteristic cobblestone appearance from the 
deep mucosal ulceration and submucosal thickening.2 Skip lesions, or discrete 
locations of inflammation surrounded by tissue without gross or histological 
abnormalities are also characteristic of Crohn’s disease. CD is often signified 
by thickened fatty mesentery in the vicinity of the disease. As the mesentery 
are inflamed fibrosis of the bowel tissue can often cause adhesion of and may 
extend into all layers of the bowel wall, forming fistulae and abscesses (Figure 
2.2).  
Crohn’s disease onset can occur at any age but most commonly begins 
between 15 and 30 years of age. There is a familial association of CD such that 
20-30% of CD patients having a family history of the disorder, further 
indicating genetic influences.2,5 In CD, the T-cell response is T-helper 1 (Th1) 
dominant. The activation of central immune-cell populations is eventually 
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accompanied by the production of a wide variety of nonspecific mediators of 
inflammation, such as cytokines, chemokines, and growth factors.22-24 These 
mediators enhance the inflammatory process itself and tissue destruction, which 
eventuate in the clinical manifestations of disease.25 
 
Figure 2.2. Histology slide of an UC and CC case (Courtesy Johns Hopkins 
Gastroenterology and Hepatology Resource Center, www.hopkins-gi.org). 
 
2.4 Ulcerative colitis 
Ulcerative colitis is a chronic inflammatory disease affecting the 
colonic mucosa from the rectum to the cecum. Characterized by rectal bleeding 
and diarrhea, remission and relapse, UC is limited to mucosal inflammation that 
does not become transmural (Figure 2.2).2,5 Sharp localized abdominal pain and 
fistula formation are uncommon. Extensive superficial mucosal ulceration 
develops in conjunction with severe inflammation and the coincident 
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production of a complex mixture of inflammatory mediators. Histopathological 
features of UC include the presence of a significant number of neutrophils 
within the lamina propria and the crypts, where they form micro-abscesses.21 
Crypt abscesses may extend laterally and undermine the integrity of the mucosa 
on three sides, resulting in the formation of a hanging fragment of mucosa that 
appears in endoscopy and radiography as a pseudopolyp.2,5 After mucosal 
destruction, epithelial healing processes cause the formation of highly vascular 
granulation tissue is formed.2,26,27 
Ulcerative colitis typically occurs in patients between 20 and 50 years 
of age either as an acute attack or a chronic course with little pain. Roughly 
70% of patients will have complete remission of symptoms between 
intermittent attacks, however another 15% will suffer from continuous 
symptoms without remission.2,11 As UC is not a distinct clinical entity and has 
histological features that overlap with several other inflammatory states in the 
colon, the diagnosis relies on the discovery of several clinical and pathological 
criteria and exclusion of other causes for colitis such as infection.2,11 In UC, the 
response is either Th2 [interleukin (IL) -4, IL-13] or is mediated by specialized 
cells such as natural killer T cells (NKT).28,29 
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2.5 IBD differentiation 
It is extremely important to accurately differentiate between CD and UC 
as they have different prognoses and differing response to medical and surgical 
treatment. One method of medical care implements a “bottom-up” approach to 
treatment, as depicted in Figure 2.3, where the level of severity dictates the 
avenue for treatment.2 certain medications have shown efficacy in the treatment 
of CD (methotrexate, natalizumab, and certolizumab), while others work well 
for UC (mesalamine). Long-term treatment with antibiotics (nitroimidazoles or 
clofazimine) is effective in patients with CD30 while its efficacy in UC is not 
observed.31 Current research and clinical trials indicate the development of new 
drugs that are specific for either UC32-34 or CD35-37 with more than 50 
personalized medications under investigation.38,39  
 
Figure 2.3. Standard approach for medical management of IBD. Courtesy of 
Crohn's and Colitis Foundation of America. 
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For surgical intervention and prognosis, it is vital to accurately delineate 
IBD because an errant diagnosis may result in serious consequences. The vast 
majority of patients with UC will benefit from surgery, such as restorative 
proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA). In contrast, 
surgery for CD patients is generally not curative and can lead to severe 
complications as malnutrition and multiple surgical procedures. In fact, up to 
50% of CD patients who undergo RPC with IPAA require removal of the pouch 
or diversion due to Crohn’s recurrence or disease flare-ups in other parts of the 
GI tract.40 For therapy and patient outcomes, the proper management of IBD 
calls for an accurate diagnostic tool that can distinguish between CD and UC, 
and potentially predict which patients will respond to specific medications and 
give clinicians an indicator for the most effective treatment option. 
Current techniques for differentiating CD and UC have deficiencies in 
terms of diagnostic accuracy. The American College of Gastroenterology 
Practice Parameters Committee recommends a combination of clinical, 
endoscopic, histologic, radiographic and surgical findings to differentiate 
between CD and UC.11,41,42 While certain features can be used to differentiate 
the diseases during routine colonoscopy and other procedures, many cases do 
not present definitive indicators of disease type. Ulcerative colitis is generally 
confirmed when a patient that presents with systemic features has colonoscopy 
and biopsy confirmed colitis and no presence of infectious or non-infectious 
causes, while the methods for CD diagnosis are more complex and dependent 
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upon patient presentation.41 This distinction cannot always be made due to 
overlapping symptoms, as well as similarities in radiographic and histologic 
features.43 Serological markers have limited sensitivity (65% for CD and 76% 
for UC) in differentiating UC from CD.44 While 40 susceptibility genes for CD 
and UC have been identified,45 testing is not readily available to the clinician 
nor do these genes account for the majority of IBD cases. The lack of a reliable 
method for differentiating CD and UC imposes a burden on the medical 
community. Up to 300,000 patients in the US cannot be diagnosed as UC or 
CD and they are labeled as indeterminate colitis (IC).7 Additionally, failure to 
recognize characteristic signs of CD such as granulomas and transmural 
inflammation often leads to errors in pathological interpretation in at least 15% 
of the cases.46 Thus, there is at least a 15% misdiagnosis rate of CD as UC in 
addition to the 15% of IC cases.46 This results in approximately 600,000 
patients in the US that cannot be correctly diagnosed as CD or UC and thus do 
not receive appropriate treatments. Limitations in current diagnostic methods, 
therefore, highlight the need for a rapid, accurate, automated method that can 
be used to differentiate patient disease as well as the degree of the 
inflammation. This could significantly improve the management of the disease 
with respect to both time and cost. 
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2.6 Clinical instrumentation and applications of Raman spectroscopy 
Clinical diagnostic devices provide new sources of information that 
give insight about the state of health which can then be used to manage patient 
care. These tools can be as simple as an otoscope to better visualize the ear 
canal or as complex as a wireless capsule endoscope to monitor the 
gastrointestinal tract. It is with tools such as these that medical practitioners can 
determine when a patient is healthy and to make an appropriate diagnosis when 
he/she is not. The goal of diagnostic medicine then is to efficiently determine 
the presence and cause of disease in order to provide the most appropriate 
intervention. The earliest form of medical diagnostics relied on the eye - direct 
visual observation of the interaction of light with the sample. This technique 
was espoused by Hippocrates in his 5th century BCE work Epidemics, in which 
the pallor of a patient’s skin and the coloring of the bodily fluids could be 
indicative of health. In the last hundred years, medical diagnosis has moved 
from relying on visual inspection to relying on numerous technological tools 
that are based on various types of interaction of the sample with different types 
of energy – light, ultrasound, radio waves, x-rays etc. Modern advances in 
science and technology have depended on enhancing technologies for the 
detection of these interactions for improved visualization of human health. 
Optical methods have been focused on providing this information in the micron 
to millimeter scale while ultrasound, x-ray, and radio waves have been key in 
aiding in the millimeter to centimeter scale.  While a few optical technologies 
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have achieved the status of medical instruments, many remain in the research 
and development phase despite persistent effort by many researchers in the 
translation of these methods for clinical care. Of these, Raman spectroscopy 
has been described as a sensitive method that can provide biochemical 
information about tissue state while maintaining the capability of delivering 
this information in real-time, non-invasively, and in an automated manner. This 
review presents the various instrumentation considerations relevant to the 
clinical implementation of Raman spectroscopy and reviews a subset of 
interesting applications that have successfully demonstrated the efficacy of this 
technique for clinical diagnostics and monitoring in large (n ≥ 50) in vivo 
human studies. 
2.6.1 Why Raman spectroscopy? 
As described by Dr. C.V. Raman in 1928, the Raman signal is usually 
weak (one in one hundred million incident photons) and “requires very 
powerful illumination for its observation.”47 Today, advances in laser sources 
and sensitive detectors enable the application of this scattering event for 
samples that are more complex than the original “dust-free liquids or gases.” 
Raman peaks are typically spectrally narrow (a few wavenumbers) and in many 
cases can be associated with the vibration of a particular chemical bond (or 
normal mode dominated by the vibration of a single functional group) within a 
molecule.48 Figure 2.4 displays an example Raman spectrum, that of 
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phosphatidylcholine, a phospholipid molecule, where each band can be 
correlated to specific stretching and bending modes of vibration in the 
molecule, thus providing a molecular fingerprint. Consequently, in tissue, 
which is composed of a complex mixture of molecules, the presence of the 
unique bands of phosphatidylcholine can be tracked resulting in the quantitative 
evaluation of the sample’s chemical composition. Such quantitative or 
qualitative assessment in turn can be used to infer specific biochemical changes 
associated with tissue pathology or physiology for diagnosis or monitoring. 
 
Figure 2.4. Raman spectrum of phosphatidylcholine, a phospholipid known to 
be present in cells and tissues, measured using a fiber optic probe based Raman 
system at 785 nm excitation. Characteristic spectral peaks correspond to 
molecular vibrations of the molecule of interest. 
 
Thus Raman spectroscopy is a molecular specific technique that can be 
used to develop a fundamental biochemical understanding of tissue physiology 
and pathology and extend this knowledge for tissue diagnosis and monitoring. 
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The optical nature of the technique makes it possible to extract this information 
non-invasively, or at the very least non-intrusively, facilitating the utility of this 
technique in a clinical setting. Because Raman scattering is both a sensitive and 
weak phenomenon, instrument considerations for adapting this technique for 
clinical applications can be challenging. Since the initial reports of in vivo 
human tissue spectra in 199349, technological development and technique 
refinement have enabled Raman measurements in humans with integration 
times of 0.5-5 seconds allowing real-time assessment of tissue state50-52. Spectra 
can now be collected, corrected for undesirable signal components, processed 
and analyzed rapidly to provide automated feedback at the time of 
measurement53-55. With these advancements, Raman techniques satisfy many 
of the criteria required for the adoption of a novel biomedical diagnostic 
technique in clinical practice: sensitivity to changes in tissue, in vivo 
application, and unique information obtained noninvasively, in real time56. This 
review will focus on the considerations vital to efficiently implementing Raman 
spectroscopy for in vivo clinical applications in diagnosis and sensing and some 
of the major clinical research under continued investigation. 
2.6.2 Clinical instrumentation 
A dispersive Raman system is similar to most optical spectroscopic 
systems and consists of three primary components – light source, sample light 
delivery and collection, and dispersive element with detector (Figure 2.5). The 
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specifics of these components are challenged by the needs of the clinical setting 
and application. Like standard medical instruments, a clinical Raman system 
should be small and easily transportable, optical alignment and calibration 
should be robust, sample light delivery and collection should be sterilizable and 
rugged, and the detection system should be sensitive to the weak biological 
signals. 
 
Figure 2.5. Basic schematic of an optical (including Raman) spectroscopic 
system. 
 
The components that comprise a clinical Raman system can be broadly 
categorized into excitation and detection branches. Excitation is achieved by 
delivering the light from a given laser source to the tissue site of interest, in 
general by means of a fiber-optic probe or an articulated light delivery arm. The 
Raman scattered light is then collected, often through the same delivery system, 
and directed to a spectrograph and detector. As the technology utilized in vivo 
for clinical measurements has developed, so too has the breadth of individual 
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components that have been investigated and accepted within these systems. The 
following sections will discuss many of the requirements for the individual 
components in order to perform clinical Raman spectroscopy. 
2.6.2.a Lasers 
Due to the weak nature of Raman scattering, it is imperative to deliver 
sufficient power to the sample in order to generate Raman scattered photons for 
detection in a reasonable integration time relevant to the clinical setting under 
consideration. However, Raman scattering is mediated by the other competing 
optical phenomena within the sample. Furthermore, it is important to consider 
issues such as maximum permissible exposure (determined by ANSI or similar 
organizations)57 and temperature increase (relevant to patient comfort and 
minimizing tissue damage).58 Laser power then becomes a function of 
identifying a compromise between signal to noise, patient safety and comfort, 
and instrumentation considerations. Choice of laser is also governed by other 
factors such as laser stability especially when using a multimode laser. Raman 
lines are narrow and highly specific for a given vibrational mode. This then 
implies that the precise position and width of the Raman line requires the 
excitation source to be stable in wavelength position, bandwidth, and spatial 
mode for consistent results. Having accounted for these factors, the properties 
of the target tissue or sample are one of the major criteria for the choice of laser 
excitation source for a clinical Raman instrument. Since Raman shifts are 
relative to the Rayleigh (excitation) line, similar results can theoretically be 
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obtained from many different instrument configurations. However, the optical 
properties of the samples, including scattering and total attenuation coefficients 
as well as excitation, emission, and yield properties for any endogenous 
fluorophores present in the sample, are critical factors for consideration. The 
impact of each of these parameters is a function of wavelength.59 Samples with 
high attenuation coefficients will limit the ability to deliver and collect the light 
beyond very superficial layers. Furthermore, strong absorbing molecules in a 
sample can also lead to the generation of excess heat deposition in the tissue, 
which can cause damage with high irradiance. Likewise, the presence of strong 
fluorophores can generate signals that overwhelm the modest Raman peaks that 
are concurrently detected. Due to the associated decrease in total attenuation 
coefficient for the major absorbing molecules in many biological tissues (water, 
melanin, oxy- and deoxy- hemoglobin), NIR excitation sources are commonly 
chosen for clinical instruments.60 Further, since few known biological 
fluorophores have their peak emission in this region of the spectrum, with a 
noted exception of melanin, moving to the NIR wavelengths for excitation 
results in lower fluorescence background in the tissue at these wavelengths and 
simplifies the signal processing needed for extracting the Raman bands 
compared with visible or UV excitation.61 As depicted in Figure 2.6, tissues 
such as the breast (A) that do not have strong autofluorescence signals relative 
to the Raman features can be collected with several different wavelengths; 
however, highly autofluorescent tissues like the kidney (B) require the use of 
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longer excitation wavelengths to obtain useful Raman spectra. Thus tissue 
properties are vital considerations when choosing the laser source for the 
clinical application of Raman spectroscopy. 
 
Figure 2.6. Raman scattering and autofluorescence polynomial fit signals for 
(A) breast and (B) kidney tissues measured ex vivo at 785 nm (blue) and 1064 
nm (green) excitation wavelengths. Strong Raman features of breast tissue are 
apparent despite tissue background while low Raman intensities of the kidney 
are completely overwhelmed by the strong intrinsic signal at 785 nm but more 
readily visible at 1064 nm. 
 
Early Raman systems were based on the Argon ion laser for visible 
excitation62,63, Nd:YAG (Neodymium doped Yttrium Aluminum Garnet) laser 
for FT-Raman applications64, and Titanium:Sapphire (Ti:Sapph) laser for NIR 
excitation. High output powers, single spatial and longitudinal modes of 
operation, and Gaussian beam profiles enable near-diffraction-limited optical 
performance for all of these sources.65 However, the size of these lasers and 
their electronic and cooling requirements limit their practicality in a portable 
clinical Raman system. Some current Raman instruments, especially those with 
confocal capabilities, still use the Ti:Sapph laser. The development and 
continued advancement of diode laser technology has completely changed the 
26 
 
footprint of a typical Raman system. Diode lasers utilize electro-optical 
components (diodes), which emit light as a function of both applied current and 
operating temperature.66 Diodes themselves are small (<1 mm3) and require 
highly accurate controlling electronics to obtain the stable output necessary for 
Raman excitation. Without highly stabilized thermal and current control, laser 
diodes are prone to thermo-elastic effects on the laser cavity length (and thus 
output frequency) and output power fluctuations, respectively. Laser diodes are 
also characterized by their elliptical beam output (rectangular shape of the 
output facet) and astigmatism (unequal beam divergence from each dimension 
of the rectangular facet). These factors complicate free beam coupling of diode 
lasers, typically requiring beam shaping optics for successful implementation. 
Most commercial diode lasers are available with a pigtail option to directly 
couple a fiber to the laser diode to minimize the losses due to astigmatism and 
elliptical nature of the beam. 
More recently, external cavity diode lasers (ECDLs) have emerged as 
robust and cost-effective light sources for Raman applications. The extended 
length of the resonant cavity of the laser diode minimizes the effect of small 
thermo-elastic changes on the output frequency by extending the distance 
between the diode’s longitudinal modes. Compared with a standard laser diode, 
the ECDL diminishes mode hops, minimizes the spectral bandwidth of output 
light, permits wavelength tunability, and decreases temperature-dependent 
frequency response.67 The laser linewidths of <0.001 nm (at 785 nm) with mode 
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locking provided by an ECDL is vital for medical applications where 
measurement repeatability and spectral resolution are important performance 
parameters. ECDLs are commercially available in tunable Littman–Metcalf or 
Littrow configurations, and can be made at specific wavelengths using 
distributed Bragg reflector configurations68,69. Mode stabilized diode lasers 
with powers on the order of 300 mW, either in single mode or multimode 
configurations, designed specifically for Raman spectroscopy are commercially 
available, lightening the burden for those developing clinical Raman systems. 
2.6.2.b Fiber Optic Probes  
Clinical application of Raman spectroscopy requires the delivery and 
collection of light to and from the sample (tissue). This is typically mediated 
through the use of optical fibers configured to maximize signal collection while 
minimizing interfering signals generated in the fibers and related optics 
themselves70. Since fiber optic probes will be discussed in a related manuscript 
in this special issue, here we only present considerations relevant to clinical 
translation. Depending upon the constraints of the clinical target, probe designs 
can be tailored to best interface with a sample and access the region of interest. 
Design considerations are dependent on the Raman configuration under study 
(discussed later), location of organ under study, microanatomy of the tissue, 
and pathophysiology of the disease. 
A critical aspect for consideration in translating Raman spectroscopy 
from the laboratory to the clinic is the inherent nature of Raman scattering. 
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Raman scattering is a weak phenomenon but most materials are Raman active, 
and therefore the materials used in the Raman system generate Raman signals 
that interfere with the detection of sample signal.71 Most fiber optic probes use 
optical fibers made of low-OH silica which has been extensively used in many 
applications of light in a clinical setting.72 Silica is inherently inert, amenable 
to sterilization, and relatively low-cost, making it the material of first choice 
when designing fiber probes. Unfortunately, silica has a strong Raman signal, 
with several bands that can overwhelm sample signal.71 This fiber signal can 
have magnitudes equal to and sometimes greater than that of the sample under 
study and thus any probe design needs to account for this behavior.73 Fiber 
signal can be generated in the delivery fiber core and cladding by the excitation 
light. In addition, background signal can also be generated in the collection 
fibers by any excitation wavelength light returning into the collection 
fiber(s).73,74 Mathematical techniques typically fail to de-convolve this 
unwanted fiber signal from sample signal as silica signal strength depends on 
the reflective and scattering nature of the sample and photon loss due to fiber 
bending. A feasible probe design that uses silica fibers must therefore prevent 
silica signal generated in the delivery fiber from illuminating the sample as well 
as prevent elastically scattered excitation light from entering the collection 
fibers and generating this signal.  
Several different designs have been proposed for potential clinical 
acquisition of Raman spectra using silica based fiber-optic probes.71,75 Since 
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the earliest design reports, most fiber designs have been based on similar 
concepts with modifications. In general, Raman probe designs utilize a band-
pass filter placed after the excitation fiber lens, thus allowing only transmission 
of the excitation light. To achieve this, dielectric bandpass filters have been 
used to blue shift the wavelength cutoff with increasing angle of incidence and 
have therefore been shown to act as a one-way mirror for elastically scattered 
light76. This phenomenon increases the overall efficiency of the probe by 
preventing multiple scattered incident photons from exiting the tissue and 
returning into the source fiber. Longpass or notch filters are placed in front of 
the collection fibers to block the transmission of Fresnel reflected excitation 
light as well as to prevent the elastically scattered light from entering the 
collection fibers. These filters can be placed either at the tip of the probe, at 
fiber connections within the probe, or deposited directly on the end of the fibers 
themselves to maximize effectiveness, generally requiring sizes in the order of 
a few millimeters or smaller for distal tip filtering. There is thus a demand for 
high-quality optical coatings and micro-optical components that will simplify 
the design of much needed compact fiber-optic probes for Raman spectroscopy 
in biomedicine. Alternatively, non-silica based materials such as crystalline 
fibers and hollow waveguides have been evaluated for Raman applications77,78; 
however, these have not been tested for clinical use and as such are not included 
here.   
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The different silica fiber based probe designs available commercially 
yield different sample geometries and probe diameters, which in turn affect the 
application under consideration. It is therefore critical to consider the anatomy 
of the sample to be studied along with the pathophysiology of the disease to be 
measured so that appropriate sampling may be achieved.79 For example, when 
studying the inner lining of the colon, where the epithelial lining has a variable 
layer thickness based on disease status, it is important that the probe be 
designed to sample only the superficial layers of the tissue and not into the 
deeper tissue.80 A number of different sampling probes have been developed in 
order to meet specific design criteria, such as rapid acquisition time, depth 
selectivity, or the collection of data sets from complementary modalities.81-85 
Some of the most common probe designs and associated vendors are listed in 
Table 2.1. 
 
Table 2.1. Summary of typical components used to build a clinically useable 
portable dispersive Raman system. 
Laser Fiber probe Spectrograph CCD 
B&W Tek Visionex* Kaiser f/1.8i, f/2,2i Princeton Instruments 
BRDD# 
Sacher 
Lasertechnik 
InPhotonics Andor Technology 
Shamrock SR-303i 
Andor Technology BRDD 
Process 
Instruments 
Emvision Princeton Instrument 
LS 785 
Horiba Synapse 
SDL  In-house Horiba Labram, HE-785 Kodak KAF 1001E 
Innovative 
Photonics 
Solutions 
  Ocean Optics QE65000 Ocean Optics QE65000 
* These companies do not exist anymore. # Back-reflected Deep Depletion 
(BRDD) CCD chip technology 
 
31 
 
2.6.2.c Spectrographs and Detectors 
A typical dispersive Raman detection system used for potential clinical 
applications consists of a short focal length imaging spectrograph attached to a 
cooled charge-coupled device (CCD) camera. Clinical implementation of 
Raman spectroscopy requires spectral acquisition of no more than a few 
seconds. This fast acquisition in turn needs a fast spectrograph and a highly 
sensitive detector, particularly given the weak nature of the Raman signal. A 
typical CCD camera used in spectroscopy consists of a rectangular chip wherein 
the horizontal axis corresponds to the wavelength/wavenumber axis and the 
vertical axis is used to stack multiple fibers for increased throughput, which can 
subsequently be binned for improved signal to noise ratio (SNR). 
Technological advances have led to CCD chips with quantum efficiencies on 
the order of 90% in the NIR (this information can be found on any of the CCD 
vendors’ (Table 2.1) websites). While different types of chips are commercially 
available for different applications, a back-illuminated, deep-depletion CCD is 
highly recommended for NIR Raman spectroscopy. These chips are however 
known to be susceptible to the so-called etaloning effect86-88, wherein the thin 
silicon chip acts as an etalon resulting in the introduction of sharp peaks in the 
sample signal that are hard to resolve from the narrowband Raman signal. 
However, CCD cameras are now available commercially that effectively 
eliminate this effect.86-88 Most CCDs in Raman use a thermoelectric (TE) 
multistage Peltier system to actively cool the camera down to at least −70°C in 
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order to realize excellent dark noise performance. In fact, current Raman 
systems for most biomedical applications are only limited by shot noise. 
Tissue background signal is the bane of dispersive Raman spectroscopy, 
swamping the detector and hindering evaluation of sample Raman spectra. This 
background, especially in complex tissue samples, can arise from both the 
broadband emission of autofluorescence and elastic scattering of both stray 
excitation light and the Raman bands themselves. Non-collimated light and 
angular dependent filter performance can add substantial background to a 
spectrum, as can the scattering and spectral broadening of Raman peaks 
themselves; these phenomena are continuously variable with wavelength.89 The 
presence of fluorophores in samples also contribute broad background signal to 
the collected Raman spectrum and are mediated by the wavelength dependent 
excitation for the comprising chromophores. However, most tissue 
fluorophores, with the exception of porphyrins and melanin,90 have their 
excitation and emission maxima at UV and visible (UV/VIS) wavelengths.91 
Therefore, longer visible and NIR sources at wavelengths such as 633, 785, and 
830 nm are preferred over those in the UV/VIS to reduce the amount of both 
fluorescence interfering with the detectable Raman signal. Selection of 
appropriate NIR wavelengths for excitation is often governed by competing 
factors. The longer the wavelength, the lower is the fluorescence and scattering 
background to be rejected; however, the Raman scattering also decreases. 
Again as demonstrated in Figure 2.6, where 785 nm excitation was plagued by 
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autofluorescence and scattering in kidney tissue (B) that was mitigated by 1064 
nm excitation. Further, while silicon CCD detectors are capable of excellent 
performance over most of the NIR, the quantum efficiency decreases rapidly 
with wavelength, falling to below 15% at 1000 nm. Therefore, competing 
parameters of Raman scattering intensity, tissue background, and detector 
efficiency need to be assessed relative to the tissue under study to determine 
the wavelength range to be used. Overall, researchers in this field tend to prefer 
785 nm excitation as a reasonable compromise for most tissues (as surveyed 
from the publications reviewed in Table 2.2). It should be noted that when 
acquiring Raman spectra in the high-wavenumber region (2400–3800 cm−1 in 
tissues) which is about 967–1118 nm for 785 nm excitation, obtaining high 
SNR Raman signals can be difficult using silicon-based detectors due to the 
decreasing quantum efficiencies. For detection of wavelengths above 950 nm, 
other types of detectors such as indium gallium arsenide (InGaAs), germanium, 
and indium phosphide (InP) detectors need to be used. However, these detectors 
suffer from lower quantum efficiency and increased noise in comparison to 
silicon detectors.92 Nevertheless, instrument configurations utilizing Nd:YAG 
sources and multichannel InP/InGaAsP detectors have recently reported the 
feasibility of Raman spectroscopy in tissues such as the lung and gastric tissue 
at 1064 nm excitation with acquisition times on the order of hundreds of 
seconds.93,94 Ex vivo reports by the authors have also recently demonstrated the 
potential for clinically relevant applications of dispersive 1064 nm Raman 
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instruments, particularly for in tissue type with a high fluorescence background 
at 785 nm (Figure 2.6).58,95 
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Table 2.2. Overview of large clinical studies (n>50) performed with Raman spectroscopy in vivo in humans. 
Disease type Raman method Group 
Publication 
year 
Patient 
number Sensitivity Specificity 
Barrett's esophagus Probe Raman Wilson et al. 2005 65 
86% (Dysplastic),  
88% (High grade) 
88% (non-dysplastic),  
89% (non-high grade) 
Barrett's esophagus Confocal Raman Huang et al. 2014 373 87% (High grade) 84.7% 
Cervical cancer Probe Raman Murali Krishna et al. 2014 63 100% 96.7% 
Cervical cancer Probe Raman Murali Krishna et al. 2014 93 100% 93% 
Cervical precancer Probe Raman Mahadevan-Jansen et al. 2009 145 
86% (all – multiclass),  
96% (premenopausal only) 
97% (all),  
90% (premenopausal only) 
Cervical precancer Probe Raman Mahadevan-Jansen et al. 2011 172 96.5% (Dysplasia) 97.8% 
Cervical precancer Confocal Raman Huang et al. 2013 84 81% (Dysplasia) 87.1% 
Cervical precancer Probe Raman Mahadevan-Jansen et al. 2007 79 89% (High grade) 81% (benign) 
Colon cancer Probe Raman (HF) Huang et al. 2015 50 90.9% 83.3% 
GI cancer Probe Raman Huang et al. 2011 107 
92.6% (gastric) and 90.9% 
(esophagus) 
88.6% (gastric) and 93.9% 
(esophagus) 
GI cancer Probe Raman Huang et al. 2011 81 97.9% (gastric) 91.5% 
GI cancer Probe Raman (HF) Huang et al. 2015 164 
92.5% (beveled probe) 
85.8% (volumetric probe) 
93.1% (beveled probe) 
88.6% (volumetric probe) 
GI cancer Probe Raman Huang et al. 2012 83 
83.33% (Dysplasia) 
84.91 (adenocarcinoma) 
 95.8% 
95.6%  
GI cancer Probe Raman Huang et al. 2010 67 94% (gastric) 93.4% (gastric) 
GI cancer Probe Raman Huang et al. 2011 67 
94.6% (gastric) 
89.3% (independent 
validation) 
94.6% 
97.8% 
GI cancer Probe Raman Huang et al. 2010 62 80% (overall) 85.7% (overall) 
GI cancer Probe Raman Huang et al. 2014 450 81.3% (prospective) 88.3 
GI ulcers Probe Raman Huang et al. 2010 71 
82.1% (malignant ulcers) 
84.7% (benign ulcers) 90.8% 
Oral cancer Probe Raman Murali Krishna et al. 2012 104 
86% (tumors) 
72% (pre-malignant) 74% 
Oral cancer Probe Raman Gupta et al. 2013 199 
96% (malignant) 
88% (premalignant), 84% 
(malignant) (multiclass) 
99% (normal) 
77% (multiclass) 
 
Oral cancer Probe Raman Murali Krishna et al. 2013 84 92.7% (tumor) 98.7% (healthy control) 
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84% (contralateral normal)  
Skin cancer 
Probe Raman + 
Fluorescence Tunnell et al. 2014 76 
100% (malignant melanoma) 
90% (non-melanoma cancer) 
100% (pigmented lesion) 
85% (normal) 
Skin cancer 
Probe Raman + 
Fluorescence Moryatov et al. 2014 50 89% (malignant melanoma) 87% 
Skin cancer Probe Raman Meinke et al. 2015 104 74% (basal +squamous cell)  82% 
Skin cancer Probe Raman Zeng et al. 2012 453 90% (cancer vs benign) 64% 
Skin cancer Probe Raman Zeng et al. 2008 289 
91% (cancer vs benign) 
97% (malignant melanoma) 
75% 
78% (pigmented lesion) 
Dermatitis 
Raman 
microscopy Irvine et al. 2010 132 98.7% 86.9% 
Skin carotenoids Resonance Raman Mayne et al. 2012 381     
Macular pigment Resonance Raman Stevenson et al. 2006 97     
Macular 
Degeneration Resonance Raman Stevenson et al. 2013 433     
Macular 
Degeneration Resonance Raman Gellerman et al. 2002 201     
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A Raman-sensitive detection system capable of clinical measurements 
requires an appropriate imaging spectrograph that couples to the sample 
interface (such as a fiber probe) on one end and the CCD of choice at the other 
end. Compact, rugged, spectrographs optimized for Raman use are now 
commercially available with f-number matching to the numerical aperture (NA) 
of optical fibers and high throughput for rapid acquisition (See Table 2.1). In 
order to resolve details of the biological Raman bands, the Raman detection 
system should have a spectral resolution of at most 8 cm−1. Since spectral 
resolution depends on coupling optics, slit size (or fiber size if no slit is used), 
and CCD pixel size, each of these plays a crucial role in the design and selection 
of the detection system.96 It is common to use 200-400 micron core diameter 
fibers in the fiber optic probe for maximum signal collection at the sample. 
However, this stack of fibers placed at the entrance port of the spectrograph will 
significantly reduce the spectral resolution of the system. If one assumes 1:1 
matching of fiber-spectrograph optics, 200 µm core collection fibers stacked at 
the entrance port of the spectrograph, no slit (or a 200 µm slit) and 25x25 µm 
CCD pixel size, the resulting spectral resolution is 15.14 cm-1 for a 6.13 nm/mm 
dispersion of the grating (typical for holographic gratings).97 One can reduce 
the entrance slit to 100 µm and/or reduce the collection fibers used to 100 µm 
core diameter and achieve a spectral resolution of 7.6 cm-1 which is close to 
what is needed to resolve tissue Raman peaks. Since the beams out of the fibers 
are Gaussian, one can speculate that when using a smaller slit size with larger 
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fibers, the loss of Raman photons is not as significant since one is only cutting 
out the tail of the beam. Further, larger fibers are easier to work with when 
building a filtered probe than smaller diameter fibers. Thus making these 
spectral calculations when designing the Raman system, particularly with 
respect to dispersion and therefore spectral resolution needs to be tracked during 
the selection of each of the components needed for the Raman detection system. 
Additional components of the detection system include rejection filters 
that remove any laser light as well as the elastically scattered light from the 
detected signal. Holographic notch filters can block the laser wavelength with 
an optical density of six with steep edges and provide 90% transmission 
elsewhere with a relatively flat curve.98 For dispersion, holographic 
transmissive gratings generally have the highest throughput performance99, 
however, most of these are implemented in fixed positions, enabling 
measurement of only part of the Raman spectrum at a time. Furthermore, the 
performance of these components can drift over long periods of time (years), 
potentially due to environmental degradation (humidity, temperature). There 
has recently been renewed interest in reflective and prism-based approaches to 
dispersion.100,101 Reflective gratings can usually cover a larger range of the 
spectrum at high spectral resolution, but often result in a longer integration time 
due to lower efficiency and movement of the grating position. Some devices 
circumvent this issue by including versatile options for either static or full-range 
spectral measurements, or include gratings with different dispersion elements 
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to achieve high resolution. In general, instruments with multiple gratings also 
have a larger footprint than those with fixed gratings. Size is an important 
consideration when designing a clinical device as the space available in most 
clinical procedure rooms is at a premium. The needed small footprint is also 
directly at odds with spectrograph designs that reduce performance-limiting 
aberrations based on long focal lengths. Some groups have attempted to account 
for field curvature distortions in transmissive systems by carefully designing 
the detector end of the fiber probe to have a parabolic shape that will 
appropriately map to a vertical line on the detector, limiting signal overlap and 
improving spectral resolution.102 Newer instrument designs have been 
implemented using corrective optics or beam shaping techniques to reduce the 
impact of aberrations, however, these instruments have yet to be reported for 
clinical investigation. Another technique available for use in the benchtop 
setting is hyperspectral Raman imaging, collecting high resolution global 
mapping via monochromatic images.103 This snapshot technique provides 
spatial information for samples rapidly however has not been implemented in 
clinical investigation to this point. Increased research studying the high-
wavenumber band has also resulted in the commercial availability of 
spectrometers with extended spectral coverage at the expense of either 
resolution, integration time or overall size. However it should be noted that 
several spectrographs that meet the needs of a portable Raman system are 
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available; these spectrograph are compact in design and rugged for portable use 
(see Table 2.1). 
Most Raman measurements in medical applications today rely on state-
of-the-art, high-cost, high-performance Raman systems that are compact and 
highly sensitive to the weak biological Raman signals.104,105 While each 
researcher has his or her preferences on the specifics of the different 
components in the system, the design is ultimately driven by the tissue/organ 
under study and the pathophysiology of the process to be monitored. Table 2.1 
presents the most common lasers, fiber probes, spectrographs and CCD cameras 
used to build clinical Raman systems as described in the papers listed in Table 
2.2.  
In describing and guiding the selection of each of the components 
described above, it is presumed that Raman spectroscopy is the only modality 
under consideration, and the Raman configuration to be used is dispersive 
Raman spectroscopy, to assess biochemical signatures associated with the 
biomedical problem under study in the fingerprint or high wavenumber region. 
These components can be obtained from any number of vendors or developed 
within a laboratory to assemble a system suitable for the specific study under 
consideration. It is vital for any clinical application that the individual 
components integrate into the most efficient instrument configuration possible 
and all spurious sources of confounding signals be minimized through design 
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2.6.2.d Data processing and Analysis 
2.6.2.d.i  Instrument Calibration 
Based on the previous section, it becomes readily apparent that to 
compare Raman spectra acquired from different tissues requires some 
standardized methods of calibration and processing that enable transferability 
of these spectra. Figure 2.7 presents a flowchart of the major procedural steps 
and their order for converting raw measurement data from the detector to 
signals ready for comparison and analysis. Source compensation is a standard 
process that can be applied to control for variability in the source from 
measurement to measurement. This step is critical only when absolute 
intensities are necessary for analysis. Instrument response variations require 
two types of calibration: spectral calibration and intensity calibration. Spectral 
calibration is used to convert the horizontal axis from CCD pixel number to 
relative wavenumber. The emission spectrum of a known calibrated light 
source, such as a neon lamp with numerous and narrow bands in the NIR, is 
typically used to calibrate the horizontal axis into absolute wavenumbers 
(cm−1). Relative wavenumber calibration is performed using the spectral 
position of the laser line and then validated using standards with well 
characterized Raman features and strong Raman scatter, such as naphthalene 
and acetaminophen. Spectral standards such as the fluorophore rhodamine 6G 
and a weak Raman scatterer such as methylene blue or vitamin E can be used 
as additional intensity standards to account for day-to-day variations in the 
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spectral intensity.106 Calibration of the intensity axis (spectral response 
correction) is necessary to account for the wavelength-dependent response of 
the various components in the detection leg of the system including the grating, 
the filters, optics as well as the quantum efficiency of the CCD chip. This is 
typically performed using a calibrated source such as a tungsten lamp certified 
by the National Institute of Standards and Testing (NIST) to generate intensity 
correction factors for variations in instrument throughput.107 This calibration 
process is essential for comparison of spectra measured across different Raman 
instruments for the same or similar sample. This calibration is typically 
performed early in a study and then on a regular basis to validate the accuracy 
of the correction factors over time. However, perturbation of any of the optical 
components including those induced by moving the system from the laboratory 
to the clinic can affect the calibration and therefore an additional method that 
accounts for day-to-day calibration of the system performance must also be 
developed. Collection of a NIST lamp intensity spectrum is often impractical 
in a clinical situation due to the experimental controls necessary to ensure that 
the bright, diffuse emission of the lamp traverses only its intended path through 
the Raman instrument to the detector, along with the safety concerns that 
correspond to the spectral intensity in the UV portion of the spectrum. More 
recently, spectral intensity standards consisting of green-colored Schott glass 
have been explored by NIST108 and other groups109 as more practical 
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alternatives for daily calibration, but no consensus has yet to be reached on their 
applicability as a Raman standard. 
 
Figure 2.7. Flowchart for typical system calibration and signal processing 
procedures for clinical Raman spectroscopy systems. The darker shaded boxes 
indicate steps that require collection of reference spectra prior to data 
acquisition while the other steps can be implemented in-line per spectrum for 
system automation. 
 
As indicated in Table 2.1, it is possible to configure a Raman system 
using different combinations of a laser, spectrograph, probe and detector. In a 
parametric study of laser, probe, and CCD detector combinations for a single 
spectrograph, the influence of each component in an instrument configuration 
on reliability and reproducibility of Raman spectra was investigated 
(unpublished). The various combinations of these components can be seen in 
Figure 2.8. By isolating the impact of each instrument, this work identified that 
44 
 
the most significant impact on the obtained signal was driven by the fiber optic 
probe. When a single probe was maintained across different lasers, 
spectrographs, and CCDs, the total variance of the detected signals decreased 
significantly relative to signals obtained when spectra were combined across 
probes. This data highlights the importance of using a single probe design for 
data collection for a given clinical application. 
 
 
Figure 2.8. Diagram for a comparison study of clinical Raman spectroscopy 
system components. By varying combinations of instruments, variability 
studies have investigated the impact of unique components on the acquired 
spectral signatures. Results show that the collection leg of the system and the 
design of the fiber probe have the most significant contribution to the 
instrument variance observed in the spectra. 
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Even when a single probe design is selected for a given clinical Raman 
instrument, it is important to precisely account for instrument-induced 
variability. The aforementioned variability study indicates the importance of 
using a single probe design for clinical data collection (Figure 2.9A). However, 
it is not feasible to conduct a large clinical study or manufacture a potential 
medical device that relies on a single probe for the lifetime of the instrument. 
As multiple probes built from a single design are used, it should be noted that 
each optical component can have a similar but ultimately unique wavelength-
dependent response. As depicted in Figure 2.9 for different in vivo tissue 
measurements with unique probes of the same design, differences in filtering 
and throughput can impact not only raw signals (Figure 2.9B) but also impact 
the resulting, processed spectra (Figure 2.9B, inset). However, current 
calibration methods do not provide adequate calibration to minimize probe 
response which in turn affects data analysis when spectra across multiple probes 
are combined.106 Practically, this data indicates the necessity of adequately 
calibrating probe-specific signals thoroughly for successful implementation of 
Raman techniques and the community needs to work together to develop such 
methods. In the meantime, it is recommended that investigators acquire 
multiple probes based from a single design and built at the same time, to 
minimize this variability. 
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Figure 2.9. Representative Raman spectral differences that can be obtained 
from a single sample acquired using two different probes. (A) A conventional 
filtered Raman probe (green) and a beam-steered Raman probe (blue) on skin 
in vivo demonstrate unique line shapes. (B) Two iterations of the same probe 
design used to measure an albumin sample demonstrate the effect of slightly 
different inline filters on the raw and resulting processed (inset) Raman 
spectrum. 
 
2.6.2.d.ii Data processing 
2.6.2.d.ii.1 Fluorescence elimination 
The increased investigation of Raman spectroscopy for biological and 
clinical purposes is largely due to its high sensitivity to subtle biochemical 
changes and its capability for nonintrusive application. One challenge faced in 
these investigations is that biological applications involve turbid, chemically 
complex, and widely varying targets. Therefore, significant challenges exist for 
both acquiring viable Raman signatures and suppressing the noise sources 
inherent to the target medium. The greatest challenge for obtaining Raman 
spectra from biological materials is the intrinsic fluorescence and elastic 
scattering of many organic molecules. Often several orders of magnitude more 
intense than the modest Raman signals, this background, if left untreated, will 
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likely dominate the Raman spectrum and hinder analysis and interpretation of 
tissue biochemistry. To extract Raman signal from the raw spectra acquired, 
elimination of fluorescence signal is necessary. While most biological 
fluorescence occurs in the UV/VIS and intensity decreases as a function of 
wavelength, the fluorescence and scattering background observed for NIR still 
interferes with the measured Raman spectrum (Figure 2.6B). The intensity of 
this background is generally dependent upon tissue but is ubiquitously present 
in almost all tissues studied, meriting attention prior to spectral analysis. 
Both hardware and software techniques have been proposed for 
background subtraction from raw Raman signals. Wavelength shifting and time 
gating are hardware-based techniques that have been shown to effectively 
minimize fluorescence interference in Raman spectra but require specific 
design considerations for the spectroscopic system to achieve their results.110,111 
Several software-based mathematical methods can be implemented without 
system modification and are generally preferred for fluorescence removal. Such 
techniques have included first- and second-order differentiation112,113, 
frequency domain filtering110, wavelet transformation114,115, multistage 
smoothing116, and polynomial fitting53,117,118. Each of these methods has been 
shown to be useful in certain situations, however all have their advantages and 
limitations that must be evaluated before selecting a method for application with 
a given system. 
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First and second order differentiation relies on invariant wavelength-
dependent fluorescence emission compared with the relative shifts measured in 
Raman spectra. One way to accomplish this differentiation is by measuring the 
spectra at two (or more) slightly shifted excitation wavelengths (within a few 
nanometers) and taking their difference.119 Integrating the difference spectrum 
results in the original Raman signal. Similar results can be achieved with a 
single excitation wavelength by taking the first derivative of the spectrum and 
integrating the noise-smoothed derivative spectrum following baseline 
correction.110,113 The derivative method for fluorescence subtraction is efficient 
and unbiased, but distorts Raman line shapes and relies on complex 
mathematical fitting algorithms to reproduce a traditional spectral form.110 
While many of these methods were developed and tested in the early 1990s, 
shifted excitation methods for removing this undesirable fluorescent signal, 
coined as modulated wavelength Raman spectroscopy, are coming back into 
vogue, utilizing multiple closely spaced excitation sources and signal 
processing algorithms to remove fluorescence signal.120 Newer sources allow 
the use of multiple excitation wavelengths to improve the accuracy of the 
method; however, removal of the DC offset remains an issue.  
Frequency filtering and polynomial fitting are other common methods 
for fluorescence elimination. Frequency filtering can be achieved with fast 
Fourier transform (FFT), transforming the spectrum to the frequency domain 
by taking the FFT which is then be multiplied with a linear digital filter to 
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eliminate the fluorescence. The inverse FFT yields the Raman spectrum free of 
fluorescence.110 If the frequency elements of the Raman and noise features are 
not well separated, this method can generate artifacts in the processed spectra. 
A more direct method to subtract fluorescence that is both simple and accurate 
is to fit the measured spectrum containing both Raman and fluorescence 
information to a polynomial of sufficient order to describe the fluorescence line 
shape without capitulating the higher-frequency Raman lineshape.53 
Polynomial curve fitting has an advantage over other fluorescence reduction 
techniques due to its inherent ability to retain the spectral contours and 
intensities of the input Raman spectra and can be easily implemented in 
MATLAB® or other computing platforms for automated performance. 
Individual techniques have advantages and disadvantages; the method 
used should be selected based on the specific application and best matched to 
measurement technique. Mosier-Boss et al. tested the use of the shifted 
excitation, first derivative, and FFT techniques for fluorescence subtraction and 
indicated a preference for using the FFT based on its ability to filter random 
noise from the spectrum.110 In an analysis of the different techniques by the 
author for in vivo tissue applications, the use of a polynomial fit was found to 
be the optimal technique for both experimental and computational 
considerations. More recently, a modified polynomial fitting algorithm that 
accounts for noise levels has been proposed118,121 which has been shown to 
minimize the presence of artificial peaks in low SNR spectra that are common 
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in measurements of tissues with high autofluorescence. It should be noted that 
order of the polynomial used is specific to the sample fluorescence line shape 
and as such should be determined before utilizing this technique (Figure 2.10). 
 
Figure 2.10. Impact of background elimination varies based on the sample or 
tissue measured. Fluorescence subtraction using (A) 5th order polynomial in 
skin and cervix yield unique shapes due to compositional differences. (B) Using 
a 5th versus 7th order polynomial in colon (processed spectra inset) 
demonstrates that a single polynomial fitting order may not be appropriate for 
all samples; higher order polynomials are used to simulate background 
fluorescence and subtracted to enhance the underlying Raman signal from the 
sample. 
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Other methods have utilized advanced signal processing techniques to separate 
underlying autofluorescence from the desired Raman signals. Wavelet decomposition, 
penalized least-squares fitting techniques122 and principal component analysis (PCA) 
have been described for suppression of the confounding signal components.123 Wavelet 
transformation is dependent on the decomposition method used and the shape of the 
fluorescence background, whereas PCA assumes that the highest signal variance is due 
to the fluorescence background, which may be invalid for some applications. Thus, 
there are tradeoffs for each method and the choice may be governed both by the 
application at hand and the preference of the investigator. 
2.6.2.d.ii.2 Noise Smoothing and Binning 
Since Raman scattering is such a weak phenomenon, the SNR of most 
measured Raman spectra require significant noise smoothing in order to extract 
the underlying Raman bands. Various types of noise smoothing filters have 
been effectively used. These include the median filter, the moving average 
window filter, the Gaussian filter whose full width at half maximum is typically 
set equal to half the spectral resolution of the system, and the Savitzky–Golay 
filter of various orders.105,124-127 Other methods include using PCA, genetic 
algorithms, and other multivariate statistical approaches to remove the higher 
order components and effectively removing noise128,129. In using any of these 
or other methods of noise smoothing, care should be taken to retain the integrity 
of the spectral line shape especially when dealing with samples with multiple 
peaks that are close to each other. Validating the method using spectra from 
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weak Raman samples (with low SNR) should be an essential step in the 
development process.  
Other preprocessing methods typically applied include binning of the 
spectral data set due to the large number of variables (which is dependent of 
CCD chip size) for computational ease. Depending on the variability in the 
acquired data and the needs of the analysis methods used, various normalization 
methods may also be applied to allow comparison of the spectra. Normalization 
methods include normalization to intensity standards, normalization to a 
spectrum’s own maximum intensity or area under the curve, and mean scaling 
to the average spectrum acquired from a given patient. Some researchers prefer 
to use difference spectra to achieve the same normalization effect to account for 
intra- and interpatient variability observed. 
2.6.2.d.ii.3 Data Analysis 
One of the advantages of spectroscopic diagnosis is automation, which 
allows objective and real-time diagnosis of pathologies. Spectral differences 
observed as a function of tissue physiology or pathology can be incorporated 
into diagnostic algorithms that can in turn be implemented in real-time to yield 
classification using univariate and multivariate statistical methods; several 
statistical approaches have been identified and applied for feature extraction 
and classification of tissues towards automated, clinical diagnosis. Since 
Raman spectroscopy is a biochemically specific technique, chromophore and 
scattering molecule contributions can be extracted from the measured spectra. 
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These can then be used in diagnostic algorithms as well as in understanding of 
the spectral signature as it pertains to the disease process. For example, the 
extracted contributions can be used to quantify blood analytes for applications 
such as glucose sensing.130  
Original analyses for Raman signals were based on differences in 
intensity, shape, and location of the various Raman bands between normal and 
abnormal cells and tissues. Observed differences between the different tissue 
types under study were selected for classification algorithms based on empirical 
methods using changes in intensity or ratios of intensities or number and 
location of peaks. For example, the intensity ratio of the CH2 bending 
vibrational mode at 1440 cm−1 to the Amide I vibrational mode at 1655 cm−1 
has been observed to vary with disease in several applications including breast 
cancers and gynecologic cancers and precancers.131,132 The limitation to this 
approach however, is that diagnostically useful information may be contained 
in more than just the peaks or valleys observed in tissue; a method of analysis 
and classification that includes all the available spectral information may be 
important for the accuracy of detection. Further, empirical methods tend to be 
biased in favor of the spectral differences specific to the data set used for the 
analysis and these methods do not hold under validation. To obtain an unbiased 
estimate of the performance of algorithms for Raman data, multivariate 
statistical techniques have become the accepted practice for the development of 
discrimination and classification algorithms for diagnostic applications.  
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In the past few years, great strides have been made in the application of 
multivariate techniques for spectroscopic data analysis in disease detection.107 
Discrimination techniques such as linear and non-linear regression as well as 
classification techniques such as neural networks have been employed.107,133 
Data compression tools such as PCA are still commonly used to reduce the 
dimensionality of the data matrix and have been used to account for the 
variability in the data.134 Linear and nonlinear methods have also been used for 
feature extraction. Subsequently, methods such as hierarchical cluster analysis 
(HCA)135 and linear discriminant analysis (LDA)133 have been used to yield 
classification algorithms for disease differentiation. Partial least squares, a 
regression-based technique, as well as hybrid linear analysis, have been used to 
model tissue based on component spectra, finding component contributions for 
disease detection and extracting accurate concentrations of analytes such as 
glucose using NIR Raman spectra for transcutaneous blood analysis.136,137 More 
complex multivariate and machine learning methods have also been utilized, 
including support vector machines138, logistic regression models95,139, genetic 
algorithms128, neural networks140, decision trees141, optimization techniques137, 
and generalized linear models. These methods allow the integration of non-
Gaussian constraints and variable weights to optimize classification 
performance. However it should be noted that these complex methods may not 
necessarily provide a significant improvement in the diagnostic performance of 
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Raman spectroscopy and as such most studies tend to rely on simpler (and often 
linear) albeit multivariate methods of discrimination. 
In small sample sets, one often relies on the leave-one-out or K-fold 
methods of cross validation, as well as nested methods for multiple optimization 
steps. Rigorous, unbiased estimates may be obtained by developing robust 
discrimination algorithms using a test set and its performance quantified in a 
validation set. Ideally, these two sets are formed by random distribution of the 
subject population into two equal data sets. The true measure of success of 
Raman spectroscopy for tissue diagnosis requires validation of the tested 
algorithm in an extensive unbiased (and independent) validation set.142 
Analyzing Raman signals for spectral differences and developing 
diagnostic algorithms for the purpose of disease classification are one facet of 
the clinical application of Raman spectroscopy for tissue diagnostics. However, 
the wealth of information provided in Raman spectra especially with respect to 
molecular composition enables identification of the nature and biochemical 
processes responsible for these changes. This information can be used to 
enhance fundamental understanding of various biological processes as well as 
inform the improvement of diagnostic performance. 
Several researchers have harnessed the benefit of extracting 
physiologically relevant markers from Raman spectra of tissues. Puppels et al. 
obtained quantitative information about skin hydration based on Raman 
spectra.143 Feld et al. developed comprehensive models for biochemical 
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component extraction that were used for disease classification.144 More 
recently, Huang et al. performed semi-quantitative biomolecular least-squares 
modeling based on representative basis spectra in order to distinguish spectral 
sources for neoplastic lesions in multiple patients.145 Each of these methods is 
based on the acquisition of Raman spectra from individually identified 
chromophores either as morphological tissue components, as extracted 
biochemical constituents, or commercially available pure chemicals. Pixelated 
Raman microspectroscopy has been used (with or without confocality) to 
measure Raman spectra from individual morphologic tissue components using 
tissue sections. A Raman spectrometer is coupled to a microscope and is 
scanned across the tissue section to obtain Raman images that can then be 
correlated with serial hematoxylin- and eosin (H&E) stained sections to identify 
relevant morphologic components and their Raman signature. Alternatively, 
tissue scatterers can be extracted from biochemical assays and Raman spectra 
can be acquired from each of these extracted chromophores using the same 
instrument as used to measure the biological specimen. Using mathematical 
models such as those developed by the Feld group, contributions of each of the 
extracted or morphologic components can be calculated for the intact tissue.  
Thus, a portable, clinically viable instrument with a fiber-optic probe 
can be used to acquire Raman spectra in vivo. The ability of Raman 
spectroscopy in a particular tissue can be tested in animals in vivo or in vitro 
and subsequently applied for in vivo human detection. The acquired spectra can 
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then be processed and analyzed and information extracted about the 
performance of the technique as well as about the biochemical components that 
contribute to the signals obtained by the method. 
2.6.2.d.ii.4 Technology interface, control, and automation 
A major feature that is paramount for translation of Raman spectroscopy 
or any other laboratory technology to a medical clinic is the constraint of an 
intuitive, automated interface. Given the inherent weakness of Raman 
scattering and the complexity of the generated signals, great care and effort 
must be spent in developing the instrument interface prior to deployment for a 
medical application. Thankfully, the instrument components discussed above 
can be combined in a manner appropriate for a detection target so that signals 
can be detected quickly. Once detected, the speed of modern computing 
technology can be utilized for real-time processing for background removal, 
component extraction, and class prediction. Optimizing algorithms for each 
step is vital for an intuitive interface along with practical considerations 
including how to best display feedback to the end-user. The first step towards 
successful integration is to implement a clinically-relevant user control. Hands-
free enabled data collection with foot pedals or buttons at the probe interface 
are features that will enable clinical use, along with instruments that operate in 
real-time and provide continuous feedback. Zeng et al. and Huang et al. have 
reported systems that integrate data collection, processing, and analysis in times 
as low as 100ms.52,102,146,147 Even with the integration of rapid processing, the 
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information provided by a complicated tool based on Raman spectra could be 
overwhelming. Combining this information into an easily interpreted display or 
audible feedback are vital steps for the clinical integration so that with minimal 
training, these devices can be deployed to benefit clinical medicine. 
2.6.3 Raman configurations 
Several different modalities of Raman scattering have been used to 
analyze the structure of various biological molecules.148,149 Some of these 
techniques include ultraviolet (UV), visible or NIR dispersive Raman, Fourier 
transform Raman (FT-Raman), surface-enhanced Raman (SERS), and 
ultraviolet resonance Raman (UVRR) spectroscopy48,150. More recently 
developed techniques include stimulation Raman (SRS), tip-enhanced Raman 
(TERS), and coherent anti-Stokes Raman scattering (CARS).151-153 Early 
adoption of Raman spectroscopy for biological applications with minimal 
interference from fluorescence relied on FT-Raman spectroscopy, where the 
Fourier transform of the scattered signal is detected, and subsequently inverse-
transformed to give the actual Raman signature. This technique yields improved 
signal-to-noise ratio of hard to detect events but requires long collection 
times143 that are not practical for clinical and in vivo implementation. With the 
recent developments in laser and detector technology, FT-Raman methods have 
become more or less obsolete at least as it pertains to clinical diagnosis and as 
such are not discussed here. Pursued extensively as a viable technique for in 
59 
 
vivo human application, NIR dispersive Raman scattering is typically excited 
in the range of 780–1100 nm where minimal fluorescence is produced making 
detection of the weak Raman signal easier, particularly in biological materials. 
However, several other configurations of Raman spectroscopy have been 
implemented in vivo and a summary of some of these as they pertain to potential 
clinical application are described below. 
2.6.3.a  UV/VIS  
While most implementations for clinical Raman spectroscopy rely on 
NIR excitation (785 or 830nm), some researchers continue to use visible 
wavelengths for biomedical applications. The tradeoff between high Raman 
scattering cross-sections at lower excitation wavelengths and decreased 
penetration depth, higher absorption, autofluorescence, and heat generation 
usually limit the potential of in vivo clinical application with visible techniques. 
However, some studies continue to apply these more readily available 
excitation sources for various studies, particularly where direct interaction with 
the patient is not required.154-156 Especially in applications of Raman 
spectroscopy for pathology analysis for which clinical protocols for ex vivo 
cytology and histology commonly employ conventional glass slides as the 
substrate, visible sources, such as 532nm, demonstrate significant 
improvements in background signal relative to NIR excitation.157 Other ex vivo 
work continues for several malignancies, including skin and oral neoplasia, with 
visible wavelengths that show promising results.158-161 
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Resonance Raman activation may be achieved when the excitation 
wavelength approaches electronic absorption of a molecule.162 Resonance 
Raman excitation increases scattering signal intensity by several orders of 
magnitude. However, typical absorption frequencies of biological molecules 
such as proteins and nucleic acids occur at ultraviolet wavelengths where these 
wavelengths may cause photolysis of the sample and destroy it over time.163 
Further, the mutagenicity of UV radiation makes this technique inviable for 
clinical in vivo use.164,165 As such, few researchers have pursued this approach 
for potential clinical applications in recent years.  
2.6.3.b Raman Imaging 
The weak nature of Raman scattering hinders the imaging of Raman 
features in biological materials such as cells and tissues with dispersive Raman 
spectroscopy in clinically feasible integration times. Intrinsic Raman imaging 
has been performed using the intensity of a specific Raman band or ratio of 
bands to build an image from cells and tissues.166 As mentioned above, one 
method acquires a hyperspectral stack of monochromatic images over relatively 
large spatial areas. Another approach involves compiling a three dimensional 
data cube by measuring Raman spectra through point or line scanning of the 
excitation and collection beams.167 The voxel size may be governed by the 
spatial resolution needed for the study and can be as small as the confocal 
pinhole up to ~100s of micrometers. Both methods of imaging are performed 
on a Raman microscope and may require several minutes to hours to acquire an 
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image depending on the spatial resolution thus making it infeasible for real-time 
clinical applications. Most studies with point or line scanned Raman imaging 
have been used to improve our understanding of biological processes in cells 
and tissues in vitro as well as in animal models.65,168,169 Other methods of 
Raman imaging include nonlinear Raman techniques such as coherent anti-
Stokes Raman spectroscopy (CARS) and stimulated Raman scattering that take 
advantage of nonlinear processes for increased and selective signals. Both of 
nonlinear methods have been applied to study biochemical interactions in cells 
and tissues in vitro and in vivo applications have been confined to mouse 
models.153,170-173 However, all these imaging techniques are restricted by the 
limited number of available Raman photons and therefore the long integration 
times necessary to acquire a Raman image successfully. As such none of these 
approaches have successfully been applied in vivo in humans and are not 
directly practical for clinical use. 
2.6.3.c Fingerprint versus High wavenumber 
While the majority of researchers applying Raman spectroscopy for 
clinical applications have primarily been focused on spectral differences in the 
fingerprint range (up to about 1800 cm-1), some studies have investigated the 
diagnostic utility of spectral features in the high-wavenumber, generally 2200 
– 4500 cm-1 where distinct and strong features of lipids, proteins and water may 
be observed (Figure 2.11). The fewer but broader features that occur in the high 
wavenumber region can be much higher in intensity relative to competing 
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optical signals. Several studies have demonstrated the potential of high 
wavenumber Raman spectroscopy alone or in combination with fingerprint 
Raman methods to discriminate and classify disease in vivo.174 Detecting high 
wavenumber Raman features pose different requirements on the Raman system 
design. Because the high wavenumber signal is inherently at a higher 
wavelength than the fingerprint, different gratings, filters and more importantly 
detectors may be necessary in order to efficiently collect signals especially 
when using common NIR Raman excitation sources (described in the detector 
section above). Alternatively, because the separation between the Rayleigh line 
and the detected Raman bands is so large, inline filtering can be mitigated, 
which has the potential to simplify probe designs and reduce cost, thus 
increasing the potential for clinical translation. 
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Figure 2.11. Fingerprint and high-wavenumber Raman spectrum of ex vivo 
breast tissue depicts the broad, strong features characteristic of lipid 
components in the tissue. Both segments of the Raman spectrum can provide 
valuable information for evaluation of complex sample composition. 
 
2.6.3.d SORS 
Perhaps the most impactful configuration of Raman spectroscopy in 
recent years has been the discovery of spatially offset Raman spectroscopy 
(SORS). Photon migration theory dictates that photons incident on the tissue 
surface that reemerge after only a few scattering events are likely to undergo 
minimal transverse shift and travel through the most superficial depths. Photons 
that undergo many scattering events are more likely to undergo a larger 
transverse shift and also travel deeper within the tissue, due to the fact that the 
scattering phase function of tissue is primarily in the forward direction. The 
combination of spatial offset with the Raman effect introduces depth selectivity 
in the spectral measurements expanding the ability of Raman spectroscopy to 
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sub-surface phenomenon in biomedical applications.175 The intensity of the 
Raman-scattered light at zero spatial offset includes contributions from both the 
superficial and underlying layers. However, as the spatial offset increases, the 
signal intensity from the superficial layers falls off more rapidly than the 
intensity of the signal from the underlying layers, which increases the relative 
proportion of signal from the deeper layers. The SORS signal can be collected 
through a range of spatial offsets, and computational techniques such as least-
squares regression can be applied to separate the spectral signatures from 
individual layers.176,177 It is important to note that while SORS can yield Raman 
spectra from deep within the tissue, it does so in a probabilistic fashion that 
relies on the layered architecture of tissues in which the spectral signatures of 
the layers are distinct. This is in contrast to confocal Raman spectroscopy, 
which explicitly rejects out-of-focus light and collects spectra from a well-
defined depth. This makes SORS better suited for low-resolution depth-
dependent measurement of features and at greater depths (~centimeters) than 
confocal Raman spectroscopy (~100s µm). Several researchers have applied 
SORS towards clinical applications in the bone and breast.176,178,179 This 
approach has been extended to other configurations such as inverse SORS 
where the source and detection fibers are switched180 and Raman 
tomography169, where SORS is combined with computed tomography and 
modeling of optical properties to obtain three dimensional Raman maps. 
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2.6.3.e  SERS 
Surface enhanced Raman spectroscopy (SERS) is used to investigate the 
vibrational properties of single adsorbed molecules.48,150,181 It was discovered 
that the rather weak Raman effect can be greatly strengthened (by a factor of up 
to 14 orders of magnitude) if single molecules are attached to metal 
nanoparticles of a suitable material and roughness to capitalize on both 
electromagnetic (surface plasmon resonance) and chemical enhancement.182-184 
Many groups have used SERS to detect single molecules attached to colloidal 
silver particles that are either adhered to a glass slide or in an aqueous solution. 
Single-molecule detection is of great practical interest in chemistry, biology, 
medicine, and pollution monitoring; examples include DNA sequencing and the 
tracing of interesting molecules such as those used in bioterrorism. In medicine, 
the feasibility of SERS to track targeted molecules in vivo in a mouse model 
was successfully demonstrated by Gambhir et al.185 Since that report, numerous 
groups have applied targeted SERS-activated nanoparticles to track various 
cancer biomarkers in vivo in animal models.186-190 However, the biggest 
limitation of SERS is the need to introduce a tag with related toxicity issues 
which makes this approach infeasible for human clinical applications at this 
time. Vo-Dinh et al. developed a single fiber SERS sensor that has the potential 
to extend SERS for in vivo human use without the need for a targeted particle.191 
However, no reports of in vivo testing of this sensor were found.  Another 
configuration is a combination of the surface enhancement with deep Raman 
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spectroscopy, known as SESORS. First reported by Stone et al., this technique 
has demonstrated the potential for detecting molecule-specific SERS particles 
buried deeply within layers of tissues.192,193 While this technology has not yet 
been implemented clinically, research for nanoparticle confinement in 
substrates may reduce the potential for toxicity issues. 
Despite the various configurations described above, the most common 
configuration used in the application of Raman spectroscopy in a clinical setting 
is based on dispersive Raman spectroscopy in the fingerprint and/or high 
wavenumber region of spectrum. Spatial offset and confocal are modifications 
to this approach that have also been implemented and tested in a clinical setting. 
All the other approaches have been mostly applied to develop an improved 
understanding of a biological and biochemical processes rather than clinical 
diagnosis. Combining dispersive Raman spectroscopy with other optical (and 
non-optical) methods has been researched in an effort to improve performance 
of Raman spectroscopy alone in solving a clinical problem. Raman 
spectroscopy has been combined with optical coherence tomography194-196, 
optical tomography197, confocal reflectance microscopy198,199, fluorescence and 
diffuse reflectance spectroscopy200,201 to provide complementary information 
that can be used to further enhance the diagnostic capability of any one of these 
methods alone. The instrumentation considerations for making such multi-
modal approaches feasible are usually challenged by the need to combine a 
narrow bandwidth laser and sensitive detector, essential for the very weak 
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Raman signals with the source and detector considerations of a much brighter 
signal acquired using these other modalities. The resulting combinations yield 
a much more complicated instrument design accompanied with a higher cost 
device. Nevertheless, various researchers have successfully demonstrated the 
diagnostic advantage of these multi-modal approaches. 
2.6.4 Clinical applications of Raman spectroscopy 
Numerous research groups have investigated the potential of Raman 
spectroscopy for clinical use over the past decades and continue to find 
interesting medical problems for which the noted sensitivity of Raman 
scattering holds great promise. Various implementations of the instruments 
described above have been utilized in clinical studies that demonstrate the 
potential of Raman spectroscopy to impact medical care. In this section, we 
present a review of large (n > 50), clinical in vivo studies that are focused on 
the application of Raman spectroscopy for disease detection and sensing.  These 
studies provide a snapshot of the current state of the field in the clinical 
implementation of this technique (Table 2.2). By far, the most common clinical 
target under investigation with Raman spectroscopy is cancer. Large clinical 
studies have seen ongoing work in several organ systems, all of which have 
traits in common: a need for improved early detection with high sensitivity and 
specificity, well-characterized disease processes, and relative ease of access to 
the organ under study. The specific instruments utilized in these studies differ 
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slightly but all of the designs are driven by the anatomical target of interest. It 
is also of interest to note that all published studies of large clinical studies have 
been performed by the same few research groups pointing to the need for more 
research to translate the scope of Raman spectroscopy to in vivo human studies 
(Table 2.2).  
2.6.4.a  Cervix 
Cervical cancer is a highly preventable disease, as progression from 
precancer (or dysplasia) to cancer takes many years, providing a wide detection 
and treatment window. Developed countries have implemented vigorous 
screening programs that have dramatically reduced cervical cancer rates. 
Unfortunately, in developing nations where limited resources prevent large-
scale screening, cervical cancer is one of the most common causes of cancer-
related death among women comprising approximately 90% of 265,000 
cervical cancer deaths worldwide.202 Raman spectroscopy has been evaluated 
as an early diagnostic tool for cervical cancers and precancers over the past two 
decades. Our group demonstrated that Raman scattering was sensitive to 
normal, benign, low grade, and high grade dysplastic tissues in vivo.203 By 
integrating analytical algorithms with data collection, diagnostic accuracies as 
high as 88% were achieved. Further investigation found that by incorporating 
hormonal/menopausal status, the predictive performance improved to 94%.204 
Continuing work has identified cervical inflammation, parity status, and body 
mass index as additional variables to be considered but identified limited 
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influence of other patient variables including race/ethnicity and socio-economic 
status on Raman scattering based disease discrimination.139,205  
 The well-defined nature of the disease and easy accessibility of 
the cervix have allowed many researchers to pursue diagnostic research in this 
organ in vivo. Several different groups have used fiber based Raman systems 
for diagnosis and correlated their findings with colposcopy. These have used a 
variety of fiber probe designs and different multivariate statistical methods to 
achieve a range of performance estimates as shown in Table 2.2.139,203,206-209 In 
other cervical cancer studies, Huang et al. developed a simultaneous fingerprint 
and high-wavenumber confocal Raman system for cervical precancer detection 
and demonstrated the performance of this combined approach in 84 patients 
with sensitivity of 81% and specificity of 87%.209 Zeng et al tested the 
feasibility of a label free blood test based on blood plasma SERS on samples 
from 60 cervical cancer patients and obtained a sensitivity and specificity of 
96% and 92% respectively when using multivariate diagnostic algorithms.210 
Other results have demonstrated the potential of Raman spectroscopy to 
differentiate between responders and non-responders to radiotherapy on 
biopsies from  patients with cervical cancer211 and to detect high risk strains of 
the human papilloma virus in cervical cells.212 However these results need to be 
independently validated in a large study cohort. A recent review article on the 
application of Raman spectroscopy for cervical cancer presents an excellent 
summary of all relevant studies in a table.213 Beyond the realm of cancer 
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detection, our group has demonstrated the potential of Raman spectroscopy to 
track biochemical changes in the cervix during pregnancy and develop an 
understanding of cervical remodeling that occurs throughout pregnancy and 
parturition.214,215 
2.6.4.b Skin 
As the major organ in the integumentary system, the skin is both the 
outer barrier of the body to the external world as well as the tissue that is easiest 
to interrogate with light. Melanocytic and non-melanocytic cancers have 
different cellular origins, but collectively comprise the most common cancers 
in the world.216 As a surface organ malignancy, skin cancers are among the 
easiest to study with optical techniques; however, the complex, turbid nature of 
the skin makes it one of the most challenging clinical targets for optical 
diagnostics and monitoring. Early studies used Raman spectroscopy to extract 
water concentration profiles in human skin while demonstrating the feasibility 
of in vivo Raman spectroscopy for clinical monitoring.217 Since then, much of 
skin Raman research has focused on the investigation of Raman based 
diagnostics. These studies also resulted in developing portable systems that 
were directly applicable to the clinical workflow, with instruments that can 
make measurements with integration times under 1 second.52,54,102 A number of 
groups have invested significant effort in studying skin cancers in order to 
improve patient care and as a result, skin cancer studies have some of the 
highest recruitment of any Raman studies published, as related in Table 
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2.2.52,200,218-220 Zeng et al. utilized a Raman instrument to study melanocytic 
and non-melanocytic as well as malignant and premalignant melanocytic 
lesions from 453 patients: discrimination of cancer and precancer versus benign 
lesions demonstrated a 90-99% sensitivity, with a related specificity of 15-
54%.52 This work suggests that Raman techniques can be used to reduce the 
need for unnecessary biopsies to a significant degree, potentially by 50-100%. 
Other groups have utilized multimodal approaches, leveraging the strengths of 
Raman spectroscopy with a combination of fluorescence and diffuse reflectance 
techniques in order to improve diagnostic outcomes. In one such report of 76 
patients, Raman spectroscopy alone was demonstrated to achieve 100% 
sensitivity and specificity for discriminating melanoma from benign pigmented 
lesions, but only 72 % sensitivity and 64% specificity in separating non-
melanoma skin cancers from precancers and 68% sensitivity and 55% 
specificity for distinguishing non-melanoma cancers and precancers from 
normal tissues. However, when combined with fluorescence and diffuse 
reflectance features, those same comparisons achieved 100/100%, 95/71%, and 
90/85% sensitivities/specificities, respectively.200 In other Raman skin research 
not related to cancer, Irvine et al. studied atopic dermatitis in 132 children, 
correlating natural moisturizing factor signals obtained via Raman scattering 
with genetic screening for filaggrin mutations common in atopic dermatitis.221 
The results of this study found that Raman signals achieved 98.7% sensitivity 
and 86.8% specificity in identifying atopic dermatitis associated with these 
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mutations. Raman spectral signatures of skin carotenoids have also been 
investigated using a 488 nm based resonance approach to profile the intake of 
fruits and vegetables in preschool aged children.161 This study demonstrated a 
correlation of Raman signatures with parent-reported family participation in a 
nutritional-education and -quality program, further demonstrating the exquisite 
sensitivity of Raman scattering to biochemical components. 
2.6.4.c Gastrointestinal tract 
The gastrointestinal tract encompasses the digestive system from the 
mouth, through the esophagus, stomach, intestines, colon to the rectum. The 
entire organ system, with the exception of parts of the small intestine, is 
accessible directly (to the mouth) or via an endoscope. In developing Raman 
spectroscopy as a diagnostic tool for the GI tract, the challenge is in the 
development of a fiber probe that can be inserted through the endoscope and 
placed in contact with the tissue of interest in a stable manner for the duration 
of data acquisition. Numerous groups have focused their attention on various 
parts of this organ for Raman based detection. 
2.6.4.c.i Mouth 
Oral tissue is particularly easy to access since endoscopy is not required, 
mitigating the size constraints of the probe for in vivo Raman measurements. 
Oral cancer incidence has been increasing over the last 40 years in the US and 
is a larger problem globally, For example, it accounts for 10% of all cancers in 
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India.202 This cancer can rapidly spread, which emphasizes the need for early 
detection and monitoring. Murali Krishna et al. report the discrimination of 
normal control, premalignant, and cancerous sites from 104 patients with 
prediction accuracies ranging from 72-96%.222 In a more recent study, the same 
group investigated the potential for Raman spectroscopy to detect malignancy 
associated changes/cancer field effects in a cohort of 84 oral cancer and age-
matched control patients.223 Comparison of non-cancer locations in a smoking 
and non-smoking population demonstrated prediction accuracies from 75-98% 
with most of the misclassifications occurring between control locations in 
cancer patients and locations in smoking healthy controls. This work further 
demonstrates the sensitivity of Raman scattering to subtle biochemical changes 
which may precede macroscopic disease.224,225 Another group reported the 
discrimination of normal oral tissue from three separate lesion categories with 
per-class accuracies ranging from 82-89% in 199 patients and 96% sensitivity 
and 99% specificities for normal versus malignant and 99% and 98% 
respectively, for normal versus potentially malignant.226 One variability study 
of age and tobacco-related pathological change for oral cancer and precancer 
demonstrated sensitivity to age-related changes in Raman spectra, however the 
inclusion of this diverse control population had no impact on classification of 
normal and abnormal conditions.227 Given the critical need for oral cancer 
detection particularly in low resource settings and the excellent performance 
that can be achieved in its detection with Raman spectroscopy, this area of 
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research is ripe for clinical translation but needs a low cost instrument for its 
success. The optical device market has seen a recent increase in the number of 
handheld Raman devices available commercially; these are sold mostly for the 
identification of pure chemicals and trace elements. However, these devices 
indicate that the technology exists for the miniaturization of current clinical 
Raman systems which could in turn make the prospect of commercial 
translation of Raman systems in low resource settings a reality.  
2.6.4.c.ii Esophagus 
Barrett’s esophagus is a consequence of gastroesophageal reflux that 
has been associated with an increased risk of esophageal adenocarcinoma. By 
adapting Raman fiber optic probe designs for endoscopic compatibility, in situ 
measurements of this disease target have been enabled by many groups. Wilson 
et al demonstrated the potential for in vivo spectral acquisition in a cohort of 65 
Barrett’s esophagus patients, with sensitivities and specificities of 86-88% and 
88-89%, respectively for discriminating dysplastic and high-risk lesions from 
non-dysplastic and low-risk cases.128 This demonstration of a clinically-useful 
Raman instrument with endoscopic compatibility and 5 second integration 
times was an early indication of the ability of in vivo Raman spectroscopy to 
access an internal organ. More recent work by another group has demonstrated 
real-time performance of Raman spectroscopy during endoscopy in 373 
patients with integration times of 0.2 seconds per acquisition and could 
discriminate high-grade dysplastic Barrett’s esophagus from normal and non-
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dysplastic tissue with 87% sensitivity and 84.7% sensitivity.147 Other work has 
demonstrated the importance of considering the anatomical location of a Raman 
measurement; in a study of 107 patients, inter-organ variability (between the 
esophagus and stomach) was significant compared to intra-organ variability and 
neoplastic change.145 These results support the need for comprehensive libraries 
of disease spectra and a thorough understanding of healthy and diseased tissues. 
2.6.4.c.iii Stomach 
As a leading cause of cancer-related death worldwide202, stomach 
cancer has been another popular detection target for Raman spectroscopy.228-230 
As with the esophagus, integrating Raman fiber probes with standard 
endoscopes has enabled in vivo evaluation of gastric malignancies. Utilizing an 
endoscope compatible probe, linear component tissue model, and classification 
and regression trees, Huang et al. reported 94% sensitivity and 93.4% 
specificity for discriminating normal gastric tissue from cancer in 67 patients 
undergoing endoscopy with biopsy.231 Huang et al. have also reported a 
statistically robust study where 450 patients undergoing upper endoscopy were 
measured with Raman spectroscopy to train a discrimination algorithm.232 This 
work was one of the first reports to prospectively discriminate gastric precancer 
in real-time using Raman spectroscopy, achieving a sensitivity of 81% and a 
specificity of 88%. In another study by the same group, researchers investigated 
stomach ulcers in 71 patients and found that Raman endoscopic measurements 
could differentiate normal mucosa, benign and malignant ulcers with 82-90% 
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sensitivity and 93-95% specificity.233 A related report by this group investigated 
the ability of Raman techniques to perform multi-class discrimination of 
normal, precancer, and early stage gastric cancer in a cohort of 83 patients, and 
demonstrated sensitivity to early stages of the carcinogenic process.234 Finally, 
a report combining Raman techniques with near-infrared autofluorescence 
signatures (n=81, 97.9% sensitivity & 91.5% specificity)235 demonstrated 
similar results for in vivo detection for cohorts gastric cancer patients. 
2.6.4.c.iv Colon/Intestine 
Colorectal cancer is a major disease entity, ranking among the top three 
cancers worldwide for estimated new cases and cancer-related deaths.202 
Colonoscopy is the most sensitive technique available for screening and early 
detection of cancer or precancerous polyps and routine colonoscopy screening 
for adults over 50 has become the standard in countries like the United States. 
However, benign polyps often develop, which can limit its sensitivity and 
potentially complicate intervention. Preliminary Raman studies based on ex 
vivo samples and small in vivo cohorts have been reported, discriminating 
benign and malignant polyps. One in vivo study has investigated the impact of 
the colon segment on the acquired Raman signal from 50 colonoscopy patients, 
but found that the between-segment variability was less influential than 
malignant status.236 The same group has since reported an in vivo study 
combining both fingerprint and high-wavenumber Raman spectroscopy during 
endoscopy in order to achieve 90% sensitivity and 83% specificity for 
77 
 
separating adenomatous and hyperplastic polyps in real-time.174 In other 
studies, our group has demonstrated the potential for endoscopic Raman 
spectroscopy to discriminate inflammatory bowel diseases in a 53 patient 
cohort, demonstrating the potential of Raman spectroscopy to detect subtle 
changes in tissues related to inflammatory diseases,80 another significant 
clinical problem that has seen a rise in incidence in recent years. 
2.6.4.d Other diagnostic targets 
While the majority of reports published on large clinical in vivo Raman 
studies have been focused on the above tissues, other diseases have also been 
studied with Raman spectroscopy. Lung cancer is one of the most common 
causes of cancer related death impacting millions of people annually.202 Similar 
to other endoscopic studies with Raman scattering, investigation of this disease 
has been conducted in ex vivo samples with near 100% accuracy. A 
bronchoscope compatible Raman fiber probe has been used to study the 
potential of Raman spectroscopy for the detection of pre-neoplastic lesions in 
the bronchial tree in 26 patients.237 However, no reports on the performance of 
this technique for a large cohort of lung cancers in vivo were found. 
Surgical guidance is another areas of active research for clinical Raman 
spectroscopy, where researchers have developed biopsy-needle compatible 
fiber probes to detect micro-calcifications for breast cancer diagnosis as well as 
SORS techniques to determine breast cancer margin status during surgical 
resection with excellent results. Raman spectra of core needle biopsies could 
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successfully be used to identify the presence of micro-calcification in these 
specimens with 82% accuracy.238 Depth-resolved SORS was used to assess the 
ability of this technique to detect the presence of cancer cells in excised breast 
specimens for margin assessment with 95% sensitivity and 100% specificity.178 
A large clinical study is currently in progress to validate these findings intra-
operatively. Another study has focused on the ability of Raman spectroscopy to 
assess axillary lymph nodes during breast surgery.239 Preliminary reports for 
this study utilized frozen tissue section of lymph nodes from 58 patients 
immediately after excision from the body and reported 81% sensitivity and 97% 
specificity. However, the authors indicate that freshly excised samples could be 
analyzed for intra-operative evaluation. Another application for Raman 
spectroscopy in surgical guidance is for brain surgery. While restricted to small 
cohort studies at this point, researchers have characterized a surgery compatible 
Raman probe based system240 and demonstrated discrimination of normal brain 
from dense cancer and normal brain invaded by cancer cells with up to 93% 
sensitivity and 91% specificity for grade 2 to grade 4 gliomas in 17 patients.241 
This work shows continued promise for surgical guidance based on Raman 
scattering techniques however, it also requires expanded recruitment for 
validation. 
A majority of the research for Raman spectroscopy techniques has 
focused on disease diagnosis of tissues in situ. However, clinically relevant 
diagnostics have also been investigated for samples removed from the body, 
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especially pertaining to blood analytes. Puppels et al. published work utilizing 
a spectral library to prospectively and rapidly evaluate blood cultures for 
bacterial and fungal pathogens, achieving 92% classification accuracy from 121 
patient samples.242 More commonly, researchers introduce SERS particles into 
ex vivo specimens in order to improve sensitivities. These have been applied for 
numerous detection endpoints including a recent publication for 
nasopharyngeal cancer detection243 where blood plasma samples from 156 
patients were analyzed with SERS. The study demonstrated 95% sensitivity and 
91% specificity for discriminating healthy volunteers from cancer patients. Liu 
et al. used SERS particles with serum from healthy and bladder cancer patients 
in order to improve early stage detection. By combining the sensitivity of SERS 
with advanced machine learning genetic algorithms, the researchers were able 
to achieve 94% diagnostic accuracy in a cohort of 91 patients.244 Zeng et al. 
have likewise investigate SERS techniques for blood plasma analysis aimed at 
improved gastric cancer detection.245 Samples from 65 patients were analyzed 
with polarized illumination of SERS particles and multivariate techniques. The 
study indicated great promise for specific circularly-polarization regimes with 
100% sensitivity and 97% specificity for non-invasive gastric cancer detection. 
Another long-standing non-invasive target includes blood glucose monitoring. 
Feld et al. developed compound hyper- and parabolic concentrators for 
transdermal blood glucose measurements, however, there have been no large 
cohort studies reported with this device.84,130 Other reports have utilized Raman 
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scattering to look at cerebral spinal fluid samples from 61 patients ex vivo to 
diagnoses tuberculous meningitis and achieved 91% sensitivity and 82% 
specificity.246 This is just a glimpse of the numerous ex vivo applications of 
Raman spectroscopic techniques that are relevant for clinical detection and 
diagnostics. 
Raman spectroscopy has been used in the eye to study such conditions 
as macular degeneration. Gellerman et al. developed a resonance Raman 
approach at 488 nm to study the impact of carotenoids in the skin and eye.159 In 
one application of this approach, Chakaravarthy et al., measured macular 
pigment from 107 patients and correlated with heterochromatic flicker 
photometry to evaluate antioxidant pigment of the retina, however, the 
correlations were low and further investigation was merited.160 Using the same 
approach, Stevenson et al. demonstrated the improved effect of antioxidant 
supplementation in age related macular degeneration patients in a study of 433 
patients in vivo.158 
2.6.5 Summary 
Despite the impressive work presented here in a selection of clinical 
fields, there remain a number of challenges that stand in the way of clinical 
translation for Raman based technologies for widespread human use. 
Demonstrating the safety of these devices to regulatory agencies is a vital step 
that must be undertaken for translation. Practically speaking, there is a need for 
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robust system design with consistent internal calibration, such that with little 
training, a user can setup a system and collect repeatable data. For this to be 
realized, low-cost or long-lasting, durable, high-performance fiber optic probes 
(or an equivalent light delivery device) are required. Having reliable and 
consistent performance for interfacing the sample and system is pivotal for the 
transition from research instrument to clinical relevance. To this end, there is 
also a need for inter-system calibration and large libraries of spectral data that 
can be transferred and compared between instruments, to expand the utility of 
the devices for multiple medical targets. Standardized and reliable methods for 
data analysis are necessary to condense the feature-rich Raman spectra obtained 
by these instruments into not only the salient features used for a clinical 
evaluation, but also communicated to the user in a simple, easily interpretable 
format, including clinically relevant metrics for evaluation (ROC, 
sensitivity/specificity). Preliminary work on many of these aspects for clinical 
translation are ongoing, but continued effort is needed to facilitate the transition 
from benchtop to bedside. Of course, it is of the utmost importance that the 
technologies developed provide new and meaningful information about a 
clinical target; therefore, seeking collaboration and input from the medical 
community is paramount to ensure that research efforts of Raman techniques 
are directed at relevant needs in medicine and surgery. Finally, the largest 
obstacle at this point to clinical translation is the need to demonstrate the added 
value of these optical technologies over or in parallel with existing medical 
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devices in large cohorts studies based on patient outcomes and relative to 
meaningful and accepted gold standards.  
The various applications described above demonstrate the potential of 
Raman spectroscopy to affect patient care. And yet few systems based on 
Raman spectroscopy have been processed through regulatory approval and 
commercialized successfully. The external barriers towards the adoption of this 
technology lies in the limited size of the target market revenue which tends to 
hold back potential industrial partners and investors. Regardless, there have 
been some successes including the system by River Diagnostics which has 
successfully sold Raman instruments for the assessment of skin in the cosmetic 
industry (albeit not for a clinical application) and Verisante Technology which 
has most recently released Raman based devices for oral and skin cancer 
diagnosis. These commercial devices indicate that the barriers to the clinical 
implementation of Raman spectroscopy are not insurmountable and widespread 
acceptance of this technology can be achieved. 
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CHAPTER 3 
 
APPLICATION DRIVEN ASSESSMENT OF PROBE DESIGNS FOR 
RAMAN SPECTROSCOPY 
 
3.1 Abstract 
In vivo Raman spectroscopy has been utilized for non-invasive, non-
destructive assessment of tissue pathology or physiological state in a variety of 
applications largely through the continued development of fiber optic probes to 
interface with samples of interest. Fiber optic probes can be designed to 
optimize collection of Raman-scattered photons from application-dependent 
depths, and this critical consideration should be addressed when planning a 
study. Herein we investigate four unique probe geometries for sensitivity to 
superficial and deep signals through a Monte Carlo model that incorporates 
Raman scattering and fluorescence for the first time. Experimental validation 
was conducted using biological tissues and TiO2 and polytetrafluoroethylene 
(PTFE) phantoms, with the intention of more accurately recapitulating in vivo 
performance scenarios. The behavior of each probe design evaluated 
(unmodified collection, Gaser, superficially focused micro lens, and deep 
focused micro lens) was modeled and demonstrated strong correlation with 
experimental results obtained through biological tissue and phantom testing. 
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Testing in biological tissues revealed that superficially focused micro lens and 
Gaser designs had superior performance at shallow depths (< 1 mm), whereas 
the deep focused design yielded the highest signals deep within tissue. The 
probes demonstrated similar performance for TiO2 and PTFE experiments at all 
depths investigated. The contrast in results between the TiO2/PTFE and 
biological tissues underscores the importance of incorporating the optical 
properties of a given application when designing a fiber optic probe, as the high 
reduced scattering coefficients of the synthetic phantoms negated the benefits 
of beveling and lenses that were originally optimized for use in air. The model 
presented here can be easily extended for optimization of entirely novel probe 
designs prior to fabrication, reducing time and cost while improving data 
quality. 
 
3.2 Introduction 
In vivo Raman spectroscopy has been utilized for non-invasive, non-
destructive assessment of tissue pathology or physiological state in a variety of 
applications.1 The majority of such applications are enabled by use of fiber optic 
probes to interface with samples of interest. Almost all fiber optic probe designs 
collect and integrate the signal obtained from a small volume of the sample 
beneath the probe tip. Due to the weak nature of the Raman Effect, it is 
important to maximize the signal to noise ratio obtained from the tissue of 
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interest at the particular depth of interest. Fiber optic probes can be designed to 
optimize collection of Raman-scattered photons from application-dependent 
depths, and this critical consideration should be addressed when planning a 
study. The desired depth alone does not provide sufficient information to 
optimize the design for a specific application. There is a need for a platform 
that allows investigators to 1) predict Raman scattered photon distribution in 
the sample of interest and 2) optimize fiber optic probe excitation and collection 
geometries to ensure maximum signal to noise at the desired depth. Such a tool 
must take into consideration Raman scattering, fluorescence, elastic scattering, 
and absorption in order to accurately predict how a probe design will perform 
for a given application.    
The clinical applications driving innovative probe designs are vast, and 
have been recently reviewed by Pence et al.1 Broadly, these applications can be 
grouped into three depth ranges: superficial (10-200 μm),2-13 subsurface (200-
2000 μm),14-18 and deep (greater than 2000 μm);19-22 examples of such 
applications are provided in Table 3.1. Raman probe designs have been 
developed within each of these depth categories to optimize data collection for 
specific applications as reviewed by Stevens et al.23 Two distinct probe designs 
have been demonstrated for superficial as well as multiple millimeter depths. 
For increased performance at shallow depths, a confocal detection design was 
implemented by Wang et al.24 This probe design combined beveled fibers and 
a spherical ball lens to achieve increased signal performance in the first 300 μm 
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of tissue relative to unmodified fiber probe designs. At the other extreme, the 
standard for detecting signals buried deep in scattering tissues is based on 
principles of random walk and multiple scattering. Spatially offset Raman 
spectroscopy (SORS) probes have been designed and constructed for specific 
applications such as bone in order to take advantage of the probabilistic paths 
for photons to travel deeper into the sample when the source and detector 
elements of the probe have a greater separation.17, 25 Between these two 
extremes lies a spectrum of probe designs that incorporate various strategies to 
steer both the excitation and collection fibers to measure relatively shallow or 
deep layers.23 Each of these probe designs collects a volume-averaged signal 
from the sample beneath the probe tip; however, properly considering the 
application can enable dramatically improved signal detection from the targeted 
sample depth.  
 
Table 3.1. Depth-sensitive pathologies from Raman spectroscopy literature. 
Superficial 
(10-200 μm) 
-Epithelial precancers and cancers  
(cervix,26 esophagus,27 stomach,28 colon,29 skin,30,31 lung,32 
oral cavity,33 and bladder34) 
-Dermatitis35 
-Inflammatory bowel disease36 
-Barrett’s esophagus37 
Subsurface 
(200-2000 μm) 
-Cervical remodeling during pregnancy (stroma)38,39 
-Vulnerable plaque assessment in arteries40 
-Tumor margin assessment (breast,41 brain42) 
Deep  
(greater than 2 
mm) 
-Transcutaneous assessment of bone43,44 
-Detection of malignant breast calcifications45 
-Detection of urologic stones46 
 
Probe designers generally use ray tracing to determine optimal light 
delivery and collection geometries for probe performance in air. Ray tracing 
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software allows for determination of the excitation and collection cone angles 
and their overlap. However, optimizing designs for use in non-scattering media 
does not fully predict performance in biological tissue where optical scattering 
can be substantial. Accounting for the interactions between light and tissue is 
vital to accurately determine probe behavior. Prediction of light transport in 
tissue can be modeled using Monte Carlo (MC) simulations, in which the 
radiative transport equation can be solved for complex scenarios with an 
accuracy that depends upon the computational burden. MC models were 
originally developed to track photon distribution and absorption in turbid media 
and have been extended for numerous and varied optical applications including 
fluorescence and Raman scattering.10, 25-30 Application-driven probe design 
must bridge these two approaches, ray tracing and laser-tissue interaction 
models, to truly optimize fiber optic probes for biological targets. 
Specifically for Raman scattering, a few groups have implemented these 
MC models. Matousek et al. developed an MC model for layered media for 
investigation of chemical powders.25 Enejder et al. investigated system 
geometry effects on blood spectra31 and Shih et al. used an MC model to correct 
Raman spectra for tissue scattering and absorption artifacts.29 Two separate MC 
models have been developed for evaluating superficial fiber optic probe 
collection geometries for epithelial detection applications.10, 30 Furthermore, 
Keller et al. developed an MC model for investigating SORS approaches in 
turbid media.28 Reble et al. implemented a Raman MC model to systematically 
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investigate the impact of tissue absorption and scattering properties on the 
performance of probes with different collection geometries.32 Each of these 
models has proven valuable for investigating detection of Raman signals in 
complex turbid media; however all have investigated Raman scattering effects 
in isolation. As a Raman fiber optic probe detects competing signals from 
tissue, especially fluorescent and diffusely scattered photons, it is vital for a 
model to consider each of these competing phenomena while identifying the 
optimal probe design for a target application.  
Herein, we investigate the impact of incorporating application-specific 
parameters when choosing or developing a Raman probe to measure depth 
dependent signals using a MC model that tracks Raman and fluorescent photons 
paired with experimental validation in both common optical phantoms and 
biological tissues. This approach allows researchers to more accurately 
recapitulate and/or predict in vivo performance scenarios. 
 
3.3 Methods 
3.3.1 Fiber optic probes 
Four unique fiber optic probes were experimentally tested and their 
performance was modeled using the MC simulation explained below. All of the 
fiber optic probes investigated in this study were designed for excitation at 785 
nm and have seven collection fibers (300 μm diameter) surrounding one 
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excitation fiber which total 2.1 mm in outer diameter. All of the probes have 
filters on the excitation fiber such that only 785 nm light passes to the sample 
and all of the collection fibers have filters that block the 785 nm laser light. 
Each probe that was evaluated has a unique configuration, which are all drawn 
to scale based upon results from ray tracing software (Radiant Zemax, Bellevue, 
WA) shown in Figure 3.1. The four probes include 1) a conventional design 
that has no lenses or beveling with standard 0.22 NA fibers (±12.7° acceptance 
angles, 400 μm diameter excitation fiber, EmVision LLC) (Figure 3.1A); 2) a 
beveled collection fiber design that has superficial overlap of the excitation and 
collection cone angles (35-55.3° acceptance angles, 400 μm diameter excitation 
fiber, Gaser probe by Visionex Inc.) (Figure 3.1B); 3) a micro lens design with 
a polished 3 mm diameter sapphire plano convex lens coupled to a 1 mm thick 
MgF2 window that yields excitation and collection cone overlap deep within a 
sample (5-33.8° acceptance angles, 200 μm diameter excitation fiber, EmVision 
LLC) (Figure 3.1C); and 4) a micro lens design with a polished 2 mm diameter 
sapphire plano convex lens coupled to a 1 mm thick MgF2 window that results 
in excitation and collection cone overlap at the surface of the sample (21.2-
35.8° acceptance angles, 200 μm diameter excitation fiber, EmVision LLC) 
(Figure 3.1D). Probe-specific acceptance angles and collection fiber surface 
cross-sectional areas are listed in Table 3.2.  
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Figure 3.1. Probe collection geometries. Probe geometry cross section based on 
ray tracing: (A) unmodified, (B) beveled, (C) deep micro lens, and (D) 
superficial micro lens. Overlap between excitation and collection cones denote 
theoretic probe performance in air. 
 
 
Table 3.2. Probe specifications.  
Unmodified Beveled Micro lens deep Micro lens shallow 
Collection surface 
cross-sectional area 
0.753 mm2 0.487 mm2 1.359 mm2 0.372 mm2 
Acceptance angle ± 12.7° -12.7° to 38.0° 4.9° to 33.8° 21.2° to 35.8° 
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3.3.2 Monte Carlo model 
A multimodal MC model, incorporating diffuse reflectance, 
fluorescence, and Raman scattering was developed in MATLAB (The 
Mathworks, Inc., Natick, MA) by incorporating a previously existing multilayer 
model for diffuse reflectance.26 Fluorescence generation and photon 
propagation were incorporated as previously described.27,28 Raman scattering 
and photon propagation were also incorporated based on prior work.29 Finally, 
angular dependent photon injection and collection was included to investigate 
the influence of probe geometry at the sample interface. The general algorithm 
for the multimodal MC model can be seen in Figure 3.2. Briefly, 100,000 seed 
photons are injected from the excitation fiber (Gaussian profile) into the top 
layer of the sample and propagate in the presence of absorption and elastic 
scattering. After a photon migrates and deposits a discrete photon weight (based 
on Beer’s law), Raman scattering can occur (probability check: 𝜉𝜉 < 𝑘𝑘𝑅𝑅𝑅𝑅 𝜇𝜇𝑠𝑠,𝐸𝐸𝐸𝐸𝜇𝜇𝑠𝑠,𝐸𝐸𝐸𝐸+ 𝜇𝜇𝑎𝑎,𝐸𝐸𝐸𝐸), where ξ is a random number [0,1].29 If no Raman event occurs, 
then fluorescence absorption and emission is possible (probability check: 𝜉𝜉 <1 −  𝑒𝑒−𝜇𝜇𝑎𝑎,𝐹𝐹𝐹𝐹𝛿𝛿), where δ is the calculated photon step size.30 For any of these 
events (elastic scattering, Raman scattering, or fluorescence), a new photon 
trajectory is calculated and the photon propagates (based on appropriate layer 
optical parameters) until either the photon weight is decremented and ended as 
per standard MC roulette routines or the photon escapes the model layers. If a 
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photon is scattered through the surface of the topmost layer and within the 
detection diameter and acceptance angle for the collection fiber, the remaining 
photon weight is considered detected. For this model, Raman scattering and 
fluorescence generation are considered competing processes with respect to 
excitation photons. A few assumptions have been made for the implementation 
of this code: 1) photon weight is deposited in the voxel at the end of the photon 
step, 2) Raman scattering determination happens prior to fluorescence 
absorption (Raman scattering is an instantaneous process whereas fluorescence 
occurs between 10-7 to 10-9 seconds), 3) secondary Raman scattering and 
fluorescence generation are neglected, 4) all Raman and fluorescence photons 
are modeled at a single wavelength for simplicity, 5) Raman scattering and 
fluorescence events are isotropic, and 6) the model is implemented as a plane 
bisecting the center of the excitation fiber and a single collection fiber, and 
could be extended via rotational symmetry. Due to the relatively low 
concentrations and cross-sections of Raman scatterers in biological tissue, the 
likelihood of a Raman event was scaled by 104 to reduce computational burden. 
This scaling factor of 104 was chosen such that the model had roughly equal 
probability for Raman scattering and fluorescence without the computational 
burden of modeling 106 fluorescence photons per single Raman scattering 
event. All modeling sets were run at least 3 times to ensure consistent 
performance.  
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Figure 3.2. Flowchart for tracing photons in multi-layered media with 
multimodal Monte Carlo simulation. Model parameters: 𝜆𝜆𝐸𝐸𝐸𝐸= wavelength, 
excitation photon; 𝑠𝑠 = photon step size; 𝑑𝑑𝑏𝑏 = distance to layer boundary; 𝜇𝜇𝑡𝑡,𝜆𝜆 = 
total attenuation coefficient at 𝜆𝜆; 𝜆𝜆𝐸𝐸𝐸𝐸 = wavelength, emission photon; 𝜉𝜉 = 
random number [0,1]; 𝑘𝑘𝑅𝑅𝑅𝑅 = Raman scattering cross section; 𝜇𝜇𝑠𝑠,𝐸𝐸𝐸𝐸 = scattering 
coefficient at 𝜆𝜆𝐸𝐸𝐸𝐸; 𝜇𝜇𝑠𝑠,𝐸𝐸𝐸𝐸 = scattering coefficient at 𝜆𝜆𝐸𝐸𝐸𝐸; 𝜇𝜇𝑎𝑎,𝐹𝐹𝐹𝐹 = fluorescence 
absorption coefficient; 𝑊𝑊𝐸𝐸𝐸𝐸 = photon weight at 𝜆𝜆𝐸𝐸𝐸𝐸; 𝑊𝑊𝐸𝐸𝐸𝐸 = photon weight at 
𝜆𝜆𝐸𝐸𝐸𝐸; 𝑊𝑊𝐹𝐹𝐹𝐹 = photon weight of fluorescence at 𝜆𝜆𝐸𝐸𝐸𝐸; 𝑄𝑄𝑄𝑄 = fluorescence quantum 
yield. 
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The optical properties used as inputs in this model (Table 3.3) were 
based on both published values26 (absorption and scattering coefficients, index 
of refraction, and anisotropy factors) as well as experimentally derived values 
(Raman cross section and fluorescence quantum yield). To mitigate the impact 
of experimental setup on model parameters, experimental results were averaged 
across all four probe designs prior to simulation.  
 
Table 3.3. Input parameters of the Monte Carlo simulation. 
Optical Properties Muscle Adipose 
μa,Ex at 800 nm (1/cm) 0.54* 1.08* 
μs,Ex at 800 nm (1/cm) 66.70* 202.00* 
μa,Em at 900 nm (1/cm) 0.32* 1.25* 
μs,Em at 900 nm (1/cm) 88.70* 108.00* 
Scattering anisotropy (g) 0.93* 0.90* 
Raman cross-section (kRS)  0.92 7.43 
μa,Fl fluorescence (1/cm) 7.20 3.60 
Fluorescence quantum yield 1.34 0.34 
Index of refraction (n) 1.37* 1.45* 
*Denotes values reported in 26 
 
3.3.3 Raman spectroscopy system 
All Raman measurements were acquired using a cart-based clinical 
Raman spectroscopy system which used a 785 nm diode laser (Innovative 
Photonics Solutions, Monmouth Junction, NJ) coupled to an imaging 
spectrograph (Holospec f/1.8i, Kaiser Optical Systems, Ann Arbor, MI) and a 
thermoelectrically cooled charge-coupled device camera (Pixis 256BR, 
Princeton Instruments, Princeton, NJ), all operated by a laptop computer. The 
system was wavelength calibrated using a neon-argon lamp, and the Raman 
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shifts were calculated using acetaminophen and naphthalene standards. Spectral 
response correction was determined using a National Institutes of Standards and 
Technology (NIST)-calibrated tungsten lamp. All measurements were 
background subtracted, noise smoothed, and fluorescence subtracted as 
described previously.27 
3.3.4 Adipose and muscle tissue experiments 
Raman signals were acquired from semi-infinite porcine muscle and 
adipose tissues to simulate biological samples. The porcine tissues were 
commercially acquired and refrigerated until use, and were kept on ice 
throughout the experiment. Three hundred μm thick slices of muscle tissue were 
obtained via cryosection and were layered over the semi-infinite slab of adipose 
tissue in 300 μm steps until a total muscle tissue thickness of 1800 μm was 
achieved (Figure 3.3A-B). Raman spectra were acquired at all thicknesses with 
each probe, and their ability to detect the superficial (muscle) and deep 
(adipose) tissues was assessed using two methods: the first method calculated 
the ratio of a peak intensity specific to muscle (1003 cm-1 peak corresponding 
to symmetric aromatic ring breathing in phenylalanine27) and a peak intensity 
specific to adipose tissue (1066 cm-1 peak corresponding to C-C stretch28) 
(Figure 3.3 C). These peaks were chosen due to the similar intensities exhibited 
in pure measurements so that stable peak ratios could be calculated.  The second 
method used non-negatively constrained partial least squares (PLS) to 
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determine the contributions made by the muscle and the adipose tissue as a 
function of muscle thickness using the full spectrum.27  
 
 
Figure 3.3. Experiment setup: (A) Schematic of experimental setup and (B) 
image for depth response characterization with probe contacting the surface of 
the superficial layers (porcine muscle or TiO2) above a semi-infinite base 
(porcine adipose or PTFE, figure not to scale). (C) Pure spectral components 
measured from porcine adipose and muscle tissue samples of semi-infinite 
thickness (beveled probe design). (D) Representative signal tradeoff between 
pure components with increasing thickness of superficial TiO2 layer (100 μm 
steps, beveled probe design). Arrows in (C) and (D) indicate peak positions 
used in ratiometric analyses. 
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3.3.5 Synthetic phantom experiments 
Raman spectra were acquired separately from a polytetrafluoroethylene 
(PTFE) puck and sheets of titanium dioxide (TiO2) particles27 in a silicone-
elastomer base to determine their “pure” Raman signals. Next, 100 μm thick 
sheets of the TiO2 phantom were serially placed over a semi-infinite PTFE puck 
(1 cm thick) until a TiO2 thickness of 1800 μm was achieved (Figure 3.3A). 
The spectral tradeoff as a function of TiO2 layer thickness is displayed in Figure 
3.3D. Pure PTFE is shown in black, which transitions down to an 1800 μm thick 
TiO2 layer shown in light gray, with steps in 100 μm increments. As the TiO2 
layer thickness increased, the signal changed from a dominant PTFE signature 
to a primarily TiO2 spectral shape. Raman spectra were collected at each 
thickness using all four probes to assess the efficacy of each probe in measuring 
superficial (TiO2) and deep (PTFE) Raman signals obtained as a function of 
superficial thickness. Again, the ratio of the TiO2 to PTFE signal was assessed 
using two methods: the first method calculated the ratio of the TiO2 layer peak 
(1412 cm-1 corresponding to CH3 bending28) to the PTFE layer peak (1300 cm-
1 corresponding to CF2 asymmetric stretching29) (Figure 3.3D). The second 
method used non-negatively constrained PLS to determine the respective 
contributions made by the TiO2 phantom and the PTFE puck.30  
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3.4 Results and discussion 
3.4.1 MC simulations 
The mean results ± standard deviation of triplicate runs from the MC 
model simulation for porcine adipose and muscle tissue are depicted in Figure 
3.4. A ratio of muscle tissue signal to adipose tissue signal was calculated by 
integrating the Raman photons detected from the muscle and adipose tissue 
layers respectively, as shown in Figure 3.4A. An increase in muscle to adipose 
tissue signal ratio as the muscle thickness increases is observed in all probe 
designs, and the modified probe designs have higher muscle to adipose ratios 
at muscle thicknesses ≥ 600 μm. The total Raman photons detected in the MC 
model from each probe at each muscle tissue thickness are shown in Figure 
3.4B. The deep focused micro lens probe detected the most photons at all 
muscle tissue thicknesses, which has the highest cross-sectional area (Table 
3.2), has the largest excitation and collection cone overlap (Figure 3.1), as well 
as wide acceptance angles (Table 3.2). The shallow focused micro lens and the 
beveled design detected about half the number of photons compared to the deep 
focused micro lens. The unmodified design detected by far the fewest photons 
of all of the designs at all depths simulated, which has the lowest volumetric 
overlap of excitation and collection cones (Figure 3.1) and narrow acceptance 
angles (Table 3.2).  
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Figure 3.4. MC simulation results for probe designs as a function of superficial 
muscle layer thickness. (A) Modeled ratio of Raman muscle to adipose tissue. 
(B) Total Raman photons detected. (C) Raman photons detected from 
superficial layer. (D) Raman photons detected from deep layer. (E) 
Fluorescence photons detected from superficial layer. (F) Fluorescence photons 
detected from deep layer. 
 
Detected photons originating in the superficial muscle tissue and the 
underlying adipose tissue were separately analyzed to evaluate depth sensitivity 
for each probe. For the detected superficial layer Raman photons, the signal 
intensity between 100 μm to 300 μm thick muscle tissue remained 
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approximately equal for all probe designs (Figure 3.4C). Beyond 300 μm thick 
muscle tissue, detected Raman signal from the superficial layer decreased with 
muscle thickness. Similarly for deep layers, detected Raman photons decreased 
monotonically from 100 μm to 1800 μm of muscle layer thickness for all probe 
designs (Figure 3.4D). It is also worth noting that as expected, the total number 
of Raman photons generated in the superficial layer did increase with the 
thickness of the muscle layer, despite the decreasing detection of these photons 
in the model. 
In addition to tracking Raman photons, detected fluorescent photons 
were plotted based on the layer of tissue in which they originated. All probe 
designs detected higher fluorescence signal from the superficial muscle layer as 
the layer thickness increased (Figure 3.4E), whereas fluorescence from the deep 
layer decreased with muscle thickness in all probe designs (Figure 3.4F). The 
highest signals for both layers were detected by the deep focused micro lens 
probe design while almost equal values for both superficial and deep layers 
were collected by beveled and shallow focused micro lens designs. The muscle 
tissue has higher fluorescence absorption and quantum yield coefficients 
compared to the adipose tissue (Table 3.3). The higher fluorescence and 
increasing thickness of the muscle layer account for the increase in fluorescence 
detection from the superficial muscle layer (Figure 3.4E) and the decrease in 
fluorescence detection from the deep adipose tissue (Figure 3.4F) as the muscle 
tissue thickness increases. Probe designs that more efficiently collect Raman 
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scattered photons are also more efficient at detecting the broad spectrum 
autofluorescence from the samples. 
With the exception of detected superficial Raman photons (Figure 
3.4C), these simulation results all agree with theoretical understanding of bulk 
material properties for photon distribution. Since nearly 90% of the excitation 
photons are converted into these optical endpoints, it is likely that the decreased 
detection of Raman photons observed in Figure 3.4C is due to the complex 
interaction of superficial layer thickness and the probabilities for Raman 
scattering and fluorescence events in that top layer. While the superficial layer 
remains thin, appreciable excitation photons are Raman scattered prior to the 
overwhelming fluorescence generation that is evident at thicker superficial 
layers. To verify this result, non-competing simulations were conducted for the 
same layers (either only Raman scattering in modeled layers or only 
fluorescence). In each of these simulations, the trends for detected Raman 
scattering and fluorescence phenomena in superficial and deep layers matched 
the curves in Figure 3.4E-F, which agree with photon distribution theory for 
turbid media. This result indicates the importance of accounting for not only 
relative changes in scattering and absorption within a tissue of interest, but also 
the relative strength of competing optical processes for a target application. 
While implementing a numerical simulation may be simpler than 
precisely controlling tissue phantoms and biological samples, models rely on 
assumptions with associated limitations. Like all probabilistic or stochastic 
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models, this simulation requires many photons to develop an accurate result. To 
exacerbate this requirement, the competing optical phenomena integrated in this 
simulation would require the use of extremely large numbers of photons if 
scaling factors were not utilized in order to obtain consistent and reliable results. 
To circumvent this requirement, the probability of a Raman scattering event 
was scaled by 104 times for layer properties relative to the probability of 
fluorescence generation. Furthermore, for every scattering step of an excitation 
photon, a discretely weighted computational fluorescence sub-photon could be 
generated that propagates based on layer parameters. As this model was 
implemented in a MATLAB environment and the inclusion of multiple optical 
phenomena add additional calculations for independent tracking, relatively 
small simulations (100,000 photons) were implemented for model comparison. 
Due to the high probabilities of both Raman scattering and fluorescence, each 
simulation resulted in roughly 108 – 109 photons that were tracked through 
extinction or detection.  To verify model stability, models with 106 seed photons 
were also run for multiple depths and probe designs (data not shown). These 
model outputs fell well within the standard deviations indicated for the smaller 
model runs. Like many MC models for Raman scattering and fluorescence, this 
model neglects secondary Raman and fluorescence events. Inclusion of these 
events would likely be incremental, but could more accurately represent optical 
interactions, especially due to the relatively high frequency of fluorescence that 
has the potential to cause secondary fluorescence and Raman scattering. These 
125 
 
secondary events could also be included as model noise for a more direct SNR 
comparison with experimental values.  
Despite these limitations, this model provides valuable insight into the 
complex interaction of multiple optical processes detected by fiber optic probes. 
These simulation results afford a probabilistic basis for comparison with 
experimental data as a means to evaluate the performance of these unique probe 
designs, including collection angle and surface area for photon collection. By 
evaluating Raman probe designs in scenarios that resemble tissue studies rather 
than ray-tracings in air, accurate selection of optimized configurations can be 
enabled for a specific application such as those listed in Table 3.1. 
3.4.2 Biological tissue experimental results 
Results from muscle tissue to adipose tissue specific peak ratio analysis 
(1003/1066 cm-1) and partial least squares analysis both reveal an overall 
increase in the muscle tissue signal as muscle tissue layer thickness increases, 
as well as a decrease in adipose tissue signal as muscle tissue thickness 
increased (Figure 3.5A-D). The signal to noise ratio (SNR) obtained from peak 
ratio analysis of muscle tissue signal and adipose tissue signal are plotted in 
Figure 3.5A and Figure 3.5B respectively. The shallow focused micro lens 
design collected the highest SNR from muscle tissue at all of the layer 
thicknesses measured, which is due to the selectively superficial overlap of the 
excitation and collection cone angles based on ray tracing results modeled in 
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air (Figure 3.1D). The highest SNR of adipose tissue was measured by the deep 
focused probe, which is explained by the deep overlap of excitation and 
collection cone angles from ray tracing models in air (Figure 3.1C), and by the 
highest cross-sectional area for photon collection of all of the probes tested 
(Table 3.2). In the PLS analysis results, the beveled probe design yields the 
most muscle tissue signal, followed by the superficial micro lens design (Figure 
3.5C). The modified probe designs appear to detect more signal from the deep 
layer than the unmodified design, especially at small muscle tissue thicknesses 
(Figure 3.5D). However, adipose tissue signal overwhelms the muscle tissue 
signal generated at small muscle tissue thicknesses and results in large variances 
and in some cases artificially low coefficients for muscle tissue signal. This is 
an inherent limitation of using the non-negative PLS analysis, which performs 
best when pure components have uncorrelated spectra,27 enabling easy 
separation of components even when a small amount of a substance is present 
in the sample. This is the main reason that peak ratio analysis was the preferred 
method for assessing deep versus superficial signal collection, as tissue-type 
specific peak ratios were more sensitive to small changes in muscle tissue 
thickness compared to the PLS analysis.  
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Figure 3.5. Biological optical phantom probe characterization. Adipose and 
muscle tissue experiments: (A) Mean ± standard deviation signal to noise ratio 
of superficial muscle layer peak signal (1003 cm-1, arrow in (3C)) as a function 
of increasing superficial layer thickness. (B) Mean ± standard deviation signal 
to noise ration of deep adipose layer peak signal (1066 cm-1, arrow in (3C)) as 
a function of increasing superficial layer thickness. (C) Nonnegative partial 
least squares for muscle tissue signal contribution versus superficial layer 
thickness. (D) Nonnegative partial least squares for adipose tissue signal 
contribution versus superficial layer thickness. (E) Ratio of superficial layer 
peak signal (1003 cm-1 muscle tissue peak) to deep layer peak signal (1066 cm-
1 adipose tissue peak) as a function of increasing superficial layer thickness. (F) 
Integrated signal intensity of peaks (arrows, Figure 3.3C) as a function of 
superficial layer thickness. 
 
A ratio of the experimentally measured peak signals from muscle tissue 
to adipose tissue was calculated for each probe (Figure 3.5E) and reveals a 
general linear rise with increase in muscle tissue thickness. This is expected due 
to the increasing thickness of muscle tissue that contributes to the overall signal. 
The shallow focused micro lens design had the highest values across muscle 
tissue thicknesses, which is in large part due to having the highest muscle SNR 
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of all four probes. The deep focused micro lens design has the lowest ratio 
beyond 1200 μm thicknesses which likely results from the more efficient 
collection of adipose tissue signal at these depths. This plot shows similar 
results as the MC simulation, with an increase in the signal ratio of muscle tissue 
to adipose tissue as the muscle tissue thickness increases observed across all of 
the probes.  
The total integrated Raman signal measured with each probe as a 
function of depth is plotted in Figure 3.5F. The deep focused design has the 
highest collection efficiency at all depths, followed by the shallow focused 
micro lens design. The unmodified design has the lowest integrated signal 
intensity at all tissue thicknesses. The MC results also show the deep focused 
micro lens design as collecting the most Raman photons, and the unmodified 
design collecting the least.  
Overall, the experimental results agree with the MC model for 
determining probe performance as a function of muscle tissue thickness when 
using optical properties that are realistic for biological tissue. The spread of 
results between the probes evaluated demonstrates how small changes in probe 
design can significantly alter their performance. This validation is an important 
first step in developing a tool for optimizing the choice or design of a fiber optic 
probe when beginning a study. In addition, the modified Raman probe designs 
demonstrate significant improvement in collection efficiency through 
experimental testing and MC models. Regardless of application, such 
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modifications can increase the excitation-collection cone overlap and collection 
fiber surface area so that maximum Raman photons can be detected.  
3.4.3 Synthetic phantom experiments 
The peak SNR obtained from analysis of the superficial material (TiO2) 
from each probe (1412 cm-1) design is shown in Figure 3.6A as a function of 
TiO2 thickness. TiO2 SNR increases as the TiO2 thickness increases up to 1000 
μm, after which the SNRs plateau. This plateau likely occurs because the 
transport mean free path (1/μs’) for TiO2 is small due to low scattering 
anisotropy (Table 3.3) and thus it takes a shorter absolute depth to be considered 
semi-infinite, resulting in a plateau in SNR.27 The shallow focused micro lens 
probe yields the highest SNR at TiO2 thicknesses between 100 - 1000 μm, with 
the highest separation observed in 100 - 400 μm thicknesses. This SNR 
improvement at small TiO2 thicknesses is in agreement with results published 
by Agenant et al.,28 and correspond to superficial overlap of excitation and 
collection cone angles determined via Zemax ray tracing (Figure 3.1D).    
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Figure 3.6. Synthetic phantom probe characterization. Controlled optical 
phantom experiments: (A) Mean ± standard deviation signal to noise ratio of 
superficial layer peak signal (1412 cm-1 TiO2 peak, arrow in (3D)) as a function 
of increasing superficial layer thickness. (B) Mean ± standard deviation signal 
to noise ratio of deep layer peak signal (1300 cm-1 PTFE peak, arrow in (3D)) 
as a function of increasing superficial layer thickness. (C) Mean ± standard 
deviation nonnegative partial least squares for TiO2 signal contribution versus 
superficial layer thickness. (D) Mean ± standard deviation nonnegative partial 
least squares for PTFE signal contribution versus superficial layer thickness. 
(E) Mean ± standard deviation ratio of superficial layer peak signal (1412 cm-1 
peak) to deep layer peak signal (1300 cm-1 peak) as a function of increasing 
superficial layer thickness. (F) Mean ± standard deviation integrated signal 
intensity of peaks (arrows indicated in Figure 3.3D) as a function of superficial 
layer thickness. 
 
The SNR of the deep layer (PTFE, peak at 1300 cm-1) is plotted as a 
function of TiO2 thickness up to 1800 μm in Figure 3.6B. As the TiO2 thickness 
increases, the SNR from the PTFE exponentially decreases in all probe designs. 
The unmodified probe design demonstrates the highest deep layer SNR in 
samples with 100 – 500 μm thick TiO2 layers. This may be explained by the 
overlap of the excitation and collection cone angles deep in the sample seen in 
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the unmodified design ray tracing results (Figure 3.1A). This result differs from 
biological testing in which the deep focused micro lens design has the highest 
SNR for the deep adipose tissue. In addition, the decay in SNR for deep layers 
is exponential in the synthetic phantom compared to a linear decrease in the 
biological tissues, highlighting the influence of optical properties on probe 
performance.  
In addition to SNR results based on TiO2 and PTFE-specific peaks, 
results from the non-negative partial least squares analyses are provided in 
Figure 3.6C-D. Similar to results in Figure 3.6A, the shallow focused micro 
lens design demonstrates the highest TiO2 component score up to 1800 μm thick 
layers of TiO2 sheets. The unmodified probe design also displays high PTFE 
component scores; however, the deep focused probe design does not appear to 
bring any advantage for enhancing detection of PTFE signal as would be 
expected based on its deep overlap range of the excitation and collection fibers 
(Figure 3.1C). It is likely that the extremely high reduced scattering coefficients 
of the synthetic phantoms help to improve the detection of PTFE in the other 
Raman probes, negating the benefits that would otherwise be seen with the deep 
focused micro lens design. It logically follows that as the transport mean free 
path decreases due to higher reduced scattering coefficients, the theoretical 
collection-excitation cone overlap volume (calculated in air) becomes 
increasingly irrelevant for highly scattering media. This finding underscores the 
large influence that application-specific optical properties have on fiber optic 
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probe performance, and provides an example in which the specialized fiber 
optic probes provide little to no advantages at probing specific depths. In this 
work we chose biologically relevant absorption and scattering coefficients for 
the MC model, but these may not be representative of all biological tissue types. 
While beyond the scope of this work, a systematic modeling evaluation of probe 
design performance with respect to scattering and absorption coefficients, 
similar to the approach reported by Reble et al., may provide more insight into 
attenuation thresholds for which tailored probe designs are beneficial.27  
The ratio of superficial (TiO2) versus deep (PTFE) signal is plotted in 
Figure 3.6E, and reveals a linear increase in TiO2 to PTFE signal with 
increasing thickness of TiO2 scatter sheets. The performance of the probes was 
similar across the TiO2 thicknesses, with a slightly higher ratio generally seen 
in the shallow focused micro lens design. Biological tissue testing similarly 
reveals a linear increase in superficial (muscle tissue) to deep (adipose tissue) 
signals, and consistent with the synthetic phantom results, the shallow focused 
micro lens design generally yields the highest ratio as a function of muscle 
tissue thickness. 
The total signal measured by each probe was determined by integrating 
the area under the curve of the peaks used for SNR calculation at each thickness, 
and these results are plotted in Figure 3.6F. Similar to results from MC 
simulations and biological tissue experiments, the deep focused micro lens 
design collects the highest overall signal. This design has wide acceptance 
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angles (4.9°-33.8°) paired with a high cross-sectional area through which 
photons can be coupled (Table 3.2) and large excitation and collection cone 
overlap (Figure 3.1C), which together results in the highest integrated Raman 
signal. The second highest signal was recorded with the shallow focused micro 
lens design, which has narrower acceptance angles (21.2°-35.8°) and low cross-
sectional area (Table 3.2), but has a superficial overlap of excitation and 
collection cone angles that appears to increase signal collection efficiency 
(Figure 3.1D). Wide cone angles, large surface areas through which photons 
can be effectively coupled per collection fiber, and high volumetric overlap 
between the excitation and collection fibers logically explain the overall 
increased collection efficiency observed with the micro lens designs. Although 
the beveled design has the widest acceptance angles, the collection efficiency 
is limited due to lower cross sectional area through which photons can be 
coupled and reduced overlap of the excitation and collection cones (Figure 
3.1B). The unmodified design has the lowest overall signal at all depths, the 
smallest acceptance angles (0°-12.7°), and the lowest degree of excitation and 
collection cone overlap, and therefore has the lowest collection efficiency for 
all four probe designs. The interplay of these three factors (collection fiber 
acceptance angles, collection fiber surface area, and excitation-collection cone 
overlap) ultimately dictates the collection efficiency of this class of fiber optic 
probes. These factors should be maximized to improve probe throughput for 
tissue applications.  
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As evidenced in Table 3.1, important biological investigations span 
many depth regimes. Work by Wang et al. which designed and evaluated a 
confocal ball lens probe remains the optimal design reported for detecting 
superficial (<100 um) signals of biological tissues with limited contribution 
from deeper layers.28 At the other extreme, spatially offset designs 
demonstrated by numerous investigators have proven most effective at 
interrogating deep layers of highly scattering media.29,30 Within these extremes 
of the spectrum of optical detection, volume integrating fiber probes can be 
tailored for preferential detection and increased SNR for an application of 
interest. This work demonstrates improved signal collection efficiency obtained 
when integrating micro lens components into a probe tip design that can expand 
the overlap in excitation and collection cone angles as well as increase the 
surface area for light detection compared with conventional fiber probe designs. 
Beyond high collection efficiencies, micro lens designs can be optimized to 
superficial and deep targets based on the choice of lens as demonstrated in the 
biological experiments and MC simulations. Beveled and superficially focused 
micro lens designs have superior performance in shallow samples whereas the 
deep focused micro lens design had highest collection efficiency and SNR in 
deep tissue layers. The conventional design has overall the lowest collection 
efficiencies and SNR at all tissue layer thicknesses. All of these evaluations 
have utilized muscle and adipose-mimicking phantoms paired with MC 
simulation results, and thus conclusions across these studies are 
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straightforward.28,29 The volume-integrating probes evaluated here demonstrate 
variable performance with depth as a function of sample optical properties 
(synthetic versus biological phantoms), most notably the reduced scattering 
coefficient. At larger scattering values, the improvements of a particular 
configuration are diminished. These results further support the need for 
instrument development within the context of tissue properties for a targeted 
application, which may perform differently from theoretical models commonly 
employed for optical design. 
 
3.5 Conclusions 
A platform for optimizing selection and/or design of a Raman fiber optic 
probe that incorporates application specific optical properties for prediction of 
probe performance has been developed and evaluated. The expanded Monte 
Carlo model includes Raman scattering, fluorescence, elastic scattering, and 
absorption, and shows strong agreement with experimental results from 
biological tissue including prediction of collection efficiency and SNR at 
superficial and deep layers. Fluorescence tracking also agrees with 
experimental results for biological samples.  As a competing optical 
phenomenon with a likelihood of generation over 1000 times higher than 
Raman photons in biological tissues, this important feature cannot be 
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overlooked when optimizing fiber optic probes for Raman spectroscopy 
applications. 
Fiber optic probe based Raman spectroscopy has been applied to many 
biological targets. Modeling and experimental testing demonstrate variations in 
performance based on probe design but also target sample properties; the depth 
of the desired signal source and the optical parameters of the sample are 
necessary considerations prior to the start of a fiber based probe study. 
Experimental results in highly scattering TiO2 and PTFE samples (μs’>50 cm-1) 
did not vary based on probe design, whereas results from muscle and adipose 
issues more closely resembled predictions made for air but with large 
variability, particularly in extremely shallow or deep samples. This underscores 
the importance of incorporating application-specific optical properties during 
probe design optimization.  
Although this investigation focused on four particular probe geometries, 
a robust Monte Carlo model allows extension to other probe designs for any 
application with known optical properties. The model presented here can be 
easily extended to both confocal and spatially offset geometries, and can be 
used to optimize entirely novel probe designs prior to fabrication, reducing time 
and cost while improving data quality. 
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CHAPTER 4 
 
CLINICAL CHARACTERIZATION OF IN VIVO INFLAMMATORY 
BOWEL DISEASE WITH RAMAN SPECTROSCOPY 
 
4.1 Abstract  
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) 
and Crohn’s disease (CD), affects over 1 million Americans and 2 million 
Europeans, and the incidence is increasing worldwide. While these diseases 
require unique medical care, the differentiation between UC and CD lacks a 
gold standard, and therefore relies on long term follow up, success or failure of 
existing treatment, and recurrence of the disease. Here, we present 
colonoscopy-coupled fiber optic probe-based Raman spectroscopy as a 
minimally-invasive diagnostic tool for IBD of the colon (UC and Crohn’s 
colitis). This pilot in vivo study of subjects with existing IBD diagnoses of UC 
(n=8), CD (n=15), and normal control (n=8) aimed to characterize spectral 
signatures of UC and CD. Samples were correlated with tissue pathology 
markers and endoscopic evaluation. The collected spectra were processed and 
analyzed using multivariate statistical techniques to identify spectral markers 
and discriminate IBD and disease classes. Confounding factors including the 
presence of active inflammation and the particular colon segment measured 
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were investigated and integrated into the devised prediction algorithm, reaching 
90% sensitivity and 75% specificity to CD from this in vivo dataset. These 
results represent significant progress towards improved real-time classification 
for accurate and automated in vivo detection and discrimination of IBD during 
colonoscopy procedures. 
 
4.2  Introduction 
Inflammatory bowel disease (IBD), which includes ulcerative colitis 
(UC) and Crohn’s disease (CD), affects nearly one million Americans and two 
million Europeans, and the incidence is increasing worldwide.1 This complex 
illness is characterized by both chronic and acute disease states, with periods of 
inflammatory flare, quiescence, and relapse. Ulcerative colitis is almost always 
confined to the colon and Crohn’s disease may occur in any part of the 
gastrointestinal tract from the mouth to the rectum. Numerous overlapping risk 
factors including ethnic origin, lifestyle, geographic region, and susceptibility 
regions on at least 12 chromosomes confound physiological understanding of 
this disease.2, 3 Patients with IBD have an elevated risk of gastrointestinal cancer 
and experience dramatic decreases in quality of life. Despite advances in 
therapy, hospitalization rates for IBD, particularly CD, have shown significant 
increase, incurring a substantial rise in inflation-adjusted economic burden. 
With the high drug costs and rates of surgery (up to 75% of CD and 25-33% of 
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UC patients), IBD is one of the costliest conditions on a per year basis in the 
US, with expenses for CD surpassing diabetes, coronary artery disease, and 
chronic obstructive pulmonary disease.4, 5 
Despite the overlap in presentation, symptoms, and progression of CD 
and UC, discriminating IBD subtype is vital for selection of the most 
appropriate therapeutic or surgical intervention and patient prognosis, a 
determination often made by assessing the severity of active inflammation 
during evaluation. For instance, UC can be cured in many patients by surgical 
removal of the colon, however, CD surgeries are rarely curative and often 
require further procedures. The goal of IBD treatment is to rapidly induce 
remission and prevent disease complications. Currently, the distinction between 
UC and CD is made based on inexact clinical, radiologic, endoscopic, and 
pathologic features6-9; in up to 15% of IBD cases indeterminate colitis (IC, or 
IBD unspecified) is diagnosed because of the difficulty in distinguishing 
between UC and CD. In these patients, diagnosis ultimately relies on long term 
follow up based on success or failure of existing treatment and recurrence of 
disease. A further challenge is that another 5-14% of cases are reclassified 
within IBD based on long-term follow up.10, 11 All of these determinations are 
complicated by the lack of a definitive, recognized gold standard for diagnosis. 
Therefore, accurate differential diagnosis of IBD is critically needed for 
appropriate medical and surgical care, intervention, and prognosis. The 
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development of new technologies that can improve understanding of IBD and 
aid objective diagnosis may help meet this need.  
Clinically, diagnosis is made primarily based upon symptom 
presentation (abdominal pain, number and consistency of stools, etc.) and 
biopsy informed video endoscopy (White Light Reflectance, WLR). While the 
disease may manifest in a typical and easily characterized fashion in some 
patients, expert endoscopists often face non-differentiating disease appearance 
and histopathologists can only identify  features of chronic or acute colon 
inflammation that are consistent with both IBD subtypes. The lack of a 
definitive, biochemically specific characterization tool that can investigate IBD 
subtypes directly hinders delivery of appropriate care. Numerous investigations 
have been pursued to develop tools to improve diagnosis, including computed 
tomography, magnetic resonance imaging, optical coherence tomography, laser 
endomicroscopy, wireless capsule endoscopy, and elastic scattering 
spectroscopy.12-16 All of these techniques are based on structure either at the 
macroscopic (appearance under widefield imaging) or microscopic scale (cell 
morphology and optical scattering properties of tissues). However, structural 
changes in tissue are a downstream effect of underlying disease presentation 
and have not proven effective for IBD differentiation. Raman scattering, on the 
other hand, is sensitive to the constituent biomolecular makeup of a sample, and 
can be utilized to capture a fingerprint of the vibrational modes of chemical 
bonds present within tissue. It is expected that unique biochemical alterations 
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associated with inflammatory response pathways will precede macroscopic 
tissue changes.17, 18 These disease specific changes in tissues that are associated 
with disease status, on both the macro- and microscopic scales should provide 
valuable information to differentiate IBD in the colon.  
Raman spectroscopic techniques have been investigated for numerous 
clinical diagnostic applications to aid in real-time objective disease 
evaluation.19 Specifically addressing IBD, Raman techniques have been applied 
for ex vivo tissues to develop preliminary biomarkers and identify spectral 
signatures consistent with disease subtype. The goal of this study is to 
demonstrate the potential for Raman spectroscopy to detect tissue changes 
consistent with inflammatory bowel disease in the colon as a potential 
diagnostic adjunct. This report presents results from an endoscopic study using 
Raman spectroscopy to characterize IBD from human subjects in vivo. This 
work characterizes the disease presentation from a diverse patient population 
and demonstrates disease discrimination based on spectral changes measured 
across subjects in vivo. Furthermore, this work sought to elucidate confounding 
factors that limit predictive performance and incorporate these factors to 
improve rates of disease classification. Overall, results demonstrate the 
potential for endoscopic Raman spectroscopy as a diagnostic adjunct for IBD. 
148 
 
4.3 Methods 
4.3.1 Subject recruitment and measurement protocol 
Following written informed consent, 23 patients with IBD diagnoses 
(Table 4.1) that were scheduled for a routine surveillance and evaluation 
colonoscopy at the Vanderbilt GI Endoscopy lab were recruited according to 
IRB protocol (IRB #111609). Furthermore, healthy control subjects with no 
history of inflammatory disease were recruited from the population of colon 
cancer screening patients at the endoscopy lab. Following standard colonoscopy 
protocol but prior to biopsy as indicated, spectra were obtained from normal 
and/or inflamed sites within the colon, making measurements at two distinct 
sites in each segment: right (cecum or ascending), transverse, and left 
(descending or sigmoid) colon, as well as two sites in the rectum. The surface 
of the colon at each measurement site was flushed with saline to clear mucus, 
blood, or debris prior to spectral acquisition. The probe was introduced through 
the endoscope accessory channel once the measurement location was reached. 
With the probe touching the mucosal surface with sufficient pressure to ensure 
gentle contact while maintaining position during each measurement, spectra 
were collected and averaged per site while the endoscope’s white light was 
disabled. The probed site was then biopsied and the tissue samples were fixed 
in formalin for routine histopathology. Spectra were compared with the 
combined physician evaluation based on endoscopy, histopathology, and 
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patient history (consistent with standard of care) for the respective gold standard 
patient diagnosis. Between subjects, the probe was detached from the system 
for cleaning, soaked in ortho-Phthalaldehyde (Cidex OPA, Johnson & Johnson, 
Arlington, TX) and rinsed thoroughly with water, in accordance with clinical 
protocols for high-level disinfection. 
 
Table 4.1. Description of study participants. 
 
 
4.3.2 Raman instrumentation, calibration and processing 
In vivo Raman spectra were collected using a portable clinical Raman 
spectroscopy system coupled to a standard clinical endoscope (Fig. 4.1). A 785 
nm diode laser (Innovative Photonics Solutions, Monmouth Junction, NJ) was 
coupled to a custom-fabricated superficially focused fiber-optic probe 
(EmVision LLC, Loxahatchee, FL) which delivered 80 mW to the surface of 
the colon. Briefly, the endoscope compatible fiber optic probe contains a 200 
μm core diameter excitation fiber with bandpass filtering surrounded by seven 
300 μm collection fibers with long pass filters. A shallow focusing micro lens 
composed of a plano-convex sapphire lens and MgF2 optical window is placed 
Normal control (NC) n=8 
Age (years) 56.6 ± 9.3 
BMI 31.3 ± 6.9 
Gender  6F, 2M 
Crohn’s disease (CD) n=15 
Age 39.7 ± 7.6 
BMI 26.1 ± 4.3 
Gender 12F, 3M 
Ulcerative colitis (UC) n=8 
Age 44.8 ± 12.2 
BMI 27.0 ± 5.8 
Gender 3F, 5M 
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in front of the filters to maximize collection efficiency at the probe tip.20 The 
probe tip is physically packaged in a 2.1 mm diameter rigid metal tube that is 
approximately 6 mm in length to couple with standard endoscope technology. 
Each measurement utilized three integrated spectra of 250 ms acquisitions to 
achieve a sufficient signal to noise ratio (SNR ≥15).21 Longer integration times 
could not be utilized due to the substantial background and autofluorescence 
signals generated by the tissue. The Raman scattered light was collected in 
reflectance mode and coupled into an f ∕1.8 spectrograph (Kaiser Optical 
Systems, Inc.) with a fixed volume phase holographic grating resulting in 
spectral coverage from 450 to 1950 cm−1 and a spectral resolution of 7 cm−1. 
The detector was a back-illuminated deep-depletion CCD which was 
thermoelectrically cooled to −70°C (Pixis 256BR, Princeton Instruments). 
Spectral calibration was performed using a neon–argon lamp with naphthalene 
and acetaminophen standards to correct for day-to-day variations. A National 
Institute of Standards and Technology-certified quartz-tungsten halogen lamp 
was used to account for the wavelength-dependent response of the instrument. 
The spectra were processed for fluorescence subtraction and noise smoothing 
using the modified polynomial fit and Savitzky–Golay methods, and 
subsequently normalized to the spectrum mean as described previously.22 All 
calibration steps were performed in the procedure room prior to the beginning 
of each case, and post-processing steps were completed within 1-2 seconds after 
each measurement. The collection parameters were optimized during the first 
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two procedures based upon sensitivity of the probe design and system. 
Statistical differences for integrated spectral intensity and colons segment were 
performed independently using ANOVA with α = 0.05. 
 
 
Figure 4.1. Schematic of integrated Raman and endoscope instrumentation for 
in vivo subject measurement. Components are not drawn to scale. 
 
4.3.3 Classification algorithm: sparse multinomial logistic regression 
The resulting spectra were classified with a Bayesian machine learning 
algorithm, sparse multinomial logistic regression (SMLR), to quantitatively 
determine the potential for Raman spectra to separate healthy and diseased 
colon tissues. SMLR is a versatile multiclass iterative algorithm that reduces 
the high dimensionality of Raman data to only those spectral basis features 
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needed for discrimination.23, 24 SMLR reduces the dataset by creating a 
transformation of the original data in which distinguishing spectral basis 
features were weighted based on their ability to successfully separate classes of 
training data. The training and classification procedure implemented here used 
a Laplacian prior, a direct kernel, no bias, z-scored spectral normalization, 
component–wise updates, and leave-one-subject-out cross validation. A 
posterior probability of membership in each class was then calculated for each 
individual spectrum using a classifier trained only with spectra from other 
subjects. The final sensitivity and specificity for each classification test is 
reported either in relation to detecting disease (control versus IBD), or for 
differential discrimination (CD versus UC), to detecting Crohn’s disease. 
Stratified classification based on variable disease presentation is achieved 
through using the appropriate subset of data prior to model training and cross 
validation. 
 
4.4 Results 
A comparison between mean spectra obtained from subjects within each 
disease category is depicted in Fig. 4.2. All signatures comprised lipid-rich 
features, with strong, narrow bands at 1300 cm-1, 1440 cm-1, and 1658 cm-1. 
These average signals exhibit subtle interclass variations that indicate 
separation across the Raman fingerprint region (450-1800 cm-1). Multivariate 
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analysis techniques can be employed for pattern recognition and feature 
selection to take advantage of the feature rich signals for Raman spectra and 
IBD.24-26 Fig. 4.3 depicts the performance of SMLR, where the separation of 
spectra measured from normal control subjects and from those with IBD is 
displayed for leave-one-subject-out cross validation along with several of the 
salient spectral features utilized for discrimination. The SMLR algorithm 
selects peaks and shoulders that significantly contribute to discrimination and 
is not limited to only prominent features. Tentative peak assignments for these 
discriminating features include 425 cm-1 (δ (CCC) skeletal backbone), 610 cm-
1 (ρ(CH) wagging in proteins), 1080 cm-1 (ν(C−C) of lipids), 1440 cm-1 shoulder 
(δ(CH2) deformation of proteins and lipids), 1160 cm-1 and 1525 cm-1 (β-
carotene), and 1741 cm-1 (ν(C=O) in lipids).27, 28  
 
 
Figure 4.2. Normalized mean in vivo Raman spectra obtained from subjects 
within each disease class. 
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Figure 4.3. (Left) Prediction performance describing the probability of group 
membership for in vivo spectra obtained from normal control and IBD subjects. 
(Right) Mean ± standard deviation spectra and 26 features utilized for 
discrimination are depicted. 
 
This in vivo dataset spans a diverse population of subjects and disease 
presentations; as such, multiple discrimination comparisons were of interest for 
this dataset as indicated in the first column of Table 4.2. Independent training 
and cross validation sets were conducted to gauge unbiased classification 
performance for each comparison of interest. Table 4.2 comprises the results 
for several of these analyses including discrimination between disease and 
control as well as differential discrimination of IBD subtype. In general, test 
sensitivity was high when discriminating IBD from normal controls, but 
specificity was poor, achieving 86% and 39%, respectively. When 
discriminating spectra from control subjects and spectra measured from IBD 
subjects with active inflammation (determined during WLR endoscopy), 
specificity increased to 57%. For comparisons of normal control and inactive 
disease, specificity was lower, indicating that active inflammation is a factor 
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that requires further attention. In discriminating between IBD subtypes, 
substantial differences in performance occur when considering subjects with 
active inflammation (83% sensitivity and 55% specificity) compared with 
quiescent disease (62% sensitivity and 22% specificity). Subsequent analysis 
addresses the impact of potential confounding factors through data stratification 
to evaluate classification performance. 
 
Table 4.2. Classification performance for in vivo comparisons. 
Comparison Sensitivity (%) Specificity (%) 
Control v. IBD 86.2 39.7 
Control v. Inactive IBD 81.1 44.4 
Control v. Active IBD 78 57.1 
Inactive IBD v. Active IBD 67.1 74.5 
Inactive CD v. Inactive UC 62 22.9 
Active CD v. Active UC 83.3 55.9 
 
As demonstrated by the results comprising Table 4.2, the impact of 
active inflammation requires investigation and can be readily visualized in Fig. 
4.4. In spectra measured from normal and quiescent IBD subjects (all inactive), 
mean spectral lineshapes exhibit strong and narrow lipid features and vary 
consistently across the majority of the fingerprint range regardless of disease 
class. By comparison, the mean spectra from actively inflamed colon segments 
are broader and less intense, resembling protein-based signatures rather than 
those of lipids. Furthermore, as visualized in Fig. 4.4 (right), there is a 
statistically significant decrease in spectral intensity as active inflammation 
occurs, and a decreasing trend as inflammation progresses in severity. These 
changes in spectral response due to severity of inflammation indicates a need 
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to account for this factor in the discrimination algorithm. However, for all of 
the analyses presented in Table 4.2 disease subtype (CD and UC) and/or levels 
of inflammation activity (inactive – severe) were combined. Likewise, these 
comparisons did not address the impact caused by the segment of the colon 
from which the spectrum was acquired. Fig. 4.5 depicts the mean and standard 
deviation of spectral variations present when in vivo measurements from 
normal control subjects are isolated to particular segments of the colon. Several 
prominent and subtle features differ in intensity between colon segment spectra: 
potential band assignments include 873 cm-1 (ρ(CH2) in proteins), 1160 cm-1 
(β-carotene), 1265 cm-1 (ν(C-N) of Amide III), 1300 cm-1 (δ(CH2) deformation 
of proteins and lipids), 1372 cm-1 (lipid), and 1658 cm-1 (ν(C=O), Amide I and 
lipids).18, 27-29 These differences indicate the potential influence of colon 
segment on measured spectra and may impact to classification performance. 
 
 
Figure 4.4. Impact of active inflammation: Mean Raman spectra from all 
disease classes when no activity is present (left) and from IBD subtypes when 
active disease is present (center). Integrated Raman spectra for all data by level 
of activity (right) indicates significant differences between disease presentation 
and the potential for the development of an objective metric to characterize 
inflammatory disease activity. 
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Figure 4.5. Mean spectra from colon segments obtained from normal control 
subjects. Shaded regions along spectra indicate standard deviations. Variations 
can be seen across the spectral lineshapes between segment and significant 
features have been identified as a function of wavenumber (vertical gray bands). 
 
Stratified classifiers were implemented by appropriately selecting 
spectra from a subset of the recruitment population in order to control for factors 
of disease location and severity. Based on the spectral changes imparted by both 
colon segment measured and the presence of active inflammation, these factors 
were incorporated into stratified classifiers, each resulting in a different number 
of patients (n, Table 4.3) that were considered for the evaluation. Table 4.3 
comprises the results of leave-one-subject-out cross validation for 2-class IBD 
discrimination. The stratified classifier improves sensitivity and specificity 
compared with the prior performance for differentiating CD and UC when 
location and disease presentation are averaged (Table 4.2, Active CD versus 
Active UC). Once the measurement location and the severity of disease are 
incorporated, sensitivity to CD increases, for example from 83% to 90% and 
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specificity from 56% to 75% in the right colon. While the performance varies 
between colon segments, in general, inclusion of inflammation and location 
factors caused an increase in a combination of sensitivity and specificity for 
spectra acquired during colonoscopy. These results support further 
investigation of influential variables for IBD discrimination, yet demonstrate 
the potential to improve classification accuracy for these complex, 
heterogeneous diseases. 
 
Table 4.3. Classification performance for in vivo spectra from subjects with 
active IBD stratified by colon segment. 
Colon Segment Sensitivity (to CD) % 
Specificity (to 
CD) % 
Right (n=9) 90 75 
Transverse (n=5) 75 67 
Left (n=12) 85 45 
Rectum (n=11) 71 56 
 
4.5 Discussion 
Here, we report our recently developed endoscopy-coupled Raman 
spectroscopy technique that enables real-time measurements of tissue 
biomolecular constituents for in vivo differentiation and characterization of 
IBD in the colon. Prior work has demonstrated that Raman spectroscopy is 
sensitive to IBD subtype specific signatures in ex vivo tissue sample 
evaluations. In this work, we have applied this technique to probe the specific 
biochemical composition of the colon in real-time to provide an objective 
characterization of the colon tissue and disease status, discerning more 
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information which could serve as a valuable adjunct for differential diagnosis 
of UC and CD and minimize the need for random sample biopsy protocols. 
While classic clinical parameters associated with a diagnosis of CD (lack of 
rectal disease, patchy colitis, and the presence of granulomas (found unusually) 
in histology) may all be indicators of a CD diagnosis, currently there is in 
general no universal feature that serves as a gold standard for differential 
diagnosis for IBD. As such, the results of this study were evaluated relative to 
the established diagnoses for the recruited patients that were made based upon 
patient history, clinical presentation, therapeutic response, histopathologic 
findings, and video endoscopy findings. The Vanderbilt Inflammatory Bowel 
Disease Center is a regional referral center, with extensive expertise following 
over 1,000 patients annually. For this study, no patients exhibiting IBD 
unspecified presentation were included in the analysis. These patients with 
indeterminate colitis are of particular interest as they could most benefit from 
new tools for disease differentiation. 
Our endoscopy compatible Raman spectroscopy system has enabled 
rapid in vivo biochemically specific measurements from a diverse patient 
population with representative disease presentations (Table 4.1). The fiber optic 
probe design utilized herein enabled rapid, high SNR (≥15) contact 
measurements of the colon constituent biochemistry (Fig. 4.2) and coupled with 
standard endoscope accessory channel (Fig. 4.1). Prior work has demonstrated 
that excess pressure can alter spectral signatures, and thus attempts were made 
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to minimize this factor.30 Preliminary distinction of the study sample based on 
disease diagnosis generally indicates high sensitivity and low specificity, with 
a wide margin of performance depending upon the classification target (Table 
4.2). When considering all study subjects together without controlling for 
disease presentation or subtype, discriminating disease from control has 86% 
sensitivity but only 39% specificity. This low specificity is further 
demonstrated in Figure 4.3 (left), where a majority of spectra from IBD patients 
are correctly classified but few spectra from control subjects were correct. This 
classification was based on the selection of 26 features from the Raman 
spectrum, however in a separate classification step using a higher sparsity 
promoting factor yielded identical performance based on only 13 features. In 
considering the differential discrimination tests, sensitivity and specificity to 
Crohn’s disease is drastically lower for quiescent (inactive) disease (62% and 
22%, respectively; Table 4.2) compared with spectra acquired from patients 
with active disease (83% sensitivity and 55% specificity). These variations in 
prediction performance based on different classification targets reinforce the 
impact of disease variables on the acquired spectra and the need to properly 
control for disease variables. 
The distinction between spectra from control subjects and those with 
quiescent disease in Table 4.2 (81% sensitivity, 41% specificity) indicates that 
colitis imparts a detectible change even when no active inflammation is present, 
a finding supported by changes to the vascular appearance of the tissue noted 
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during WLR endoscopy.6  When separating controls from IBD, combining 
spectra from subjects with and without active disease causes significant blurring 
of spectral distinct lineshapes (Fig. 4.4) and confounds the classifier. This result 
prompted further investigation of the influential sources of variance within the 
dataset that, if accounted for, may allow improved performance. Active disease 
in the colon presents in a gradient of severity that has been discretized by the 
endoscopists in this study. However, when considering signals measured from 
subjects without active disease (including the normal control population), 
spectra are significantly stronger and exhibit intense lipid features (Fig. 4.4). 
However, when considering only spectra from active locations from IBD 
subjects, regardless of disease, the spectra are much weaker, and exhibit peak 
broadening consistent with increased protein content, potentially from fibrin 
and collagen and consistent with ulceration and edema.14, 17 While these 
features themselves do not provide discrimination between CD and UC, there 
remains the potential that an objective metric for disease activity could be 
developed; such a metric could be used to evaluate therapeutic response after 
initiation of medication, for which a relative measure of active inflammation 
over time could be critical. 
The differences in tissue for both disease presentation and healthy 
colon, which is functionally and biologically varied, require a thorough 
evaluation of inter-anatomical sites in order to characterize the impact on 
performance for disease separation. Based on the low sensitivity displayed for 
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several tests in Table 4.2, including differential discrimination of active CD and 
UC, we hypothesized that other factors were confounding disease prediction. 
This in vivo study represents a pilot evaluation of some of these native factors 
that cannot be investigated with ex vivo tissue sections and indicates the 
potential for in vivo characterization and discrimination. Studies by other 
groups investigating ex vivo discrimination of IBD or the influence of colon 
segment and disease activity have produced outcomes that support our findings 
and may lead to an improved understanding of the factors that belie the detected 
spectral differences.17, 25, 26 While the report of spectral differences between 
anatomical sites (Fig. 4.5) is corroborated by other investigations in the stomach 
and colon31, 32, the exact cause of the spectral changes is thus far uncertain. 
Potential differences include bowel thickness and mucosal morphology, 
vascular density, proximity to mesentery, gland content and microbe 
distribution, among others.33-35 The complexity of these in vivo measurements, 
impacted by both biomolecular and morphological changes in the tissue, require 
further characterization that is beyond the scope of this study. However, 
classification performance improved when colon segment was integrated into 
the algorithm, further supporting the need of improved characterization. 
Disease severity and colon segment are only a few of the potential 
influences on the performance for IBD evaluation and discrimination based on 
in vivo Raman spectra. Other factors not yet considered based on subject 
recruitment for this pilot study include gender, age, BMI, diet, and prior 
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therapeutic treatments, among others. While such factors likely impact 
classification, incorporation of both colon segment and disease severity factors 
into the IBD discrimination algorithm achieved increases to 90% sensitivity and 
75% specificity to IBD subtype in the right colon (Table 4.3). The variation in 
prediction performance appears to be linked to the relative distribution of IBD 
subtypes for patients included in the classification but with expanded 
recruitment, these values will approach the true prediction rate. These results 
demonstrate that by properly assessing disease related variables and including 
them in the analysis, prediction performance can be improved for in vivo Raman 
spectroscopy applications. This also implies the need for a priori knowledge for 
inclusion in distinct classifiers; however, colon segment and disease activity 
can be determined during video endoscopy in real-time. Furthermore, the 
duration of data acquisition, processing, and prediction are short enough that 
such information could be incorporated into the real-time interface providing 
immediate feedback to the clinicians during routine evaluations. The results of 
this work demonstrate the potential for in vivo Raman spectroscopy to impact 
IBD evaluation and the prospect for staging and discrimination. Continued 
development of this sensitive technique could also provide new information to 
better understand and categorize disease for patients with indeterminate colitis 
diagnoses. 
In summary, this study indicates that in vivo Raman spectra for IBD can 
be acquired non-destructively and in real-time in human subjects from the colon 
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during routine surveillance endoscopy with high SNR. The resultant spectra 
have a wealth of information content that can discriminate between IBD and 
normal colon, as well as indicate the level of disease activity present. 
Furthermore, preliminary investigation of influential factors for discrimination 
indicate that disease severity and colon segment measured should be accounted 
for during evaluation. In combination with standard endoscopic evaluation, 
Raman spectroscopy has the potential for providing previously unobtainable 
biochemical information that may be useful as a diagnostic adjunct for IBD. 
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CHAPTER 5 
 
CHARACTERIZING THE INFLUENCE OF DISEASE VARIABLES ON 
RAMAN SPECTRA ACQUIRED FROM COLECTOMY SAMPLES OF 
INFLAMMATORY BOWEL DISEASE 
 
5.1 Abstract 
 
 Inflammatory bowel disease (IBD), including Crohn’s disease and 
ulcerative colitis, is a complex condition that affects millions of people around 
the world. These diseases are both caused by autoimmune responses to gut flora 
but medical management can differ greatly. To aid the provision of optimal 
treatment, new tools for in vivo characterization and discrimination of IBD are 
under investigation. One such tool is Raman spectroscopy, an optical technique 
that is sensitive to subtle biochemical constituents in tissues related to disease 
and physiological processes. Raman techniques have shown great promise for 
disease detection and differentiation, however several groups have reported that 
measured spectra are sensitive to variations between patients, anatomy, and 
disease presentation. To investigate the complex interactions that disease and 
patient variables impose on Raman spectra in IBD cases, this study utilized 
resected colon tissues from colon resection (colectomy) patients. Raman 
170 
 
measurements were made in many locations across the excised specimens, and 
each measurement location was marked, biopsied, and independently 
processed. Tissue biopsies were assessed by a trained gastrointestinal 
histopathologist for evaluation of disease metrics related to anatomical changes, 
chronic disease, and acute inflammation. Multivariate statistical models based 
on generalized estimating equations and generalized linear models of Raman 
peak ratios and histolopathological markers were implemented to decouple the 
influence of individual disease metrics and colon segment. Patient BMI was a 
significant predictor for Raman peak ratio response while age had no effect. 
The IBD diagnosis was highly correlated with multiple peak ratios and indicate 
large interclass differences between ulcerative colitis and Crohn’s disease 
tissues. Raman peak ratios were significantly associated by chronic changes to 
the colon tissue architecture and acute inflammation severity, along with 
differences between anatomical segments of the bowel. Finally, Raman peak 
ratios were modeled by the presence of submucosal fat deposition, a reported 
physiologic occurrence with potential associations to IBD, in combination with 
disease severity. The results reported here agree with prior work indicating the 
influence of both anatomic location and disease severity, and identify patient 
and disease specific factors that should be included in algorithms for improved 
IBD discrimination. 
171 
 
5.2 Introduction 
Inflammatory bowel disease (IBD) is a complex autoimmune condition 
that affects more than one million Americans and more than two million 
Europeans, with incidences increasing around the world. IBD is characterized 
by disease flares separated by periods of remission and significant patient 
morbidity.1 Both ulcerative colitis (UC) and Crohn’s disease (CD) are forms of 
IBD with overlapping symptoms and often have large variations in patient 
presentation. These complex diseases arise due to dysregulated immune 
responses to commensal bacteria in a genetically susceptible host.1 As 
autoimmune diseases with differing treatments and gaps in understanding 
pertaining to etiology, new tools are needed to help quantify disease 
presentation and provide objective diagnosis. One such tool that has seen 
increased interest in the past two decades is Raman spectroscopy, an optical 
technique that can be applied in vivo and is sensitive to the vibrational bonds in 
a sample or tissue. While prior work has demonstrated that Raman spectroscopy 
has the potential to discriminate IBD type and stage disease severity based on 
differences detected in the biochemical profiles of disease, there is a wide range 
of sensitivity and specificity values.2,3 Bi et al. was the first to report 
discrimination of IBD tissues based on ex vivo Raman spectra with 100% 
sensitivity and specificity, however the sample set for this pilot evaluation was 
relatively small.2 Subsequently, Bielecki et al. performed high resolution 
Raman microspectroscopic mapping of IBD tissues.3 This work found that after 
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isolating signals detected from the epithelial cell layers, a statistical algorithm 
was able to separate measurements from CD, UC, and healthy controls with 
over 98% classification accuracy. Our research group has used a portable probe-
based Raman spectroscopy system with colonoscopy to evaluate the 
performance of these techniques in vivo for the first time.4,5 The sensitivity and 
specificity rates of this work have ranged between 62-90% and 22-75% 
respectively, depending upon which patient and measurement variables were 
accounted for during analysis. Based on the previous reports of the sensitivity 
of Raman spectroscopy to both normal patient variations and disease processes, 
there is a demonstrated need for a thorough assessment of which of these factors 
significantly impact Raman spectra acquired from colon tissues. 
Developers of Raman spectroscopy techniques must overcome 
variations in classification rates for disease detection for this technology to 
benefit clinical medicine.6 Significant sources of variation, attributable only to 
the inherent variability in healthy physiology, establish a minimum threshold 
for any detection technique: if the differences between disease classes (or other 
discrimination targets) are smaller than those found within natural, healthy 
variation, there is little chance for successful separation of target classes. Such 
variations have been reported for colon tissue measurements, as noted above. 
Fortunately, several groups are advancing Raman spectroscopy for 
colonoscopy applications and have shown that by accounting for patient 
variations, sensitivity and specificity for Raman discrimination increase. 
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Similar work on innate patient variability has been demonstrated in the breast7, 
upper gastrointestinal (GI) tract8, cervix9, and skin10. In most cases, accounting 
for the variations in tissue has resulted in increased sensitivity and specificity 
rates for classifying disease spectra relative to healthy controls. 
In each of the previous reports of using Raman spectroscopy in the 
colon, significant variability has been noted throughout the organ.11 Similar to 
the other organs of the GI system, the anatomy of the colon and rectum vary 
along the length of the tissue. The distributions of cellular content and 
composition of the bowel wall, as well as the anatomical connections each differ 
between the separate right, transverse, and left colon segments and the rectum. 
12,13 Several major factors have been implicated as impacting in vivo 
discrimination performance of Raman spectra for IBD including bowel segment 
and severity of disease presentation. The proximal colon is primarily 
responsible for absorbing water and electrolytes as well as promoting 
fermentation of undigested sugars in the chime, while the distal colon is 
responsible for storing and evacuating stool. These functional differences 
correlate with distributions of epithelial cells that vary according to anatomical 
location within the colon and rectum; it is likely that these cellular differences 
also impart molecular changes along the colon that are detected by Raman 
spectroscopy.12,13 The influence of these and other factors on measured Raman 
spectra remains to be fully understood. The need exists to characterize the both 
extent of variability in Raman spectra acquired from different locations of 
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colorectum and the interaction of disease severity and inter-anatomical 
variation. Bergholt et al. has investigated the impact of these different 
anatomical locations with respect to changes associated with colorectal cancers 
and noted that inter-anatomical variability was a non-significant factor for 
discrimination between healthy and cancerous tissues.11 Similar findings have 
also been reported for in vivo Raman spectra for skin cancer discrimination.14 
However, it is possible that the biochemical differences relied upon to 
discriminate between normal and dysplasia are more pronounced than those 
present between two related inflammatory processes. In fact, most Raman 
spectroscopy studies that have included inflammation classes in the analyses do 
so as a transition grouping between normal and low grade dysplasia.15,16 Hence, 
this study aims to characterize the variability in Raman spectra acquired from 
different anatomical locations and disease presentations for excised colorectal 
tissue associated with IBD. 
In this work we seek to characterize the influence and interactions of 
variable anatomy and heterogeneity of disease presentation on Raman spectra 
acquired from ex vivo human colon tissues. By comparing Raman spectra 
acquired from numerous anatomical locations along the colon and rectum with 
histopathological evaluation of the measurements, and also with global patient 
variables that may correlate with underlying patient markers for disease, we 
will determine which variables need to be accounted for due to their imposed 
influence on optical measurements. To this end, we have applied clinical Raman 
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spectroscopy and multivariate statistical analysis to measurements of various 
healthy and diseased colorectal specimens (i.e., ascending colon, transverse 
colon, descending colon, sigmoid, and rectum) following colectomy. The goal 
of this work is to characterize the impact of disease variation on Raman spectra 
obtained from human colon tissues. 
 
5.3 Materials and methods 
5.3.1 Patient recruitment 
Colorectal specimens for this study were collected from patients 
following standard partial or total (procto-) colectomy procedures (surgical 
removal of the colon). Potential study subjects were identified based on 
diagnosis (UC, CD, or diverticulosis) and planned procedure at Vanderbilt 
University Medical Center (VUMC). Patients with expected dysplasia were 
excluded to mitigate potential confounding factors. Following written informed 
consent (IRB #150157) specimens were excised and immediately transported 
to a surgical pathology suite according to standard clinical practice for optical 
measurements. The specimen was opened lengthwise to expose the entire 
lumen of the colorectum. Excess blood and debris was rinsed with saline and 
blotted prior to measurement. All measurements were acquired within two 
hours of resection and prior to formalin fixation in an interior pathology room 
with no lights. Patient specific variables including gender, age, body mass index 
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(BMI, kg/m2), relevant diagnosis, and the procedure performed where recorded 
for subsequent analysis (Table 5.1). For this analysis, diverticulosis colon 
tissues were utilized as non-IBD controls. 
Table 5.1. Study subject description. 
Case ID Gender Age BMI Diagnosis Procedure* 
1 F 66 23.3 Ulcerative colitis Proctocolectomy (R,T,L,M) 
2 M 78 19.7 Diverticulosis Partial colectomy (L) 
3 F 46 27.4 Ulcerative colitis Proctocolectomy (R,T,L,M) 
4 F 46 25.0 Ulcerative colitis Proctocolectomy (R,T,L,M) 
5 M 54 24.6 Crohn’s disease Total colectomy (R,T,L) 
6 M 36 22.8 Crohn’s disease Partial colectomy (R,T) 
7 M 44 21.7 Diverticulosis Partial colectomy (L) 
8 F 29 20.5 Crohn’s disease Partial colectomy (R) 
9 M 54 16.2 Crohn’s disease Partial colectomy (R) 
* Indicates segments resected/measured: R – right colon, T – transverse colon,  
L – left colon, M – rectum. 
 
5.3.2 Raman instrumentation and measurement 
The spectroscopic system utilized for this study as depicted in Figure 
5.1, is identical to that used for the previously reported in vivo IBD study.4,5 
Briefly, the excitation leg of the Raman system consisted of a 785 nm diode 
laser (Innovative Photonics Solutions, Monmouth Junction, NJ), a 7-around-1 
superficially focused micro lens fiber optic probe with tip filtering (EmVision 
LLC, Loxahatchee, FL) to deliver 80 mW of power at the sample. Light 
collected by the probe was delivered to a holographic imaging spectrograph 
(Holospec f/1.8i, Kaiser Optical Systems, Inc. Ann Arbor, MI) and detected by 
a thermoelectrically cooled, deep-depletion charge couple device (Pixis 256BR, 
Princeton Instruments Acton, MA). With the probe touching the mucosal 
surface in gentle contact, 5 spectra were acquired from each tissue location with 
177 
 
250 ms acquisition times and 3 summed accumulations. The measured sites 
were immediately marked with medical marking dye (Davison marking system, 
Bradley Products, Inc. Bloomington, MN) for histopathology and subsequent 
comparison with the measured spectra. Each site was initially categorized for 
disease presence by the surgeon using visual inspection. After pathology 
sections were collected from the specimen according to standard of care, 
separate sections were collected from measured locations. All marked sites on 
the specimen were separately processed and read by a fellowship trained 
gastrointestinal (GI) histopathologist at VUMC for several markers of acute and 
chronic disease as well as physiological differences (Table 5.2). The 
histopathological identities of these sites formed the gold standard for spectral 
analyses. Other patient specific variables including age, gender, and BMI were 
recorded for correlation with the spectral data. Between patients, the probe was 
detached from the system for cleaning, soaked in ortho-Phthalaldehyde (Cidex 
OPA, Johnson & Johnson, Arlington, TX) and rinsed thoroughly with water, 
following protocols for high-level disinfection. 
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Figure 5.1. Schematic of Raman spectroscopy system and colon specimen for 
experimental setup. Black dots on colon indicate locations of Raman 
measurement. 
 
Table 5.2. Histopathology scoring metrics for colectomy specimen sections. 
Acute Inflammation  
Severity Absent (0) – Severe (3) 
Extent of coverage Minimal (0), Patchy (1), or Diffuse (2) 
Depth Absent (0), Mucosal (0), Submucosal (2), Transmural (3) 
Basal plasmacytosis Absent (0) or Present (1) 
Surface ulceration Absent (0), 25% ≤ x < 50% (1), x ≥ 50% (2) 
Chronic disease  
Architectural distortion Absent (0) – Severe (3) 
Extent of distortion Minimal (0), Patchy (1), or Diffuse (2) 
Lymphoid hyperplasia Absent (0) – Severe (3) 
Gross changes  
Submucosal fat deposition Absent (0) – Severe (3) 
Submucosal vascular prominence Absent (0) or Present (1) 
Bowel layer thickness  
mucosa Percentage of section thickness 
submucosa  Percentage of section thickness 
muscularis mucosa Percentage of section thickness 
 
5.3.3 Multivariate statistical analysis 
Raman spectra were analyzed using ordinary least squares regression 
based on generalized linear models (GLM) in the statistical software R, using 
the rms package. The rate of change of various Raman peak ratios was modeled 
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as the dependent variable and regression coefficients were calculated for 
independent variables such as patient descriptors and histopathological scoring 
metrics (listed in Table 5.1 and Table 5.2, respectively). To make comparisons 
as these independent variables changed with disease presentation, generalized 
estimating equations (GEE) were employed (as previously described) to enable 
clustering of measurements obtained from a single specimen.17,18 The generated 
regression curves for different segments (right, transverse, left, rectum) and 
disease variables were compared. Raman peak ratios were used as a way to 
normalize comparisons across many data sets that have varying levels of signal 
intensity and signal to noise ratios. Specifically for this analysis, the Raman 
peak ratio of interest was the dependent variable and the disease severity 
(continuous), colon segment measured (categorical), or other patient descriptors 
were included as independent variables. Peak ratios of interest were identified 
based on Pearson’s correlation (r ≥ 0.7) with histopathological scoring values 
evaluated for the corresponding tissue section (Table 5.2). Due to the highly 
variable signal strength that can be detected during Raman spectral 
measurements of biological tissue, the spectral intensity (measured as the 
intensity of the 1440 cm-1 peak) was utilized as another dependent variable 
(continuous) in every model to control for these intensity fluctuations. 
Heteroscedasticity in the dataset was addressed by using the robust covariance 
function created in the rms package (‘robcov’) to adjust the standard errors. 
Finally, to look at interactions between specific disease and anatomic variables, 
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an ANOVA was performed on the generated GLM regression curves from the 
developed regression model.  
 
5.4 Results 
Mean Raman spectra from each colon segment without acute 
inflammation are presented in Figure 5.2 and represent averages of colon 
segments measured across the nine tissue specimens. The spectra depict several 
regions that differ between segments despite the similarities in overall line 
shape. Of particular interest are the changes seen in the protein and lipid 
features (indicated by gray bands at 1006, 1265, 1300, and 1658 cm-1) between 
segments. The visually apparent differences between these few spectral features 
indicate the significant changes imparted by the colon segment measured, 
especially in the tissue that is free of disease. Prior studies have demonstrated 
that disease presentation and colon segment should be decoupled. A thorough 
evaluation of several patient and disease variables are investigated herein to 
address this need. 
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Figure 5.2. Mean spectra from colon segments without histopathological 
markers of acute inflammation. Spectral line shapes agree with previously 
reported differences between colon segments. Gray bands indicate protein and 
lipid spectral features that dramatically vary between segments. 
 
5.4.1 Patient variables 
An initial comparison of spectral features in relation to patient specific 
variables was conducted for patient age and BMI. Overall, the GEE models for 
patient age had low robustness (R2 = 0.15) and therefore no relationships were 
considered. Alternatively, patient BMI strongly correlated with several peak 
ratios that are assigned to collagen and tryptophan (1209 to 1559 cm-1, r = -
0.71; 1335 to 1559 cm-1, r = -0.73). Figure 5.3 depicts a representative GEE 
regression curve where the peak ratio (1335 to 1559 cm-1) is modeled versus 
BMI as a continuous variable, as an example of the consistent trends 
demonstrated by both ratios. These ratios were robust models across the dataset 
(Table 5.3), however because each patient has only one BMI value for all 
spectral measurements, it is not appropriate to investigate interactions for either 
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colon segment or disease presentation. A larger data set may enable further 
clarification regarding the impact of these patient specific variables on the 
variability of detected Raman spectra. 
 
 
Figure 5.3. GEE for peak ratio of 1335 cm-1 to 1559 cm-1 versus patient BMI 
demonstrate high correlations and robust model performance across the entire 
data set. 
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Table 5.3. Multivariate statistical model results for associations between 
Raman spectral data and histological scores of colectomy specimens. 
Comparison Peak Ratio Coefficient p-values 
Model 
R2 
Tentative band 
assignments 
Patient and tissue variables 
Age All ratios Age: p > 0.05 NS  
Body Mass Index 
(BMI) 
1209 to 
1559 cm-1 BMI: p < 0.0001 0.58 Collagen19 to 
Tryptophan19 1335 to 
1559 cm-1 BMI: p < 0.0001 0.55 
Disease Diagnosis 
754 to 
1209 cm-1 Disease type: p < 0.0001 0.85 
Lipid20 to 
Collagen19 
1125 to 
1160 cm-1 Disease type: p < 0.0001 0.75 
Lipid20 to 
Carotenoid21 
Thickness ratio 
(mucosa/submucosa) All ratios Thickness ratio: p > 0.05 NS  
Chronic disease 
Chronic disease and 
colon segment 
1006 to 
1209 cm-1 
Architectural distortion: p < 0.0001 
Segment: p < 0.0001 0.55 
Phenylalanine19 
to Collagen19 
Lymphoid 
hyperplasia All ratios Lymphoid hyperplasia: p > 0.05 NS  
Acute disease 
Active disease and 
colon segment 
1265 to 
1304 cm-1 
Inflammation: p < 0.0001 
Segment: p < 0.0001 0.56 
Protein19 to  
Lipid20 
859 to 
1524 cm-1 
Inflammation: p > 0.05 
Segment: p < 0.0001 0.53 
Collagen19 to 
Carotenoid21 
1335 to 
1332 cm-1 
Inflammation: p < 0.0001 
Segment: p < 0.0001 0.49 
Collagen 
content 19 
Submucosal fat and 
active inflammation 
1265 to 
1304 cm-1 
Inflammation: p < 0.0001 
Fat deposition: p > 0.05 0.55 
Protein19 to  
Lipid20 
 
5.4.2 IBD type differentiation 
Analyses comparing peak ratios modeling inflammatory bowel disease 
type (CD, UC, or non-IBD/normal) are presented in Table 5.3 and Figure 5.4. 
The first ratio (754 to 1209 cm-1) represents lipid to collagen content while the 
second represents lipids to carotenoids (1125 to 1160 cm-1). Both ratios are 
robust predictors across patients/specimens (R2 ≥ 0.75) and have significant 
coefficients for disease diagnosis (p < 0.0001). For both of these ratios, the 
difference between ulcerative colitis and the other diagnoses exhibits a large 
separation, while Crohn’s disease and non-IBD/normal colon are not 
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significantly different. A histologic feature related to disease type is the relative 
thickness of mucosa to submucosa. As scored by the GI histopathologist, 
relative mucosal thickness did not strongly correlate with any other markers of 
disease, including diagnosis. In agreement with the global correlations for 
histological metrics, all of the peak ratios modeled by GEEs had non-significant 
coefficient values for the ratio of thickness for mucosa to submucosa (p > 0.05). 
Based on this dataset, the relative thickness of the bowel wall layers did not 
significantly alter the Raman spectra obtained from the colon. These trends 
represent the average signals for disease types while combining all levels of 
either acute or chronic disease severity. It is likely that these factors could 
significantly alter the ratios obtained from CD or UC specimens, however, 
further patient recruitment/specimen collection is warranted prior to drawing 
conclusions.  
 
Figure 5.4. Results for GEE models of peak ratio versus patient disease 
diagnosis (mean & 95% confidence interval). 
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5.4.3 Chronic disease 
Having isolated Raman peak ratios that correlated with patient variables 
and inflammatory bowel disease type, GEE models were developed for markers 
of chronic inflammation and colon segment. Some of the markers for the 
presence of chronic disease (severity of architectural distortion and extent of 
distortion, Table 5.2) were highly correlated in histopathological evaluation (r 
= 0.79), but lymphoid hyperplasia was not strongly correlated with any other 
inflammatory metrics. As listed in Table 5.3, a similar result was obtained for 
correlations between lymphoid hyperplasia and Raman peak ratios. As before 
with patient age and mucosal thickness ratio, all models of lymphoid 
hyperplasia demonstrated low scores for robustness and non-significant 
coefficients. On the other hand, one GEE model of chronic disease severity and 
colon segment displayed significant differences for both coefficients (p < 
0.0001). The Raman features that contribute to this ratio are tentatively assigned 
to phenylalanine and collagen. However, regression curves for individual 
segments displayed different slopes as severity increased, limiting the utility of 
this feature. Despite the differences in regression curves between segments, 
mean values from segments without chronic disease were significantly lower 
than those with markers of severe chronic disease (p < 0.05). 
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5.4.4 Acute inflammation 
The complex presentation of active disease and colon segment have 
been confounding factors in previous investigations of Raman spectroscopy for 
IBD. To evaluate the impact of colon segment and acute severity, GEE models 
were implemented that allow for modeling the peak ratios of interest with each 
dependent variable. For the GEE models, acute severity score (Table 5.2) was 
utilized to evaluate acute disease. This was determined after all markers for 
acute inflammation were verified as highly correlated (r ≥ 0.73). Results for the 
three most robust GEE models are reported in Table 5.3. As depicted in Figure 
5.5, the 1265 to 1304 cm-1 ratio reveals monotonic decreases in protein to fat 
across all colon segments as acute disease severity increases. The curves for 
mean peak ratio values and 95% confidence intervals indicate that for this ratio, 
there are no differences between segments at a fixed level of active disease. 
However, the mean value for each segment in the absence of active disease is 
significantly higher than the mean value for each segment in the presence of 
severe activity, supporting the interplay between disease severity and colon 
segment in this pilot data set. All colon segments demonstrate a similar 
monotonic increase in collagen to carotenoid with increasing acute severity 
(859 to 1524 cm-1, Table 5.3). However, for the latter ratio, there is not a 
significant difference between the mean values of different colon segments with 
inflammation.  
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Figure 5.5. GEE for peak ratio mean and 95% confidence interval for 1265 to 
1304 cm-1 modeled by severity of acute inflammation and colon segment. 
 
The GEE regression curves in Figure 5.6 reveal that in the proximal 
colon (right and transverse segments), the collagen content (1335 to 1332 cm-
1) increases with severity while in the distal colon (left and rectum) this same 
ratio decreases. In the absences of acute disease (severity 0), these curves show 
that the mean values for collagen content in the proximal colon segments are 
not significantly different from one another. However, at moderate and severe 
acute disease levels (severity 2-3), the mean ratio for the right colon is 
significantly lower than that of the transverse colon (p < 0.05). The GEE 
regression curves for the distal colon (left colon and rectum) show that if the 
severity of acute disease is held constant, there are no significant differences 
between the collagen content. This ratio is significantly different for inactive 
disease in both of these segments compared with severe disease (p < 0.05). 
Furthermore, the transitions in collagen content are more pronounced in the 
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rectum than the left colon as acute disease severity increases. Table 5.3 also 
shows that the GEE model results for the global comparisons of acute 
inflammation and colon segment for each of these ratios have significant 
coefficients (p < 0.0001) for colon segment (all three models) or acute 
inflammation severity (protein to lipid ration and collagen content). These 
significant p-values indicate that there are differences detected in the Raman 
spectra between colon segments and disease states. As both of these factors are 
significant, it follows that an algorithm based on Raman spectra must account 
for the influence of colon segment as you measure IBD severity. 
 
Figure 5.6. GEE for peak ratio mean and 95% confidence interval for 1335 to 
1332 cm-1 modeled by severity of acute inflammation and colon segment. 
 
5.4.5 Submucosal fat deposition 
When modeling peak ratios as a function of acute disease and 
submucosal fat deposition, the most robust ratio (R2 = 0.55), representing 
protein to lipid content, slightly decreases with increasing fat deposition (Table 
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5.3). Interestingly, this ratio indicates a significant coefficient value for acute 
disease severity (p < 0.0001) but a non-significant coefficient for submucosal 
fat. As these factors may not be truly independent, it is interesting to note that 
the peak ratio for moderate or severe submucosal fat deposition (2-3) is 
significantly lower than the ratio for samples absent of this fat deposition, 
regardless of inflammation severity. The GEE model of this spectral feature 
supports the relationship between IBD severity and submucosal fat deposition 
as detected by Raman spectroscopy. 
 
5.5 Discussion 
Raman spectroscopy is an optical technique that is sensitive to subtle 
biochemical changes associated with disease processes and physiological 
variation. However, as a sensitive technique, Raman spectroscopy can also be 
influenced by patient variables not associated with disease processes. The 
healthy human colon is a large organ with diverse and complex functions that 
differ along the extent of the tissue. As depicted in Figure 5.2, segmental 
variations exist in the complex Raman spectra measured from healthy colon. 
The variation in organization of this tissue enables the unique functions 
performed by different parts of the organ. However, these variations also 
complicate detection based on light-tissue interactions. The movement of fecal 
matter through this organ is accomplished by unique formations of musculature 
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across the length of the colon. In the rectum, motility is enabled by the 
continuous sheet of muscle that lines the outside of the tissue as compared to 
the tenia coli which are three equidistantly spaced longitudinal muscles that run 
the length of the colon.22 This increased muscularity of the rectum may account 
for the increase in protein signatures (1247-1265 cm-1 Amide III, 1006 cm-1 
phenylalanine, 1658 cm-1 Amide I) and decreased lipid peaks in the rectum 
compared with the colon (Figure 5.2). Another difference between colon 
segments is the connection to peritoneum in the abdominal cavity. Both the 
ascending (right) and descending (left) colon are retroperitoneal, and not 
directly connected to the sheet of adipose tissue that stabilizes the colon in the 
abdomen. Conversely, the transverse and sigmoid (left) colon segments are 
suspended by the fat-rich mesocolons. The low absorption of near infrared light 
coupled with the high scattering coefficients and the forward dominated 
scattering of tissues allow for 785 nm light to travel deep within biological 
tissues (>5 mm) to generate detectable Raman scattering signals. The increased 
lipid signals in the left colon (Figure 5.2, 1265 cm-1 and 1300 cm-1) may be 
caused in part by the excess mesocolon attached to the outside of this tissue 
after resection relative to other colon segments. Similar to the added mesocolon, 
the distal colon has larger and more prevalent appendices epiploicae (fat 
protrusions on the serosa) that may contribute to the added adipose signatures 
detected in these colon segments.22 These natural variations in the anatomy of 
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the healthy colon support the need for careful consideration of latent effects that 
confound ex vivo and in vivo Raman spectral measurements. 
While diverticulosis specimens were included in this study as non-
inflammatory controls, a more appropriate analysis of healthy colon might be 
obtained from cadaver tissues with no indications of GI pathology. For this 
work, these diverticulosis patient specimens were confirmed through 
histopathologic evaluation to lack all markers of inflammatory processes and 
were thus utilized as controls. 
5.5.1 Patient variables 
Numerous patient variables associated with the specimens could impart 
significant influences on the measured Raman spectra. Due to the limited size 
of this pilot investigation, and the disease conditions indicating surgical 
resection of the colon, many of these factors are not addressed in this analysis. 
Specifically, no effort was made to control of duration of patient disease nor 
prior therapeutic/surgical interventions. Both of these features, as well as other 
variables not related to IBD such as patient age, gender, or BMI could have 
significant impacts on the measured Raman spectra.9 The interpretation of such 
variables is therefore limited. Age related effects did not exhibit robust 
correlations across the recruited patients. However, the peak ratios that 
significantly correlated with patient BMI indicated that with increased BMI 
there may be more reserves of tryptophan in the tissue that can act as part of a 
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small labile reserve of protein. Alternatively, this signal ratio could be related 
to the remodeling of the colon tissue as a result of disease, and requires both a 
larger data set and greater investigation to elucidate the relationship. 
5.5.2 IBD type differentiation 
One of the goals for utilizing Raman spectroscopy in vivo for IBD is to 
help enable discrimination of the disease type. Preliminary work has 
demonstrated the potential for this discrimination through Raman fiber optic 
probe and microspectroscopic investigations. Accurate distinction for these 
diseases is essential for optimal medical management. Treatment options, 
especially surgical interventions, are dramatically different between these 
diseases, and the difference in disease response indicates the need for improved 
evaluation and discrimination of IBD types. To this end, GEE models were 
implemented for peak ratios that were strongly correlated with disease 
diagnosis in this colectomy specimen dataset. The regression models depicted 
in Figure 5.4 reveal that disease specific trends support discrimination of IBD 
type based on differences in the Raman spectroscopic signals from excised 
tissues. The ratio of lipid to collagen content (Figure 5.4A) shows no difference 
between CD and control specimens but a significant increase (p < 0.05) for UC 
specimens. This is likely a combination of the decreased collagen content 
associated with superficial UC disease. Similarly, for the ratio of lipids to 
carotenoids (Figure 5.4B), no significant differences were found between 
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control and CD specimens, however there was a significant decrease for UC 
specimens (p <0.05). This may be attributed to the increased oxidative stress 
seen in the UC specimens that would reduce the prevalence of reactive oxygen 
species scavenging carotenoids in the tissue.23,24 One confounding factor in this 
analysis is the impact of disease severity on Raman spectra and the distribution 
of severity in each colon segment as a function of disease type. This analysis is 
not adequately powered to consider the impact of activity in combination with 
IBD type and thus other latent factors may be impacting the separation (as seen 
for other comparisons in Table 5.3). Despite this limitation, the differences in 
peak ratios here further support the potential for disease discrimination based 
on Raman spectroscopy. 
The impact of IBD on the colon wall differs between disease types. CD 
is generally a deep disease with inflammation extending into the submucosa 
and muscularis layers of the bowel wall, often resulting in thickening of the 
colon with fibrotic changes, fissuring ulcers, and transmural inflammation. 
Conversely, UC is generally a superficial disease that is characterized by 
erosion and sloughing of the epithelium and mucosal ulceration with severe 
disease.22 Bowel layer thicknesses were expected to significantly differ between 
disease severity and IBD type based on the differential presentation of these 
diseases (superficial versus deep effects). However, none of the model 
relationships pertaining to bowel wall thickness were robust or significantly 
correlated with spectral features for this histological score (Table 5.3). A 
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challenge for the scoring of this metric during histopathological review is the 
effect of tissue orientation in the cassette, which can create artefactual 
differences in the relative thickness of these layers on a per sample basis. In 
many tissue sections, layers were absent from a section or the thickness of a 
particular layer was highly variable across the extent of the section. 
Furthermore, due to handling of the specimens, it is not possible to say that 
every sample represented a full-thickness section of the colon tissue. However, 
it is possible that with more control and an objective metric, this ratio could 
provide information about the Raman spectral differences observed. 
5.5.3 Chronic disease 
Analysis of markers of chronic disease and colon segment revealed a 
general increase in the ratio of phenylalanine to collagen as severity of chronic 
disease increased (Table 5.3). Amino acid content (peak ratio numerator) is 
considered to be a marker of cellularity in the colon wall.25 In the healthy colon, 
the mucosal crypts are generally 400 μm – 700 μm deep and rich with mucous 
secreting goblet cells. During severe disease activity, there is an influx of 
inflammatory cells (PMN leukocytes) that can form abscesses at the crypt bases 
in the mucosa. The crypt architecture can be completely obliterated by wound 
healing and epithelial recovery mechanisms.24,26 This remodeling of the 
mucosal layer of the colon wall has implications on nutrient and water 
absorption and is likely accompanied by changes in the molecular profile that 
195 
 
Raman spectroscopy detects. The influx of inflammatory cells and the higher 
density of cellular components in the absence of healthy crypt architecture 
accounts for the increased cellularity measured by Raman spectra with 
increasing chronic severity. Interestingly, there were no strong correlations 
between lymphoid hyperplasia and other global markers of chronic 
inflammation in these tissue sections. Lymphoid hyperplasia refers to a 
proliferation of lymphocytes in the lamina propria or submucosa, sometimes 
forming organized germinal centers as seen in a lymph node. In the context of 
IBD, lymphoid hyperplasia can be considered a marker of chronic disease. 
However, in the proximal colon there is normally a natural abundance of 
lymphoid hyperplasia that is highly organized in contrast to the rather 
disordered proliferation in IBD.27 It is likely that as volume integrating fiber 
optic Raman probes are more sensitive to concentrations of biomolecules than 
the organization of these molecules in tissue, that no differences in lymphoid 
presence were detected based on natural variations in content. 
5.5.4 Acute inflammation markers 
To decouple the complex interplay of the effects of inflammation and 
colon segment, GEEs were implemented for Raman features that were highly 
correlated with disease activity as a function intra-specimen variations. Figures 
5.5 and 5.6 depict curves for two peak ratios modeled by both disease activity 
and colon segment measured. An initial comparison of these curves indicates 
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that disease severity causes different responses between segments when 
comparing Raman spectra. For example, Figure 5.5 indicates a consistent 
decrease in protein to lipid content for increasing inflammation severity across 
all segments of the colon. The protein to carotenoid ratio (Table 5.3) increases 
for all segments and could be a combined effect of increasing collagen as 
inflammation damages the tissue as well as decreased carotenoids present in the 
tissue based on the cellular protection mechanism of scavenging reactive 
oxygen species.23 The discrepancy between these GEE modeled peak ratios 
indicate that not all features of a Raman spectrum are sensitive to the same 
sources of variability. The greatest differences between segment responses to 
worsening disease are seen in Figure 5.6 where the prevalence of collagen has 
opposite trends between the proximal and distal colon segments. This is likely 
a function of the different disease presentations of CD and UC. Nearly 70% of 
CD involves a combination of the colon and small bowel. Many cases of severe 
disease will have pancolitis (inflammation in colon spreading proximally to the 
splenic flexure) with rectal sparing; however 30% of CD patients will have 
segmental disease, with the majority of the inflammation confined to a single 
segment of the tissue. Conversely, 97% of UC involves inflammation in the 
rectum and 80% of mild UC is confined to the rectum and sigmoid colon 
segments.22 Since severe CD exhibits fibro-collagenous changes in colon 
tissues, it is likely that the increase in the collagen signatures in the proximal 
colon (Figure 5.6) is likely due to the higher percentage of the measurements of 
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severe disease in those segments coming from patients with CD while in the 
distal colon, most of the severe disease was measured from UC specimens. This 
differences in severe CD and UC disease presentation and disease processes 
further emphasize the importance of decoupling disease severity and colon 
segment effects on the obtained Raman spectra. 
5.5.5 Submucosal fat deposition 
Each biomolecule has an associated Raman cross-section that is related 
to the likelihood of causing a Raman scattering event. Raman scattering cross 
sections for lipids are larger than many other biomolecules encountered in soft 
tissues.20 Therefore, sensitivity to signals related to adipose content in the 
sample is a strength of this non-invasive Raman technique. Submucosal fat 
deposition is a clinical feature that has been reported in potential association 
with IBD in the past. While this aspect of disease presentation does not indicate 
discrimination of IBD, submucosal fat deposition has been observed in 
radiological studies. Called the “halo effect,” this deposition of fat in the bowel 
wall that may represent a response to diffuse injury in the context of IBD and 
commonly manifests as a ring of fatty attenuation in cross sectional computed 
tomography evaluations of the abdomen.28,29 The large Raman scattering cross-
section of fat and the use of NIR excitation wavelengths enable the interrogation 
of submucosal changes between 400 microns and 1 mm deep in tissue. The 
histological scoring of submucosal fat deposition and markers of active and 
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chronic disease were significant (r > 0.5). The GEE regression coefficients 
(Table 5.3) indicate that, when accounting for the severity of disease, the ratio 
of protein to lipid content decreases as submucosal fat deposition increases. 
Furthermore, there is a more pronounced effect of submucosal fat deposition on 
Raman spectra when active disease is more severe, which is consistent with 
reports of the halo effect in IBD. 
This analysis is based upon a large number of spectra collected across 
the extent of excised colon specimens. It should be noted that the GEEs used in 
the analysis of these relationships do not fully account for complex correlation 
structures that may be present in the data obtained in this study with spatial 
relationships. It is likely that measurements made closer to one another in space 
are more correlated, both histopathologically and spectrally, than measurements 
collected with greater distance. Future investigations could incorporate 
spatiotemporal models30,31 that more fully define the correlation structure 
relationship of these interacting variables, which could more precisely evaluate 
these complex interactions. However, fully defining the correlation structure of 
these variables could be extremely difficult. Thus, GEEs were selected such 
that the importance of the specific correlation structure is minimized and 
comparisons are made by grouping measurements from a single subject. The 
results reported here support the individual and combined influence imposed by 
both patient and disease-based sources of variation. Analysis and discrimination 
techniques may be able to achieve higher sensitivity and specificity rates by 
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accounting for these influential variables, as has been demonstrated in other 
investigations using Raman spectroscopy for disease evaluation. 
 
5.6 Conclusions 
 Inflammatory bowel disease is a complex entity with diverse. This 
complexity continues to present challenges for medical management and 
indicates the need for better understanding of the association between tissue 
changes and disease pathways. While Raman spectroscopy has demonstrated 
potential for ex vivo and in vivo discrimination and characterization of IBD type 
and severity, numerous sources of variability have been implicated as 
confounding factors. This work has utilized tissue specimens from excisional 
procedures of the colon to investigate the complex interactions of several 
variables with respect to disease presentation: active and chronic disease 
markers, gross tissue changes, and patient specific factors such as age, BMI and 
diagnosis. Variables whose interaction had previously been considered 
confounding have now been decoupled using regression modeling of spectral 
feature combinations against histological scoring. Significant differences were 
identified between colon segments in the presence of active and chronic disease 
that strongly correlate with spectral features related to the disease process and 
anatomy of the colon. Age and BMI demonstrated weaker effects, while disease 
specific variables including IBD type and submucosal fat deposition were 
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significantly predictive of Raman spectral signatures. These complex 
interactions between disease and anatomy support the need for thorough 
investigation of the latent factors that can impact measured Raman spectra from 
tissues, either ex vivo or in vivo, and to account for these variables when 
developing algorithms for discrimination. Despite these disease interactions, 
the results presented further support the sensitivity of Raman spectra to disease 
and physiological variations in colon tissues and the potential for disease 
discrimination for complex conditions like inflammatory bowel disease. 
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CHAPTER 6 
 
CHARACTERIZING THE IMPACT OF ACTIVE INFLAMMATION ON 
RAMAN SPECTRA IN EXPERIMENTAL COLITIS 
 
6.1 Abstract 
Inflammatory bowel disease (IBD), comprising Crohn’s disease and 
ulcerative colitis (UC), causes appreciable morbidity for patients and poses a 
challenge to medical management. Raman spectroscopy, a biochemically 
specific optical technique, has demonstrated potential as an adjunct tool to 
improve in vivo discrimination and objective characterization of disease 
severity. Prior in vivo and ex vivo investigations of colon tissues for IBD and 
cancer have implicated patient and disease variations as significant influences 
on measured Raman spectra. One potential factor that has been uncontrolled in 
studies thus far is the influence of acute disease severity. Using a dextran sulfate 
sodium (DSS) as a murine colonic injury model with similarities to human UC, 
we assessed the impact of mucosal injury on the Raman microspectroscopic 
biochemical profile of tissues relative to clinical parameters and histological 
scores of disease severity. Tissue maps were acquired with a 785 nm Raman 
microscope from the rectum and areas of most severe disease presentation from 
17 mouse colon specimens and spectral features that significantly correlate with 
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mucosal injury metrics were identified for further analysis. Spectral profiles for 
carotenoids and amino acids related to oxidative stress significantly decreased 
with increasing disease severity, while lipid signatures that may be linked to 
prostaglandin regulation increased. Furthermore, several features demonstrated 
linear changes in Raman spectral features as a function of disease while others 
demonstrated a binary response, indicating that some Raman features are 
sensitive to the biochemical processes associated with mucosal injury prior to 
the manifestation of microscopic histological changes of disease. These spectral 
changes in a controlled model for colon inflammation and mucosal injury 
support the need to account for disease severity in differential analysis of 
inflammatory bowel disease with Raman spectroscopy techniques. 
 
6.2 Introduction 
Inflammatory bowel disease (IBD) is a complex condition that is 
characterized by cycles of disease flare and quiescence. Depending upon the 
type of IBD a patient has, disease may affect the entire gastrointestinal tract. 
IBD is commonly first diagnosed in 15-30 year old patients, and generally 
requires life-long treatment.1,2 Millions of Americans and Europeans suffer 
from the serious detriments to quality of life associated with IBD and incidence 
is increasing worldwide, including emergence in Asian, eastern European, 
Indian populations.3,4 As a continuing challenge to the medical community, the 
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exact etiology of IBD is unknown, but the disease is characterized by 
dysregulated immune responses to commensal flora in genetically susceptible 
individuals. 
Crohn’s disease (CD) and ulcerative colitis (UC) represent two distinct 
forms of IBD, and have different causes and discrete mechanisms of tissue 
damage.2,5 Different immune responses to microbial antigens of commensal 
microorganisms have been proposed for UC and CD. In CD, the T-cell response 
is T-helper (Th)1 dominant, while in UC, the response is either Th2 [interleukin 
(IL) -4, IL-13] or is mediated by specialized cells such as natural killer (NK) T 
cells.6,7 The activation of central immune-cell populations is eventually 
accompanied by the production of a wide variety of nonspecific mediators of 
inflammation, such as cytokines, chemokines, and growth factors.8-10 These 
mediators enhance the inflammatory process itself and tissue destruction, which 
eventuate in the clinical manifestations of disease.11 The alterations in the 
micro-environment and macro-morphology of the inflammatory tissue are 
evident, and ultimately result in clinical manifestation of IBD. Key features of 
UC include diffuse mucosal inflammation that is restricted to the colon. In 
conjunction with severe inflammation and the coincident production of a 
complex mixture of inflammatory mediators, extensive superficial mucosal 
ulceration develops. Histopathological features include the presence of a 
significant number of neutrophils within the lamina propria and the crypts, 
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where they form micro-abscesses.12 CD is characterized by aggregation of 
macrophages that frequently form noncaseating granulomas.12 
A tool that has seen recent investigation for translational medicine is 
Raman spectroscopy. This non-destructive optical technique can be applied in 
vivo for disease detection and physiological monitoring.13 The strength of 
Raman spectroscopic techniques is its inherent sensitivity to vibrational bonds 
that comprise a tissue or sample of interest. The interaction of the excitation 
light with the vibrational bonds result in biochemical specific peaks and valleys 
that can be used to distinguish changes within a sample.13 
A majority of previous Raman spectroscopy studies in colon research 
have focused on cancer and pre-cancer detection. Early work on colon cancer 
using near infrared Raman spectroscopy found differences between normal 
tissue and adenocarcinoma corresponding to nucleic acid changes.14 More 
recently Wilson et al. reported the study of this technique in the colon for 
classifying colon polyps and obtained an accuracy of 93-95% in distinguishing 
between adenomatous and hyperplastic polyps both in vitro and in vivo.15 A 
higher diagnostic accuracy (> 99%) was reported in following ex vivo 
studies.16,17 Stone et al. has developed a database cataloging the intrinsic Raman 
signatures of various gastrointestinal cancers including those of the colon and 
showed that colon tissues can be classified with near 90% efficiency.18 Finally, 
Bergholt et al. have reported clinical evaluation of colorectal cancers in vivo 
using Raman spectroscopy in combination with colonoscopy procedures with 
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high diagnostic accuracy compared with histology.19 These reported successes 
demonstrated the capability and efficacy of Raman spectroscopy in detecting 
subtle changes in diseased tissue.  
Several research groups, including ours, have investigated IBD in 
humans with Raman spectroscopy. Raman scattering is sensitive to subtle 
changes in diseased tissues and to the physiological environment in the body. 
Hormone status, disease, and treatment history have an impact on the optical 
properties of tissues, and thus result in subtle changes in Raman spectra.20 Bi et 
al. was the first to demonstrate that Raman spectra are sensitive to the subtle 
changes between CD and UC in a small set of ex vivo patient biopsy samples.21 
Bielecki et al. has previously investigated the potential for IBD classification 
based on high resolution Raman microspectroscopic imaging of ex vivo colon 
specimens.22 Subsequent work by our group has demonstrated for the first time 
sensitivity of Raman spectra obtained in vivo during colonoscopy to changes in 
tissue that correlate with IBD type, severity, and anatomical location of 
disease.23,24 The success of these studies demonstrate the need for further 
refinement of Raman spectroscopic techniques prior to clinical utility. 
Prior work has indicated that there are variations in detected Raman 
spectra that are dependent upon severity of disease presentation.23,24 As specific 
disease presentation cannot be controlled in vivo in a patient population, many 
studies of IBD rely on ex vivo human tissues and animal models with 
similarities to human IBD. Such studies also enable the evaluation of new 
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strategies for adjunct therapeutic options for this complex disease.25-27 The 
preliminary in vivo work for IBD demonstrates the need to understand the effect 
of active inflammation on the spectral characteristics of IBD. To objectively 
quantify inflammation in the colon, this study will use an animal model. Mouse 
models are an imperfect replicate of human IBD; however, it will enable a 
systematic study of the course of disease development for colitis (colon 
inflammation) in a shortened time frame (7-10 days depending on protocol), 
and thoroughly analyze the colon tissue of an epithelial injury model with 
immune dysregulation. The goal of this work is to compare normal mouse colon 
tissue with induced inflammatory injury tissues at points of disease progression 
to investigate which underlying biochemical and structural properties correlate 
with Raman spectral features. 
Dextran sulfate sodium (DSS) is a heparin-like polysaccharide that has 
been successfully utilized to induce colonic mucosal injury in mice.25,26,28 This 
model was selected for the current research due to the similarities that the DSS-
induced colitis model exhibits with respect to the characteristics of UC disease 
in humans. Manifestations of injury include weight loss, diarrhea, rectal 
bleeding, and loss of epithelium followed by ulceration and leukocyte 
infiltration.27,29 
Here, we report the use of the DSS-induced colitis model to assess the 
effects of active inflammation on Raman spectra obtained from colon tissues 
during acute colitis. Results from Raman microspectroscopic mapping are 
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correlated with clinical parameters of mucosal injury and effects are decoupled 
from the bowel wall layer measured. Specific Raman features are identified that 
are sensitive to tissue changes consistent with acute inflammatory responses 
and provide a basis for comparisons between different levels of disease severity. 
The results of this pilot study demonstrate that Raman spectral changes from 
the mouse colon are sensitive to biomolecular processes of colitis as a function 
of injury severity. 
 
6.3 Materials and methods 
6.3.1 Animals 
Seven week-old female house-bred WT C57BL/6 mice were used for 
this study. All procedures using mice were reviewed and approved by the 
Institutional Animal Care and Use Committee of the Vanderbilt University 
Medical Center and the Research and Development Committee of the Veterans 
Affairs Tennessee Valley Healthcare System. 
6.3.2 Induction of DSS colitis 
DSS (mol wt 36,000 –50,000; TdB Consultance, AB, Uppsala, Sweden) 
was added to the drinking water as a 4% (wt/vol) solution for the time periods 
indicated. The animals were allowed free access to the DSS-containing water 
during the experiment. On the day the animals were euthanized, the colons were 
removed and colon length was measured; then the colon was cut longitudinally, 
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cleaned, and Swiss-rolled for histology, with two proximal and two distal 2-
mm pieces preserved for RNA and protein analysis. 
6.3.3 Body weight measurement 
For assessment of the effects of DSS treatment on changes in mouse 
body weight, the animals were monitored daily over the course of colitis 
development.  
6.3.4 Assessment of histological injury scores 
Swiss-rolled colons were snap frozen (Super Friendly Freeze’It media, 
Fisher Scientific) and embedded in OCT mounting media (Fisher Healthcare 
Tissue-Plus O.C.T Compound, Fisher Scientific). Serial sections of 20 μm and 
8 μm were cut; 8 μm sections were placed on standard microscope slides and 
stained with hematoxylin and eosin (H&E), while 20 μm sections were placed 
on 75 mm x 20 mm × 1 mm Raman-grade CaF2 microscope slides (Crystran, 
Poole, UK), fixed in 100% ethanol and allowed to air dry in a sterile hood under 
laminar flow for 24 hours. H&E slides were examined in a blinded manner by 
a gastrointestinal pathologist; the summation of inflammation severity (0 –3) 
and inflammation extent (0 –3) was multiplied by the percent involvement (1 = 
0–25%, 2 = 25–50%, 3 = 50–75%, and 4 = 75–100%) to yield the inflammation 
score (0 –24). The parameter of crypt damage (0–4) was multiplied by the 
percent involvement to yield an epithelial injury score (0 –16). These scores 
were then added together to yield the histological injury score (0–40), as 
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described previously.25,30,31 H&E stained slides were then imaged at 40X 
magnification by the Digital Pathology Shared Resource (VUMC) for further 
section comparison and analysis. Reviewing the images for each colon, an area 
of the swiss-rolled colon that is consistent with the mouse rectum as well as an 
area consistent with worst disease severity were identified for subsequent 
Raman imaging. 
6.3.5 Raman imaging analysis 
Raman spectra were acquired using a confocal Raman microscope 
(inVia Raman Microscope, Renishaw PLC, Gloucestershire, UK) with a 785 
nm laser diode (Renishaw PLC, Gloucestershire, UK). Illumination and epi-
detection of Raman scattered light were accomplished through a 50X (N PLAN 
EPI, NA=0.75, Leica, Weltzlar, Germany) objective, with a ~1 µm laser spot 
focused onto the tissue surface. Collected light passed through a 35 µm slit and 
was dispersed by a holographic grating (1200 lines/mm) onto a 
thermoelectrically cooled (-70 ˚C) deep-depleted, CCD providing 1 cm-1 
spectral resolution. The theoretical spatial resolution of the confocal Raman 
microscope system is ~0.6 µm. Laser power was measured daily at the sample 
before and after measurements to ensure consistent exposure to 35-mW laser 
power. System Raman shift calibration was accomplished using a neon lamp 
and a silicon standard with Renishaw software to account for grating motion. 
The calibration measurements before and after data collection ensured 
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consistency of wavenumber calibration and collection arm throughput. Samples 
were held on a motorized XYZ stage and spectral collection was controlled by 
WiRE 4.2 software (Renishaw PLC). Raman maps were collected from 
identified tissue regions at an acquisition time of 20 s per pixel at 5-μm spatial 
resolution. A total of 127 661 spectra from 18 tissue maps were analyzed. All 
spectra were background subtracted with EMSC and linear baseline 
subtraction.32 
6.3.6 Multivariate analysis 
White light reflectance images of unstained sections were compared 
with the digital bright field images of serial H&E sections to identify sample 
regions that correspond to lamina propria, muscularis mucosa, submucosa, and 
muscularis externae. Regions of interest for each bowel layer were selected and 
average spectra were utilized to identify Raman peaks that differ between layers 
and severity of inflammation. Peak ratios were correlated (Pearson’s |r| > 0.8) 
with indicators of disease severity: colon length; inflammation severity score; 
inflammation severity, depth and extent; architectural distortion and extent. 
Identified peak ratios were then compared across disease groups with one-way 
ANOVA with multiple comparisons tests performed based on Tukey's honestly 
significant difference criterion. Peak ratios were used to recreate image 
projections from the detected spectral data for visualization of maps. 
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6.4 Results 
Clinical indicators of DSS-induced colitis are presented in Figure 6.1. 
Body weights of the 17 mice (control, n=6; DSS 3 days, n=5; DSS 6 days, n=6) 
were measured daily and presented as a percentage of their initial body weight. 
No significant differences in mouse body weight were seen during the acute 
phase of DSS injury (Figure 6.1A). At sacrifice, colons were removed, 
measured, cleaned, and swiss-rolled for further analysis. Colon length is 
presented in Figure 6.1B and displays significant difference between the DSS 
day 6 treatment group and both control and day 3 treatment groups. The 
decrease in colon length is consistent with DSS injury and correlates with DSS 
injury score (Figure 6.1C). The injury scores for 3 days of DSS administration, 
similar to the results from colon length do not display significant differences in 
disease presentation; however, there is marked increase in histologic score at 
peak inflammation for 6 days of DSS administration in agreement with prior 
work.25,26 The histologic scoring, as previously reported and utilized, along with 
the other clinical features of disease serve as the basis of comparison for spectral 
analysis. 
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Figure 6.1. Clinical parameters and histologic scoring of DSS-induced colitis. 
 
Raman imaging was performed on 17 swiss-rolled colon specimens, 10 
of which are used in this analysis (control, n=2; DSS 3 day, n=4; DSS 6 day, 
n=4). For each sample, comparison of digitally imaged H&E slides and bright 
field microscopy images of the unstained serial sections enabled the co-
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localization of Raman mapping with regions of interest indicated by a 
collaborating histopathologist with extensive expertise in DSS-induced colitis. 
Once the region of interest was matched in an unstained slide, a grid-based 
Raman map was initialized to acquire spectra from the tissue surface at high 
spatial (5 μm) and spectral (1 cm-1) resolution. A representative Raman 
spectrum from a control mouse is depicted in Figure 6.2 including tentative 
labels for peaks based on literature. The tissue mapping enables acquisition of 
high SNR spectra (>15) from identified spatial locations of the swiss-rolled 
colon.33 These spectra provide a fingerprint of the biomolecules comprising the 
tissue. Strong bands from amino acids, lipids, proteins, and DNA/RNA bases 
are consistent across colons.  
 
 
Figure 6.2. Representative spectrum from rectum of control mouse with 
tentative peak assignments listed. Assignments are based on reported reference 
libraries.34-36 
 
To investigate the impact of inflammation severity on the Raman 
spectra from the colon, several steps were taken to minimize the influence of 
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potential confounding factors. Previous Raman studies of human colon tissues 
have indicated that inter-anatomical variability from colon segment and bowel 
wall layer can significantly influence acquired data.22,23,37,38 To verify that 
Raman microspectroscopic imaging of mouse colons were also sensitive to 
these inter-anatomical variations, regions of interest from the mucosa (lamina 
propria), submucosa, and muscularis externae were identified in each digital 
image of H&E section with corresponding Raman maps. Figure 6.3 contains 
the average spectra obtained from the regions of each bowel wall layer of a 
control mouse colon. The spectral line shapes differ as a function of bowel layer 
measured, especially in wavenumber regions indicated by vertical gray bands. 
This comparison was performed in control mice to avoid confounding influence 
of disease severity and indicated the need to consider spectral changes in bowel 
layers individually. 
 
Figure 6.3. Mean spectra obtained from Raman maps corresponding to different 
layers of bowel wall in control mice. Gray bands indicate peaks and regions that 
qualitatively differ between layers and justify stratification of analysis. 
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After selection of regions of interest in the Raman maps that correspond 
with mucosal and submucosal bowel layers, correlation analysis was performed 
between Raman peak ratios and clinical and histological indicators of DSS-
induced colitis injury. All separate clinical and histopathological parameters 
highly correlated with duration of DSS administration (|r| > 0.7). Peak ratios 
were individually correlated with each disease metric (DSS duration, colon 
length, histological injury score, and individual parameters (described in 
Assessment of histological injury scores). Peak ratios that correlated with 
disease metrics (|r| > 0.8) were selected for subsequent analysis. The individual 
peaks from the identified ratios are listed in Table 6.1 along with tentative peak 
assignments based on reported library values for Raman active biomolecules. 
Separate comparisons between Raman maps were evaluated: (1) comparison of 
map data acquired from the rectum area of each swiss-roll, and (2) comparison 
of map data acquired from the area of greatest injury in each DSS swiss-roll. 
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Table 6.1. Raman spectral features that significantly correlated with DSS-
induced colitis.34-36 
Raman feature (cm-1) Tentative Peak Assignment 
642 Tyrosine 
670 Fatty acids, Glycoprotein ν(C-S) 
697 Cholesterol 
747 Thymine, Tryptophan 
757 Membrane lipids, Tryptophan  
828 Tyrosine 
854 Serine, Tyrosine 
879 Membrane lipids, Tryptophan 
901 Fatty acids, Proline 
935 Arginine, Collagen ν(C-C) 
958 Fatty acids 
991 Thymine 
1004 Phenylalanine 
1043 Fatty acids 
1063 Arginine, Cholesterol, Fatty acids, Triglycerols 
1099 Cholesterol, Fatty acids, Triglycerols 
1156 β-carotene, Fatty acids, Thymine 
1207 Amide III (β-sheet), Thymine 
1265 Amide III (α-helix) 
Cholesterol, Fatty acids, Triglycerols 
1301 Amide III δ(N-H), ν(N-C) 
Cholesterol, Fatty acids, Membrane lipids, Triglycerols 
1317 Histidine 
1339 δ(C-H), Threonine, Tryptophan 
1421 Adenine, Guanine, Thymine, Tryptophan, Uracil, 
Fatty acids 
1616 Tryptophan 
 
Based on the identified peak ratios that correlate with DSS-induced 
colitis, analysis was performed to investigate what Raman signatures are 
significantly changing with mucosal injury. Significant peak ratios from the 
mucosal and submucosal layers measured in the rectum of each swiss-rolled 
colon are depicted in Figure 6.4 and Table 6.2. In general, ratios with lipid 
signals that are associated primarily with cholesterol, fatty acids, or triglycerols 
(denominators of 747/1043 cm-1, 991/1063 cm-1, 642/1156 cm-1) indicate that 
the concentrations of these lipids decrease in rectal tissues with increasing 
severity of DSS-injury. Membrane lipid signatures (757/828 cm-1, 757/854 cm-
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1) increase while independent of other lipid signatures, although when all lipid 
signatures are present in a ratio, the influences conflict (879/958 cm-1 versus 
757/1043 cm-1). Amino acid peaks are ubiquitous across the ratios that 
significantly vary and indicate complicated fluctuations in the proteomic profile 
of the tissues during the mucosal injury and epithelial recovery process. Of note 
is the decreasing ratio of 757/854 cm-1 which may correlate with decreases in 
serine content in the mucosa, and the increase of 642/1156 cm-1 which may 
indicate that β-carotene content is decreasing relative to amino acids in the 
submucosa. The trends for some Raman peak ratios indicate linear trends with 
increasing severity of disease (Figure 6.4, 879/958 cm-1) while others appear 
more as a binary function between mild or no disease and severe injury.  
 
Figure 6.4. Peak ratios from spectral regions of interest in the mucosal layer of 
maps acquired from the rectum area of the swiss-rolled colon tissue. Significant 
differences were calculated based on the Tukey's criterion for multiple 
correction of one-way ANOVA. 
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Table 6.2. Mean Raman peak ratios significantly correlated with parameters of 
DSS injury. 
Mapped regions in the rectum 
Mucosa 
Peak Ratio (cm-1) Control DSS day 3 DSS day 6 P-value 
747/1043 0.43 0.48 0.51 0.047 
757/828 0.65 0.73 0.75 0.017 
757/854 0.56 0.62 0.65 0.035 
757/1043 0.58 0.60 0.66 0.017 
757/1099 0.51 0.52 0.58 0.008 
879/901 1.06 1.05 1.02 0.011 
879/958 0.96 0.93 0.91 0.040 
879/991 1.06 1.05 0.98 0.009 
991/1063 0.80 0.81 0.89 0.002 
Submucosa 
642/1156 0.29 0.32 0.34 0.008 
697/747 0.50 0.44 0.40 0.023 
757/854 0.43 0.48 0.52 0.003 
Mapped regions of worst mucosal injury 
Mucosa 
Peak Ratio (cm-1)  DSS day 3 DSS day 6 P-value 
670/854  0.20 0.23 0.007 
670/879  0.25 0.28 0.018 
670/935  0.21 0.24 0.006 
828/1004  0.43 0.38 0.014 
901/1004  0.40 0.35 0.005 
935/1004  0.49 0.44 0.003 
1265/1616  2.67 2.62 0.033 
1339/1421  1.70 1.76 <0.001 
Submucosa 
1004/1043  2.13 2.84 0.009 
1156/1207  0.66 0.62 0.024 
1301/1317  0.90 0.88 0.007 
1317/1421  1.64 1.69 0.010 
1339/1421  1.65 1.72 0.009 
Blue = Upregulated, Red = Downregulated 
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Investigating the changes is DSS-induced colitis tissues that have the 
greatest insult are likely to most completely capture the influence of active 
inflammation on Raman spectra. Figure 6.5 displays scores for colon tissue 
maps for some of the peak ratio comparisons listed in Table 6.2. Significant 
changes in peak ratios again indicate that disease severity impacts the 
biomolecular profile that Raman scattering detects. Consistent features that 
correlate with disease severity in the most damaged areas of tissue are related 
to amino acids, carotenoids, DNA/RNA bases, glycoprotiens, and lipids (Table 
6.2). Significant increases are observed in ratios associated with fatty acids, 
glycoproteins (collagen), and certain amino acids like threonine and 
phenylalanine; decreases occur for ratios associated with collagen, carotenoid, 
and histidine signatures. The total change in ratio value between groups is 
minimal, but despite a small sample set, the differences are singificant. The 
changes in amino acid, DNA base, and lipid proiles between different regions 
of the colon tissue further suggest that visualizing peak ratios of interest in a 
two-dimensional format that allows co-localization of histologic features with 
spectral markers of disease severity could be informative. Figure 6.6 depicts the 
comparison of bright field images from H&E and unstained slides with the 
corresponding Raman spectral maps. As a demonstration of this technique, the 
1004/1339 cm-1 ratio is presented, showing the treadeoff of phenylalanine to 
threonine and tryptophan. The increasing disorder of the crypt architecture that 
coincides with increasing mucosal injury is well captured by this map. 
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Furtehrmore, the submucosa can be more readily visualized at severe disease 
relative to control and minimal injury indicating layer specific interactions with 
inflammaiton. 
 
Figure 6.5. Peak ratios from spectral regions of interest in the mucosal layer of 
maps acquired from the swiss-rolled colon tissue area of most severe injury. 
Significant differences were calculated based on a one-way ANOVA. 
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Figure 6.6. Example bright field and Raman images of tissue sections from 
DSS-induced colitis. Top row: Bright field images of H & E stained sections. 
Middle: Bright field images of unstained serial sections on CaF2 slides of 
identified regions. Bottom: Raman image projection of 1004/1339cm-1 peak 
ratio after mapping protocol. Control mouse in A, D and G; DSS Day 3 mouse 
in B, E, and H; DSS Day 6 mouse in C, F, and I. Colors are consistent across 
all panels. 
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6.5 Discussion 
Raman spectroscopy is a biochemically specific technique that has 
potential to aid in the medical management of complex conditions like 
inflammatory bowel disease. Previous work has demonstrated the sensitivity of 
Raman spectra to IBD class for differentiation, and our group has begun to 
investigate potential latent factors that decrease classification performance.23 In 
prior work based on in vivo and ex vivo measurements from patients, numerous 
factors have been outside the control of researchers: the anatomical location of 
disease, the level of disease severity, the duration/chronicity of disease, the 
prior therapeutic or surgical interventions, and the lifestyle or dietary habits of 
study subjects. In this work, we have employed a model of experimental colitis 
that exhibits similarities to the mucosal injury process of ulcerative colitis in 
order to target the impact of inflammation severity on Raman spectra, 
independent of these other latent factors. 
The DSS-induced colitis model for mucosal injury has been 
demonstrated and established by several research groups to investigate mucosal 
injury and potential adjunct therapies for bowel inflammation.25,26,28 The DSS 
concentration utilized in this study is expected to reach peak inflammation 
damage at day 7 of administration. As seen in Figure 6.1, the clinical markers 
of disease and histological scores indicate that DSS administration causes 
dramatic alterations in colon tissues in a time course that can readily be initiated 
and controlled for thorough comparison of injury effects. Measurements of 
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control mice, and mice at days 3 and 6 of DSS injury were selected to represent 
different stages of inflammatory disease, including a baseline for comparison 
with mild and severe acute response and the initial stages of wound healing and 
epithelial recovery.39,40 By inducing different levels of colon epithelial injury, 
we are now able to investigate the impact of disease severity in a controlled 
manner. 
The results presented in Figure 6.2 and Figure 6.3 support previous 
reports of the sensitivity of Raman spectra to subtle changes in tissues. As 
demonstrated by these results, the Raman spectra obtained from the mouse 
colons were highly sensitive to amino acid, lipid, and protein features.34-36 
However, despite the level of control afforded to research by moving from 
human populations to animal models, there is concern that experimental colitis 
models do not completely recapitulate the human IBD process. By comparing 
the results reported by Bielecki et al. who performed similar Raman spectral 
mapping of human IBD tissues towards disease discrimination, the spectral 
shapes from mouse colons presented in Figure 6.2 and Figure 6.3 are nearly 
identical to those obtained from human colon sections.22 Furthermore, in the 
previous analysis, the authors indicated the influence bowel layer specific 
signals and used multivariate statistical algorithms to isolate only one layer for 
comparison. While the approach utilized herein is simpler, the results in Figure 
6.3 indicate the importance of making comparisons between consistent layers 
of tissue when using Raman microspectroscopy. 
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When comparing Raman spectra from mucosa and submucosa tissues 
across the levels of DSS administration, several peak ratios were found to 
strongly correlate with colitis. Presented in Table 6.2, only features that were 
strongly correlated with inflammatory severity (|r| > 0.8) were considered for 
further analysis. This threshold was selected due to the high-dimensionality of 
the Raman data from the mapping procedure (each spectrum has over 1000 
variables) and the high correspondence between parameters of experimental 
colitis (|r| > 0.7). A few peak ratios that significantly differ between regions of 
the mucosa and submucosa in the rectum are presented in Figure 6.4 and Figure 
6.5. Numerous biomolecules contribute to the differences between disease 
severities (Table 6.2). The contribution of lipid signatures present interesting 
trends. In these samples, there are increases in cholesterol, fatty acid, and 
triglycerol signals with increasing disease severity. The increase in lipid 
constituents may be the result of prostaglandin production. Prostaglandins are 
fatty acid based molecules that are upregulated at the onset of an inflammatory 
response prior to leukocyte recruitment.41 Other biomolecules, such as arginine 
have demonstrated decreases in concentration with immune response. Arginine 
is a semi-essential amino acid that in important for protein synthesis. Oxidative 
stress can deplete arginine in the body and supplementation of this amino acid 
in the diet of DSS colitis mice improves responses to injury and 
inflammation.25,31,42 In agreement with these reports, arginine signals decrease 
as inflammation worsens in the spectra obtained from colon sections. A similar 
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trend is apparent for β-carotene, which acts as an antioxidant scavenger of free 
radicals associated with oxidative stress pathways, such as those activated 
during inflammation.43,44 
Similar to the results depicted in the rectum, for spectra acquired from 
tissues with the most severe presentation of inflammation and mucosal injury, 
numerous biomolecular components demonstrate significant differences with 
disease. Again, consistent increases are demonstrated for fatty acid content that 
likely correlates with prostaglandin upregulation. Also, β-carotene and histidine 
are significantly decreased in colon tissues with higher levels of inflammation. 
Histidine is an efficient scavenger of both hydroxyl radicals and singlet oxygen 
species and has been shown to inhibit oxidative stress and secretion of cytokines 
including interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α).45 Both 
IL-8 and TNF-α are dysregulated in the immune response of intestinal 
epithelium associated with IBD. The depletion of histidine in the colon tissue 
is likely the result of increased reactive oxygen species in the colon tissue 
during inflammatory response. 
A few of the features implicated in these significant peak ratios 
demonstrate conflicting signatures. Serine/threonine are strongly correlated 
with the Raf family of kinases that are essential for the activation of tissue 
protective nuclear factor (NF)-κB pathway in colon epithelium.46 In the ratios 
identified, serine content in the rectum appears to decrease with severity as 
expected while in the areas of worst disease, threonine content increases. 
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Conversely, in human UC and DSS colitis alike, mucus secreting Goblet cells 
that usually reside in the mucosa become depleted. The resulting decrease in 
mucin production with disease would likely cause decreases in serine and 
threonine which comprise nearly half of a large central region of the mature 
mucin glycoprotein structure.47 The conflicting signatures for these amino acids 
are also demonstrated for collagen signatures. Amide III complexes and 
collagen peak ratios identified in this analysis generally decrease with disease 
severity. This is counterintuitive with respect to the formation of granulation 
tissue in epithelial would healing. As part of the mucosal healing process, a 
dense population of macrophages, fibroblasts, and neovasculature is embedded 
in a loose collagen, fibronectin, and hyaluronic acid matrix known as 
granulation tissue. As this tissue is predominated by types I and III collagen, 
these features are expected to increase with disease severity based on the 
acquired Raman spectra.39,40,42 However, as this is an acute model of disease, 
granulation tissue formation may still be in an early stage. Potential 
investigation of these granulation tissue changes may be more evident in a 
cyclic DSS-injury and recovery model as previously reported.25,26,28 
Similar to other microscopic techniques that enable the projection of 
hyperspectral information onto an image (like overlaying multiple images from 
immunohistochemical staining), Raman peaks and ratios from mapping can be 
converted into images. Figure 6.6 demonstrates the relationship of images 
acquired in this study for bright field imaging of the H&E and unstained tissues 
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with Raman map data. The ratiometric presentation of Raman data here 
represents only two data points per image pixel; over 1000 such wavenumbers 
exist for each image pixel and indicate the need for more complex analysis 
techniques. Potential avenues for combining this high-dimensional data include 
principal component analysis, vertex component analysis, or k-means 
clustering.32 While such steps are currently beyond the scope of this preliminary 
study, further investigations of the complex interactions of subtle Raman 
features may be possible. Despite the algorithmically simple analysis performed 
here, the Raman map images displayed in Figure 6.6 reveal that phenylalanine 
to DNA and lipid features recapitulate the crypt architecture from H & E 
staining. Furthermore, the relative intensity of this ratio is maintained in the 
mucosa of these samples as disease severity increases, again likely correlated 
with consistent metabolism of both phenylalanine, tryptophan, and threonine 
with increase disease. However, the expansion and appearance of submucosal 
layers becomes more appreciable as colitis injury occurs. This Raman imaging 
analysis and the significant biochemical changes that occur in the submucosa 
as a function of inflammatory disease may help to elucidate the underlying 
changes that occur in the bowel wall’s potential space that is not significant 
prior to disease onset. 
Some limitations exist for this study that require further attention in 
moving forward. Some features identified in the correlation analysis appear to 
have binary responses to disease, while others are more linear relative to 
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severity. A potential explanation is that for features that do not exhibit a 
gradient with disease, the tissue changes are too subtle to be detected by Raman 
scattering at the mild inflammation present with 3 days of DSS administration 
while other features are significantly different between day 3 and control 
specimens. Further including Raman mapping data from the remaining 7 mouse 
colons, will increase the statistical power for these analysis and aid inferences 
between group differences. A final challenge in this analysis is that several of 
the features of interest demonstrate correlations with numerous biomolecules 
of interest, potentially adding to the conflicting signatures indicated for amino 
acids and collagen. Building a descriptive model of inflammation based on 
Raman spectral measurements of pure components would be both cumbersome 
and likely ineffective based on these feature correlations. It is likely that to 
isolate the exact influence of competing biomolecules, alternate strategies 
including imaging mass spectrometry or proteomic analysis are necessary 
complementary techniques to fully evaluate the complex processes occurring 
within these tissues. 
 
6.6 Conclusion 
The results presented in this study show that Raman spectroscopy is 
sensitive to subtle biochemical changes that coincide with the severity of acute 
inflammation in the colon. In detail, 18 Raman maps of mouse colon tissues 
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from 10 control and DSS-induced colitis animals were generated and evaluated 
relative to clinical and histopathological parameters of disease severity. Raman 
peak ratios that significantly differ between treatment groups were isolated for 
mucosal and submucosal layers of the tissues and linked with biologically 
relevant contributors in colon tissue and mucosal injury of inflammatory 
disease, including lipid, carotenoid, amino acid, and collagen related features. 
Furthermore, Raman peak ratios were found that depicted significant 
differences between control and DSS administration for 3 days, time points that 
did not demonstrate significant differences based on traditional DSS disease 
metrics. Contrary to the arguments that this experimental colitis model does not 
recapitulate human IBD, the spectra presented here from mouse colon tissues 
were consistent with previously reported human tissue biopsies for IBD 
patients. This work demonstrates the influence of active inflammation on 
Raman spectra acquired from the colon and the potential for objective staging 
of inflammatory disease severity based on Raman spectroscopy. 
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CHAPTER 7 
 
CONCLUSIONS 
 
7.1 Summary and integration 
This dissertation represents the ongoing development of Raman 
spectroscopy for detecting changes in the colon associated with inflammatory 
bowel disease. Despite the continued advances by the medical community for 
managing IBD, a universally definitive gold standard for differential diagnosis 
is elusive.1 This project has demonstrated the potential for a new diagnostic 
method to accurately differentiate Crohn’s disease and ulcerative colitis, 
regardless of patient differences. With continued development, the resulting 
tool may provide doctors with another indicator of a patient’s disease in a matter 
of seconds during standard colonoscopy procedures. Furthermore, this tool has 
demonstrated feasibility for objective scoring of disease severity, with the 
potential to aid in evaluating relative therapeutic response. These advancements 
could significantly improve the management of inflammatory bowel disease 
with respect to both time and cost. 
The first part of this work established a platform for evaluating fiber 
optic Raman spectroscopy probe designs in regards to specific applications for 
translational medicine. These probes are the primary tool used to interface with 
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patients and tissue samples, yet have largely been designed based on theoretical 
performance in non-scattering situations that do not represent most biomedical 
applications. The modeling and experimental validation results indicate the 
improved superficial performance of probe designs with maximized overlap for 
excitation and collection cones at the sample surface. Conversely, the probe 
design to interrogate deep signal sources becomes less important depending 
upon the optical properties of the sample of interest. These findings suggest that 
probe designs should be selected in the context of the specific optical properties 
of the target application rather than informed only by the theoretical depth 
interrogated. 
The second segment of work reported here utilized an optimized fiber 
optic Raman spectroscopy probe for the first in vivo study applied to IBD during 
colonoscopy. Preliminary discrimination performance was poor, but upon 
subsequent investigations accounting for the impact of the disease process and 
other patient variables, classification based on measured Raman spectra was 
improved to rates as high as 90% sensitivity and 75% specificity. This 
demonstration of the success of Raman techniques for detection of IBD in a 
diverse, relevant clinical population establishes the potential for Raman 
spectroscopy as a clinical adjunct in objective disease discrimination and 
staging of disease severity. 
The final pair of investigations comprised in this dissertation work 
investigated the influence of patient and disease variables from excised human 
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tissues and the influence of disease severity in a controlled animal model of 
experimental colitis. These studies underscored the influence of disease 
severity, patient variables, and colon segments on the measured Raman spectra 
and provided support for implementing stratified classification schemes 
incorporating these factors. 
Current protocols for clinical discrimination of IBD cannot provide 
definitive information for every patient and underline the need for further 
development of adjunct technologies.1,2 Previous work in the field of 
biophotonics has demonstrated the potential of Raman spectroscopy techniques 
for differentiating IBD types.3,4 This work, applied to ex vivo tissue biopsy 
samples, merited extension to a clinical population with measurements 
performed during colonoscopy procedures.  
The preliminary studies, referenced in Chapter 2 laid the foundation for 
work presented in this dissertation. Work spanning the past two decades 
demonstrate the technological and application developments for Raman 
spectroscopy for clinical and translational medicine.5 The studies we conducted 
in this dissertation evaluated the fiber optic probe technology used for data 
collection from colon mucosal tissues during colonoscopy, measured a patient 
population with IBD for discrimination, and investigated ex vivo and 
experimental colitis tissues to understand the contributions of disease and 
patient variables on measured spectral data. The previous reports applying 
Raman spectroscopy for IBD achieved promising classification performance 
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based on small sample sizes of ex vivo tissues and multivariate classification 
algorithms.3,4 However, studies utilizing Raman spectroscopy for the colon and 
other tissue in vivo demonstrated potential confounding factors that were not 
investigated in the initial IBD studies.6-9 A major challenge for translationing 
applications of biophotonics to clinical medicine is extending of findings from 
a controlled and often simplified ex vivo model of pathology to the native 
presentation of disease in the body. With this transition to in vivo studies, care 
mus be taken to consider alterantive sources of signals that were previously 
controlled. This PhD dissertation has sought to not only implement Raman 
spectroscopy in vivo for IBD detection but also to characterize the sources of 
confounding signals and develop a tool that is broadly applicable to clinical 
colonoscopy prodecures. This challenge required that this tool work not only in 
a controlled laboratory setting but in a clinical setting without ideal conditions. 
To enable this translation, care was required to thoroughly characterize 
equipment, diease, and physiological variations to identify the features relevant 
to disase presentation. 
The first step of this PhD dissertation, as presented in Chapter 3, 
addresses Aim 1 and the evaluation of fiber optic probe designs utilized for in 
vivo Raman spectroscopy studies. As the target application for this dissertation 
required integration of Raman instrumentation with standard colonoscopy 
systems and the disease processes for these inflammatory disease differed from 
many prior clinical applications, a thorough evaluation of the tools utilized for 
242 
 
data collection was necessary. To this end, a probabilistic model was developed 
and experimentally validated with biological tissue phantoms. The model 
reported here is novel as it explicitly incorporates multiple distinct and 
independent optical phenomena all of which are simultaneously detected during 
Raman spectroscopic measurements. By evaluating the performance of Raman 
probes for detecting Raman signals with respect to the competing light-tissue 
interactions for biologically relevant optical properties, more realistic 
estimation of in vivo performance may be obtained. This work highlights the 
importance of proper selection of fiber optic probe designs for interfacing with 
tissue targets based on the intended biomedical application. The developed 
model also has the potential to improve the way fiber optic probes are tailored 
for biomedical applications by providing a platform for assessment that is 
relevant to most fiber optic probe based detection modalities. Considering the 
superficial disease target and reported tissue properties, this work supported the 
selection of a micro lens probe design for undertaking in vivo investigation of 
clinical IBD. 
In Chapter 4, a clinical Raman spectroscopy system with a superficially 
focused probe design was implemented to address Aim 2. By recruiting a 
sample population of IBD and control patients undergoing surveillance 
colonoscopy procedures at the Vanderbilt University Medical Center (VUMC), 
we were able to demonstrate in vivo Raman spectroscopy the potential for 
disease discrimination. Initially, the heterogeneity of disease presentation 
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proved challenging for differentiation of spectral signatures based multivariate 
statistical analysis, achieving 62-83% sensitivity and 22-55% specificity for 
separating Crohn’s disease and ulcerative colitis. This performance, while 
providing an early benchmark for in vivo detection, is not as promising as the 
previous ex vivo studies of IBD samples. However, by integrating patient and 
disease variables into the classification algorithm, improved performance was 
attained, reaching values as high as 90% sensitivity and 75% specificity. This 
improvement in disease discrimination indicated promise for in vivo Raman 
techniques for IBD applications. Unlike in the previous reports where small, ex 
vivo samples were utilized and controlled for measurement locations and tissue 
condition, this in vivo assessment provides a more realistic indication of the 
performance of Raman spectroscopy as a clinical tool. These results also 
confirmed prior reports of the potential influence of patient and disease 
variables on classification performance. Due to the lack of control over patient 
tissues and limited access to patients during colonoscopy procedures, it was not 
feasible to assess most patient variables from the data obtained during 
endoscopy. The questions of which factors were most influential on Raman 
spectra of colitis required ex vivo human and animal tissues for more thorough 
investigation and control. 
To evaluate variables that impact IBD differentiation based on in vivo 
Raman spectroscopy tissue measurements, the research reported in Chapter 5 
and Chapter 6 was conducted. For this part of the research, different methods 
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of evaluating colon tissues relating to IBD were investigate to characterize the 
influence of patient and disease variables. The first of these studies utilized 
tissue specimens from patients recruited at VUMC scheduled to undergo partial 
or total resection of the colon in relation to inflammatory diseases. Exploring 
the interplay of the anatomical position in the colon from which a measurement 
was made and the histological markers of inflammatory disease, Chapter 5 
demonstrated that several patient and disease variables significantly impact 
Raman spectra. To decouple these effects, generalized linear models were 
implemented to model Raman peak ratios as a function of patient and 
histological disease scores. Generalized estimating equations were utilized to 
group measurements from a single specimen to account for complex 
correlations within the dataset. Patient BMI and IBD type significantly 
impacted Raman spectra acquired while patient age was a non-significant 
parameter. Colon segment, chronic disease, and acute inflammation were all 
significant factors predictive of Raman peak ratios confirming the importance 
of these variables reported in Chapter 4. Other factors of chronic and acute IBD 
that had not been previously explored with Raman techniques were identified 
based on histopathological evaluation and may provide further avenues for 
investigation. 
While the work reported in Chapter 5 took steps to control for several 
patient (age, BMI, colon segment) and disease variables (active & chronic 
inflammation, lymphoid hyperplasia, submucosal fat deposition) while 
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investigating IBD presentation, measurements from a patient population are 
often rife with latent variables. To avoid unintended influence of patient 
variables such as the gender, diet, smoking status, duration of disease, and prior 
surgical and therapeutic interventions, Chapter 6 reports work that utilized a 
well characterized mouse model of experimental colitis. In this model, chemical 
induction of mucosal injury enables a graded response of disease severity that 
can be controlled on a relatively short time scale and has established metrics for 
scoring independent parameters of inflammation and damage.10-12 Utilizing 
high-resolution Raman microspectroscopy of mouse colon tissue after mucosal 
injury, spectral maps of tissue were acquired that provide spatial context to the 
biochemical changes that occur as a function of disease severity. The results of 
this pilot evaluation of DSS-induced experimental colitis reveal several Raman 
features that are highly correlated with clinical and histological scores of 
disease severity. Furthermore, specific Raman peak ratios could be tied to 
biological processes associated with inflammation, oxidative stress, epithelial 
recovery, and wound healing.13-15 A concern for utilizing animal models to 
study human disease stems from the uncertainty regarding the extent to which 
mouse models are representative of the human disease process for IBD. The 
Raman spectra obtained from this model of mucosal injury in mice were nearly 
perfect replicates of spectra collected from ex vivo human biopsy tissues from 
IBD patients previously reported in literature.4 From this finding, we can assert 
that the DSS-induced colitis model in mice is relevant for human UC in multiple 
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aspects including clinical presentation of symptoms, histological features of 
disease presentation, and biomolecular composition of control and diseased 
tissues. The results of this study further indicate the sensitivity of Raman 
scattering to subtle biochemical changes associated with acute inflammatory 
processes and the need to account for disease severity in discrimination of IBD 
type. 
In Appendix I, results from an in vivo assessment of numerous sources 
of variability that influence Raman spectra are reported. While the 
demonstration for some of these variables is conducted in skin due to the ease 
of access, the impacts of users, instruments, and the inherent physiological 
changes present across an organ are all support our findings relevant to the in 
vivo application of Raman spectroscopy during colonoscopy for IBD. The 
Raman data reported herein relates that physiologically induced variability is 
highly influential relative to other sources when instruments are properly 
designed and calibrated and the users of those instruments are adequately 
trained. These results have clear and significant implications for the future 
application of Raman spectroscopic tools with respect to clinical and 
translational medicine, extending far beyond the specific applications presented 
as part of this dissertation. 
A number of significant challenges were overcome during the course of 
this PhD. While our group had conducted a number of other in vivo studies 
utilizing Raman spectroscopy, none had previously been integrated with 
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endoscopic procedures prior to this work. Based on demonstrations of 
endoscope compatible probe designs from other research groups and the 
physical constraints of the instruments used by our clinical collaborators, new 
endoscope compatible instrument designs and data collection and processing 
software were created and implemented for real-time feedback for in vivo 
evaluation of IBD during brief colonoscopy procedures. However while the 
fiber optic probes utilized for Raman studies are made with materials and 
methods that allow for clinical implementation, they are not rugged and durable 
devices. Over the course of the patients recruited during this dissertation, five 
separate Raman probes of identical design were utilized for data collection, four 
of which were broken during clinical measurement or disinfection. As alluded 
to in Chapter 2, strict calibration procedures are not standardized across the 
global Raman spectroscopy community at large and inter-device calibration is 
an ongoing challenge. To that end, nearly 70% of the patients recruited for this 
work have not been included in the analysis, yet stand as a potential independent 
validation set pending further developments in the field for instrument 
comparison. Another obstacle in this work is the challenge of controlling 
disease presentation for a human population. A broad range of patient 
backgrounds, BMIs, ages, disease durations, and prior therapeutic interventions 
are represented in the data reported, most of which could not be controlled in 
the analyses. Despite this latent and potentially confounding factors for in vivo 
investigation, the performance of disease classification was improved by 
248 
 
accounting for disease and patient variables. By more thorough investigation of 
influential factors that impact in vivo Raman spectra from colon tissues, such 
as both those listed above and those considered in Chapter 5 and Chapter 6, we 
can develop a comprehensive understanding of the variables that must be 
integrated into the prediction algorithms to further improve IBD discrimination. 
 
7.2 Recommendations 
Based on the conclusions from the work presented here, there are a 
number of recommendations for immediate research avenues as well as long-
term studies. With the multimodal Monte Carlo model for evaluating 
fluorescence and Raman scattering for differing fiber optic probe designs, the 
immediate need is to implement the code in a parallelized and efficient 
language, such as C++. The results from this improvement would enable the 
use of significantly higher numbers of photons in models for more powerful 
conclusions. This combined model has the potential to facilitate further 
investigation of optimized probe designs for specific applications relevant to 
translational medicine for any instrument based on fiber optic detection, 
including spectroscopic techniques for Raman scattering, fluorescence, elastic 
scattering, and diffuse reflectance. A direct next step would be to systematically 
evaluate the impact of reduced scattering coefficient on detected signals for 
Raman fiber optic probe designs. The results from investigation would have 
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direct implications for the entire field of Raman spectroscopy for clinical 
applications. As a majority of the probe designs utilized for detection have not 
been optimized in reference to specific tissue optical properties, this model 
based evaluation could improve the designs of instruments utilized for 
applications in almost every human tissue or disease target.  
The in vivo investigation of Raman spectroscopy for discrimination of 
IBD type should be expanded to include a larger patient population and perform 
independent validation of the results reported here. To this end, a primary need 
is to establish methods for instrument standardization that is capable of 
accounting for fiber optic probe specific signals as a result of fabrication. By 
improving the procedures and algorithms for inter-instrument standardization, 
it would be possible to conduct multi-center trials and combine data collected 
by multiple independent groups for maximized statistical power. The obstacle 
of correcting for fiber optic probe dependent responses is the direct limitation 
to utilizing the total combined dataset for analysis and evaluation the 
performance of Raman spectroscopy for IBD discrimination. A directed 
investigation utilizing multiple probes fabricated from the same batch of 
materials and utilized to collect spectra from identical standard and biological 
tissue samples is a necessary step to establish the between instrument 
standardization needed. This obstacle remains a challenge facing the entire field 
of Raman spectroscopy for clinical biomedical applications, and merits 
concerted effort. 
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As this work represents the first in vivo study utilizing Raman 
spectroscopy for IBD applications, there is a direct need to independently 
substantiate the results presented here. Further studies, ideally conducted in 
clinical IBD populations of different regions or demographics, are needed to 
demonstrate that the performance reported for discrimination extends to a larger 
patient population. Furthermore, as the classification performance for IBD 
discrimination improved based on the stratification of measurements by disease 
and measurement location, a larger more robust dataset is essential to establish 
realistic estimates of the prediction performance after incorporating the 
appropriate factors. A powered study with a complete block design for age 
matched patients with consistent prior therapies would provide a controlled 
comparison of the performance while minimizing the influence of some 
previously uncontrolled factors. 
A limit to the practical adoption of Raman spectroscopy for IBD 
differentiation is the requirement for endoscopic evaluation. Based on the 
differences between the common disease presentations of ulcerative colitis and 
Crohn’s disease, an interesting approach would be to utilize only measurements 
obtained from the rectum to investigate minimally-invasive disease 
discrimination. While sigmoidoscopy procedures are less commonly performed 
for clinical IBD evaluation, successful demonstration of this evaluation may 
reduce the need for colonoscopy procedures with anesthesia and the associated 
preparation protocols, benefitting both patients and medical providers. 
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Another interesting, if long term, investigation is the extension of 
Raman spectroscopy for disease discrimination in the patient population of 
greatest need: indeterminate colitis or IBD unspecified. A longitudinal study of 
IC patients to evaluate disease classification based on Raman spectra relative to 
eventual differential diagnosis would demonstrate the potential value of this 
clinically relevant optical technique as an adjunct for IBD evaluation during 
colonoscopy. A primary difficulty in such a study is the unknown timeline 
associated with the determination of a differential diagnosis; as such, this study 
may require a set time frame for recruitment and evaluation prior to analysis 
and subsequent follow-up. By investigating the biochemical signatures of this 
challenging disease entity, the potential for disease discrimination and 
assessment by Raman spectroscopy may prove to be of greater utility to 
clinicians. A similarly informative investigation, utilizing this technique to 
objectively score active inflammation prior to and at a set time point after 
initiating a new therapeutic intervention, such as anti-TNF-α medication, would 
provide another indicator of the value of Raman techniques for IBD evaluation. 
Based on the in vivo study that showed sensitivity to the severity of active 
inflammation, and the confirming data from the ex vivo studies of sources of 
influential variation, Raman scattering may provide a valuable tool for unbiased 
characterization of disease severity. By investigating the sensitivity of Raman 
scattering relative to outcome based interventions for therapeutic response, this 
tool could aid in the clinical care of IBD patients. 
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Finally, with respect to the studies characterizing the impact of patient 
and disease variables on Raman spectra of inflammatory disease, there are a 
number other studies that should be pursued. One investigation should target 
true control colon specimens for anatomical heterogeneity and spatial 
variability. As healthy colon tissue is not generally removed from the body, 
these investigations may be best performed with cadaver tissues that are truly 
independent of inflammatory disease effects. A promising continuation of the 
studies of experimental colitis would be to correlate the acquired Raman 
signatures obtained from mouse colon tissues with proteomic analysis of the 
frozen colon collected as part of the protocol for tissue removal. This study 
could further establish the sensitivity of confocal Raman mapping to 
biochemical changes associated with inflammatory disease presentation. 
Exploring the Raman profiles of colon tissues from mice after the 
administration of supplements that inhibit inflammation, such as L-arginine, 
may provide interesting insights into the biomolecular changes that are 
employed for tissue protection and broaden our understanding of anti-
inflammatory pathways. The final suggestion for integrating the disease 
characterization studies would be to compare human and experimental colitis 
specimens under the same conditions for clinical, histological, and spectral 
similarities. Such a study, combining the information content obtained from 
patient samples and the controlled model of mucosal injury would confirm the 
appropriateness of this experimental colitis model for studying the human 
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disease process and enable stronger conclusions to be made from experimental 
investigations about the potential application to patients. 
 
7.3 Contributions to the field and societal impact 
The work detailed in this dissertation comprises contributions to the 
field of biophotonics and gastroenterology, but more broadly to the clinical 
translation of optical technologies for unmet medical needs. To that end, 
combined data collection and real-time processing software was written for 
clinical implementation. The in vivo study performed here is the first report of 
colonoscopy coupled Raman spectroscopy in patients for IBD. Furthermore, 
while Raman scattering techniques have often been applied to cancer 
applications, this work is, to our knowledge, the first set of Raman spectroscopy 
studies focused on differentiating the biochemical changes that occur between 
two inflammatory processes in vivo. This demonstration of the potential of 
vibrational spectroscopy represents a new area of research for biophotonics 
with numerous research targets for clinical medicine such as Eosinophilic 
esophagitis or gastroesophageal reflux disorder. 
The probabilistic Monte Carlo model reported in this dissertation 
represents a novel combination of models for the competing optical phenomena 
that are detected during probe based Raman spectroscopy measurements. Based 
on the model predictions and experimental validation that enable direct 
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comparison of multiple probe designs, these results demonstrate the 
fundamental need for instrument designs based on tissue applications with 
respect to the optical properties of the targets. Subsequent investigations may 
reveal optimized instrument designs and clarify the tissues and optical 
properties for which certain probe designs are of greatest benefit.  
The development of data collection and processing algorithms for 
clinical implementation and the design of the instrumentation to meet the 
constraints for integration in a clinical workflow mark essential developments 
that are paramount for the translation of Raman spectroscopy, and other fiber 
optic probe based optical techniques, to clinical use. By combining the 
optimized instrumentation and algorithms developed, real-time data collection, 
processing, and multivariate analysis can be performed such that immediate 
feedback is available without disrupting clinical workflow. This work has also 
extensively characterized the biochemical changes that occur in in vivo, ex vivo, 
and animal model tissues as a function of inflammatory disease. These 
combined evaluations of variability sources associated with IBD represent the 
most extensive investigations of colon heterogeneity for clinical deployment of 
Raman spectroscopic techniques. 
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APPENDIX 1  
 
ASSESSING VARIABILITY OF IN VIVO TISSUE RAMAN SPECTRA 
 
A1.1 Abstract 
Raman spectroscopy (RS) has received increasing attention as a 
potential tool for clinical diagnostics. However, the unknown comparability of 
multiple tissue RS systems remains a major issue for technique standardization 
and future multi-system trials. In this study, we evaluated potential factors 
affecting data collection and interpretation utilizing the skin as an example 
tissue. The effects of contact pressure and probe angle were characterized as 
potential user-induced variability sources. Similarly, instrumentation-induced 
variability sources of system stability and system-dependent response were also 
analyzed on skin and a non-volatile biological tissue analog. Physiologically-
induced variations were studied on multiple tissue locations and patients. The 
effect of variability sources on spectral line shape and dispersion was analyzed 
using analysis of variance methods and a new metric for comparing spectral 
dispersion was defined. In this study, in vivo measurements were made on 
multiple sites of skin from five healthy volunteers with four stand-alone fiber 
optic probe-based tissue RS systems. System stability and controlled user-
induced variables had no effects on obtained spectra. By contrast, 
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instrumentation and anatomical-location of measurement were significant 
sources of variability. These findings establish the comparability of tissue 
Raman spectra obtained by unique systems. Furthermore, we suggest steps for 
further procedural and instrumentation standardization prior to broad clinical 
applications of the technique.  
 
A1.2 Introduction 
Numerous research groups have capitalized on the sensitivity of Raman 
spectroscopy (RS) to subtle changes in biochemistry to study tissues in vivo 
without exogenous dyes, contrast agents, or extensive sample preparation. 
Raman scattering has been utilized for decades to identify substances, detect 
changes in chemical bonding, and monitor the quality of chemicals by probing 
inherent vibrational modes. Publications using RS to study disease markers 
associated with several organs are available, including the cervix,1-4 bladder and 
prostate,5 lung,6 skin,7-12 bone,13, 14 breast,15, 16 and GI tract.17-20 Providing 
information regarding healthy tissues, disease progression, and the effects of 
treatment, RS has been noted as a potential tool for medical screening, 
diagnosis, and guidance. Due to the underlying weak optical phenomenon, the 
technology for in vivo measurement has only become available in the last 2 
decades with NIR sources and detectors to minimize competing 
autofluorescence signals and avoid tissue scattering and absorption peaks. A 
typical tissue RS system consists of an NIR excitation source, fiber optic probe 
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to interrogate the tissue and collect the scattered photons, a high-throughput 
spectrograph, and a NIR-optimized, back-illuminated, deep-depletion charge 
coupled device (CCD) detector.21 Several excitation wavelengths have been 
investigated, including 785 and 830nm, but reports suggest tissue-dependent 
responses and indicate advantages for using 785nm for epithelial applications.22 
In general for in vivo implementation, the parameters for generating Raman 
signal are optimized to provide the best SNR in a short measurement time with 
minimal laser power. Since the initial reports of human tissue spectra in 1992,23 
technological development and technique refinement have enabled in vivo 
Raman measurements. Spectra can now be collected, corrected for undesirable 
signal components, and processed to rapidly provide feedback for users.12, 24, 25 
Previous work has identified criteria required for adopting a novel biomedical 
diagnostic technique, which is a primary goal for many tissue spectroscopists.26 
In medical applications, many of these requirements are satisfied by RS for in 
vivo use: sensitivity to changes in tissue, application to in vivo studies, and 
novelty of information obtained non-invasively.27 However, standard Raman 
spectral databases are not available for tissue, limiting RS’s role in influencing 
clinical decisions and patient prognoses. Both research lab and private industry 
studies using RS to diagnose disease or understand tissue are becoming more 
common, but the RS community lacks standardization and a thorough 
understanding of the comparability of measurements made across multiple 
systems, tissue locations, and collection times. 
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Epithelial tissues such as the cervix, skin, oral mucosa, esophagus, and 
GI tract have been common targets of study with RS. Because of several 
characteristics, including ease of access, the skin is a convenient organ for 
conducting the necessary standardization studies. Skin is a complex and turbid 
tissue, with a layered structure, multiple functions, and inhomogeneous 
composition that can vary widely between patients and among various locations 
on a single patient. Thus, as a challenging organ, standardization findings 
should translate to other tissues. Beyond studying the tissue itself, the skin also 
acts as a good model for other epithelial tissues that are common targets for 
optical detection. Most importantly, all sources of potential variability 
identified for the skin are generalizable to other tissues as well. 
Several research groups have reported using RS for a variety of 
applications including the detection of subtle changes in the skin related to 
wound healing,28 disease progression10, 29, natural moisturizing factor levels30, 
protective antioxidants such as carotenoids β-carotene and lycopene,8, 31 and 
cosmetics.32 The non-destructive nature of RS is ideal as an analytical or clinical 
tool for non-invasively monitoring the skin for changes associated with 
damage, disease, or treatment. Several groups have demonstrated the feasibility 
of using RS to differentiate between skin malignancies and healthy tissues in 
vitro.11, 12, 33 These studies also showed that different spectra correlate with 
specific skin disease types. Tissue components and structural conformations for 
several biomolecules related to skin function, including proteins, lipids, and 
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carotenoids, have been determined based on Raman vibrations. These results 
have yielded new information about skin aging and structural properties that 
may differentiate disease types from normal tissues.8, 9, 31 Furthermore, the 
healing of acute and chronic skin wounds has been monitored non-invasively 
with RS to provide new information on the biochemistry and progression of this 
complex process.28, 34, 35 Benign conditions like psoriasis and atopic dermatitis, 
hydration differences, and the effect of topical treatments have also been 
studied using RS.29, 30, 36-38 
Before RS can be effectively applied to a clinical problem, technique 
standardization is necessary to account for confounding sources of variability. 
Current reports suggest that RS can be translated into the clinical setting with 
portable systems and fiber optic probes. However, as a clinical tool, RS 
measurements must be repeatable and free of confounding factors introduced 
by the system operator. With the probe-tissue interface of these systems, both 
contact pressure and probe angle can change, so the effects of user-induced 
variability must be understood and controlled. Other research groups have 
reported the effects of probe contact pressure on measurements of diffuse 
optical spectroscopy and fluorescence spectroscopy in soft tissues.39-42 Shim et 
al. reported no specific major spectral artifacts from contact pressure and probe 
angle on in vivo RS measurements during clinical gastrointestinal endoscopy.20 
To ensure that user perception of contact pressure and probe angle will not 
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confound spectral measurements of tissue, the effect of each user-induced 
variability source will be isolated in this study.  
Recent studies have demonstrated the effectiveness of RS for in vivo 
detection.10 To our knowledge, previous reports include measurements made 
with a single instrument, thereby eliminating factors of instrumentation-
induced variability.  When limited to one instrument, however, multi-system 
studies or simultaneous data collection from multiple patients are impractical. 
Unlike other established medical tools, RS lacks standardized methods for 
system calibration, measurement, processing, data analysis, and reporting. 
Many Raman systems used in research are assembled from several vendors’ 
components, and while core components remain the same, system response may 
vary. Even for multi-system studies where investigators will likely have 
identical or nearly-identical instruments at each collection site, there are 
currently no reports indicating how measurements from the instruments would 
compare for tissue spectroscopy applications. Reports on inter-device 
comparison and cross-validation studies of multiple medical instruments are 
available for other optical techniques such as confocal spectral imaging, dual 
energy x-ray absorptiometry, functional magnetic resonance imaging, and 
fluorescence spectroscopy.43-47 The only report using RS, by Rodriguez et al. 
addresses chemical analysis.48 The consistency of pharmaceutical spectra 
measured across multiple devices suggests that reliable spectral libraries can be 
generated from Raman spectra of homogeneous samples. Measurements of 
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tissues, like the skin, pose more rigorous challenges for cross-validation, as the 
tissue characteristics may vary between location and time of measurement. If 
system variation is accounted for, RS offers diagnostic potential because it can 
discriminate between subtle changes in normal, benign, and malignant tissues. 
Using multiple RS systems during data collection will likely add instrument-
dependent variables. If these variables are ignored, changes in the data may be 
incorrectly attributed to the samples measured and limit diagnostic accuracy. 
The resulting potential decrease in sensitivity and specificity indicate the need 
for standardizing RS systems, regardless of the application. This manuscript is 
concerned with parameters that most likely affect the signals obtained during 
data collection once the study and research instrument have been developed. To 
evaluate the influence of utilizing multiple systems on the comparability of 
Raman spectra, system stability and measurement repeatability will be 
validated and the effects of instrumentation-induced variability sources will be 
isolated. 
For tissue, physiological variations may exist due to age, gender, race, 
measurement location, tissue type, thickness, and hydration. Any of these 
patient variables could be used to distinguish or characterize measurements. 
Previous in vivo Raman studies have demonstrated depth-dependent changes in 
tissue composition and anatomical location-dependent changes in obtained 
spectral shape and intensity.32, 49, 50 Knudsen et al. investigated variations in 
skin Raman spectra between persons, spots on the same body region, repeated 
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measurements on a single spot, diurnal, day-to-day, and different levels of 
pigment.51 In these reports, however, the authors utilized either Raman 
microspectroscopy, which has different instrumentation considerations than 
probe-based techniques, or Fourier-Transform Raman Spectroscopy, which has 
practical limitations for clinical efficacy. Along with the differences between 
techniques, the reports do not consider the influence of multiple instruments. In 
this study, the effects of physiologically-induced variability sources will be 
examined including multiple patients and anatomical locations. 
The goal of this study is to examine potential sources of variability for 
in vivo tissue RS, specifically for the skin, and to suggest steps for limiting the 
influence of confounding factors to standardize Raman for clinical applications. 
The effects of contact pressure and probe angle were characterized as potential 
user-induced variability sources. Similarly, the instrumentation-induced 
variability sources of system stability and system dependent response were also 
analyzed on skin and a non-volatile biological tissue analog. Physiologically-
induced variations were studied on multiple tissue locations and patients. The 
effect of variability sources on spectral line shape and dispersion was analyzed 
using statistical methods. In this study, in vivo measurements were made on 
healthy human skin with four stand-alone fiber optic probe-based RS systems. 
This manuscript reports the results from this study of influential variability 
sources when comparing Raman spectral measurements of tissue. 
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A1.3 Methods 
A1.3.1 Instrumentation, data processing, & statistical analysis 
Raman spectra were acquired using RS systems with similar optical 
components. Based on what is widely accepted as a standard tissue system, 4 
unique instruments were used as described in Table A1.1.21 Each instrument 
was controlled by a laptop computer. A custom fiber optic probe consisting of 
7 collection fibers (300 μm), without beam-steering modifications, surrounding 
a central excitation fiber (400 μm) was used to deliver 80mW of power to the 
sample surface. The tissue was cleaned with an alcohol swab prior to the initial 
spectral measurement. Spectra were collected with a 3 second acquisition time 
with the room lights and computer monitor turned off. 
 
Table A1.1.  Instrumentation components for standard tissue Raman 
spectroscopy systems utilized for multiple system comparison. 
System Fiber Optic Probe Excitation Source Spectrograph Detector 
1 7x1 fiber optic probe 
(EmVision LLC, 
Loxahatchee, 
Florida) 
785nm laser (Process 
Instruments, Inc., Salt 
Lake City, Utah, # PI-
ECL-785-300) 
Holospec f/1.8i 
imaging 
spectrograph (Kaiser 
Optical systems, 
Ann Arbor, 
Michigan) 
Pixis 256BR CCD 
camera (Princeton 
Instruments, 
Princeton, New 
Jersey) 
2 7x1 fiber optic probe 
(EmVision LLC) 
785nm laser (Innovative 
Photonics Solutions 
(IPS), Monmouth 
Junction, New Jersey, # 
I0785MM0350MS) 
Acton LS 785 
imaging 
spectrograph 
(Princeton 
Instruments) 
Pixis 400BR CCD 
camera (Princeton 
Instruments) 
3 7x1 fiber optic probe 
(EmVision LLC) 
785nm laser (IPS, # 
I0785MU0350MS) 
Holospec f/1.8i 
imaging 
spectrograph 
(Kaiser) 
Newton DU920-
DR-BB CCD 
camera (Andor 
Technologies, 
Belfast, Northern 
Ireland) 
4 7x1 fiber optic probe 
(EmVision LLC) 
785nm laser (IPS, # 
I0785MM0350MS) 
Holospec f/1.8i 
imaging 
spectrograph 
(Kaiser) 
Pixis 256BR CCD 
camera (Princeton 
Instruments) 
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Spectral calibration was performed for each system independently using 
a neon-argon lamp with naphthalene and acetaminophen standards to correct 
for day to day variations. A National Institute of Standards and Technology-
calibrated tungsten lamp was also used to account for the wavelength-
dependent response of the instrument. The spectra were processed for 
fluorescence subtraction and noise smoothing using the modified polynomial 
fit and Savitzky–Golay methods, as described previously.24 
Data analysis was performed on the spectral range 900-1800 cm-1, a 
spectral region rich with information from proteins, lipids, and other tissue 
constituents. Following data processing, each spectrum was normalized to its 
mean spectral intensity across all Raman bands to account for intensity 
variability. This normalization method was chosen to ensure that all 
wavenumbers retained statistical independence, which is required for statistical 
analysis and is compromised when spectra are normalized to the intensity of a 
single peak. Statistical analysis was performed on the data at each relative 
wavenumber. An Analysis of Variance (ANOVA) model was used at each 
wavenumber to separate groups and calculate appropriate confidence intervals. 
To quantify the changes in spectral dispersion between groups of 
measurements, a metric was defined: total spectral variability (𝑇𝑇𝑇𝑇𝑇𝑇 =  ∑ 𝜎𝜎𝑖𝑖𝑛𝑛𝑖𝑖=1 ), 
or the sum of calculated standard deviation (σ) at each relative wavenumber i 
across the entire spectrum. A common measure of relative dispersion, the 
coefficient of variation (CV = σi/μi) was also used to compare spectral spread. 
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The minimum and maximum values of CV for major Raman bands were 
reported to provide a consistent indicator of variability. The TSV is an absolute 
measure, indicating the combined dispersion in the measured data, while the 
CV indicates the variability as a percentage of the spectral mean. Samples with 
low variability would have TSV values approaching zero and a low range of 
CV, indicating reproducible and consistent spectral measurements. 
 
A1.3.2 Patients and samples 
Since inter-patient differences have been previously addressed by 
Knudsen et al., volunteers were of similar age and phototype with no history of 
skin disease; measurements were obtained from multiple, visibly-normal 
locations avoiding hair follicles, nevi, and other dark spots. Skin is a potentially 
variable standard that undergoes continuous changes in hydration; therefore, a 
non-volatile biological tissue analog was also measured in each study to 
standardize spectral measurement and comparison. In this manuscript, generic 
intact vitamin E gel capsules were chosen as a homogeneous sample to isolate 
the impact of each variable, independent of tissue changes. Vitamin E gel 
capsules were chosen because they have several Raman scattering bands of 
varying intensity within the fingerprint region. Its peaks are broader than other 
drug formulations and measurements exhibit broad fluorescence signal likely 
due to the capsule composition (gelatin and glycerol). The layered composition 
and spectral traits of the capsules mimic the structure of skin and detected 
268 
 
signals; accordingly, identical collection, processing, and analysis procedures 
were used to draw comparisons. 
 
A1.3.3 User-induced variability 
Contact pressure and probe angle were the user-induced sources 
investigated. To isolate the impact of probe pressure, force values were 
quantified while five instrument operators applied probe pressures at three 
different levels. Raw chicken breast, used as a tissue phantom, was placed on a 
calibrated scale, and the force applied by each operator was recorded as the 
operator held the probe in contact with the tissue for 3 seconds. The contact 
pressure tests were repeated at arbitrarily defined low, medium, and high levels, 
as perceived by the user. For these tests, operators were instructed that low 
pressure should minimally indent the skin surface while maintaining contact for 
the duration of the simulated measurement. Similarly, high pressure should 
simulate firm, stable contact with tissue that deforms. Subsequent RS 
measurements were made with calibrated weights attached to a fiber optic probe 
mounted in a uni-axial stage, as previously described.42 Spectra were acquired 
while applying different pressures at levels encompassing the range of values 
observed during the probe operator tests. The effect of the angle between the 
tip of the probe and the tissue surface was examined by incorporating a 
rotational stage into the previous setup. Replicate measurements were acquired 
in 2° increments up to ±10° from normal and the order randomized to remove 
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bias. For consistency, all measurements of the skin were obtained from the volar 
surface (palm side) of the forearm. 
A1.3.4 Instrumentation-induced variability 
System stability was investigated for drift between collections and 
measurement repeatability after probe replacement. For measurement 
repeatability across time, measurements were made from vitamin E and a 1 cm2 
region of skin on the inner surface of the forearm. Measurements were made 
over the course of 1-1.5 hours at 10 minute intervals in 2 sets over the course 
of a single day. A uni-axial translation stage held the probe in gentle contact 
with the sample controlling for pressure and angle. Six time points were 
collected in the morning and 9 more in the afternoon. For probe replacement, 
the uni-axial translation stage was used to measure skin and vitamin E 
controlling for contact pressure and angle of incidence. Repeated collections 
were acquired with the probe in contact with the sample. Subsequent 
measurements were made after the probe was translated away from and back 
into contact with the sample to mimic a controlled replacement of the probe and 
limit any photobleaching effects. 
The performance of the 4 different systems was assessed through 
measurements of both the skin and vitamin E. Measurements were made of the 
skin using the systems listed in Table A1.1. All measurements were obtained in 
a single room on a single afternoon to control for temporal or environmental 
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effects. Contact pressure, probe angle, and the presence of visible superficial 
blood vessels were controlled during probe placement. 
A1.3.5 Physiologically-induced variability 
The measurements obtained with each of the 4 systems were repeated 
on 5 volunteers (3M, 2F, age 24-28) at multiple anatomical locations. The 5 
skin sites measured were: 1) crease in index finger, 2) base of palm, 3) inner 
surface of forearm, 4) outer surface of forearm, and 5) cheek. In addition, 
measurements were also made on the inner surface of the forearm above and 
adjacent to a visibly-appearing large superficial blood vessel to probe the effect 
of subsurface blood vessels on the acquired spectrum. All measurements were 
controlled for temporal and environmental variables, as well as for contact 
pressure, probe angle, and the presence of visible superficial blood vessels. The 
biological analog was measured with each RS system for reliability analysis. 
Data was processed as described above. 
 
A1.4 Results 
A1.4.1 User-induced variability 
Figure A1.1 illustrates the influence of low, medium, and high pressure 
levels on RS of the skin. Significant differences were found between forces 
applied by probe operators and between pressure levels applied (p<0.05) using 
a 2-way ANOVA, as indicated by Figure A1.1A. However, significant 
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differences were not detected between low and moderate pressure levels. The 
applied pressures, which were subjectively determined by each probe operator, 
exhibit large standard deviations for each of the three levels. As a result of the 
bimodal distribution of high pressures applied by probe operators during 
simulation, an extreme level, which is beyond what is expected for clinical 
application is included. Raman spectra (n=120) were acquired from normal skin 
at 22 different force values spanning the 4 pressure levels listed in Table A1.2. 
The resulting spectra exhibit many visual similarities (Figure A1.1B) as peak 
positions remained constant across test parameters, but intensities varied. 
Statistical analysis determined that over 56% of wavenumbers significantly 
differed between extreme pressure versus high, medium, and low pressure 
levels at the 95% confidence level, indicated by asterisks in Figure A1.1. By 
comparison, fewer than 2% of wavenumbers were significantly different 
between high, medium and low pressures and fewer that 1% of wavenumbers 
differed between medium and low pressures at the same confidence level. 
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Figure A1.1. (A) Averaged forces applied by probe operators during RS 
collection simulation. Values were obtained from blinded tests performed on 
raw chicken breast. (B) Raman spectra acquired from healthy normal skin 
(volar forearm) during application of probe pressure. Asterisks indicate 
statistical difference between extreme pressure and other measures. 
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Raman measurements (n=150) were compared at 11 different angles on 
the inner surface of the forearm accounting for normal (n=50), counter-
clockwise (n=50) and clockwise (n=50) changes in the probe angle. The 
differences in probe angle had minimal impact on the obtained Raman spectra 
and resulted in no systematic change in fluorescence or background signal. 
Mean spectra from each group displayed minor changes in peak intensity. 
Significant differences between groups occurred in fewer than 5% of 
wavenumbers (data not shown). 
 
Table A1.2. Contact force (μ ± σ) applied by multiple probe operators during 
simulated RS collection experiment. 
Low 4.4±2.9 mN 
Medium 33.8±9.4 mN 
High 122.5±39.7 mN 
Extreme 645.9±382.3 mN 
 
A1.4.2 Instrumentation-induced variability 
In this study, Raman spectra (n=15 for each) of vitamin E and the five 
anatomical locations on five healthy volunteers were obtained on the four 
different RS systems. Mean results from the biological analog and one location 
(cheek) from a single patient are presented for each RS system in Figure A1.2A 
and B, respectively. The skin spectra obtained were visibly similar and 
reproducible with minor variations in peak intensities. Significant differences 
(p<0.05) were found among systems at over 50% of the wavenumbers after 
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system calibration and spectral processing, which was observed across all tissue 
locations measured. 
 
Figure A1.2. (A) Raman spectra of Vitamin E as a biological analog measured 
by 4 RS systems. Identical signals were obtained after uniform collection and 
processing algorithms were used. (B) Mean Raman spectra (n=15) of one skin 
site measured by 4 RS systems. 
275 
 
To test for system stability between measurements, Raman spectra 
(n=15 for each) were acquired from skin and vitamin E at 15 times over the 
course of a day. Spectral shape and intensities were reproducible and consistent 
with the results obtained from 4 different systems. However, changes in spectral 
intensity of the skin resulted in significant differences (p<0.05) for over 50% of 
wavenumbers after calibration and processing. Measurements for probe 
placement were compared with measurements after the probe was replaced at 
nearly the same location via the uni-axial translation stage, to more accurately 
replicate probe position than replacement by a human operator. After 
replacement, 5% of wavenumbers significantly differed between the groups for 
skin (data not shown). 
To confirm that the observed variations between spectra were associated 
with the skin sample, vitamin E was measured during each study protocol. 
Vitamin E was included to represent a best case scenario as a completely 
repeatable biological sample, and serves as the benchmark for performance. For 
all variables considered, including contact pressure, angle, repeatability, probe 
replacement, and measurements made across systems, there were no systematic 
differences between vitamin E spectra. For example, as depicted in Figure 
A1.2A and quantified in Table A1.3, vitamin E spectra acquired across systems 
after data processing were completely reproducible. Measurements by a single 
system are expected to have a low total spectral variability (TSV) and CV range. 
When the data collected from multiple systems are pooled prior to calculation, 
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the TSV indicates the absolute dispersion induced by data collection with 
multiple systems, assuming no changes in the sample. A single system had a 
maximum TSV of 2.84 for vitamin E and 17.44 for a single skin location. 
Similar trends were demonstrated by the CV for vitamin E peaks, ranging from 
0.2-2.73%, while for skin the CV ranged from 1.44-12.06%. The pooled data 
across all systems for vitamin E had a TSV of 10.92 and maximum CV of 
5.47%, while the pooled measurements on a single skin location resulted in a 
TSV of 36.58 and maximum CV of 26.38%. For both individual system and 
pooled calculations, the values for a single skin location are higher than for 
vitamin E. The greater values for skin compared with vitamin E suggests that 
detected changes are primarily the result of the sample and not the system. 
Comparison of a single system and pooled data for vitamin E suggests a high 
level of overlap in the measurements obtained by different RS systems, while 
more complex interactions are associated with the skin. 
Table A1.3. Quantified spectral variability for skin and biological analog for 
individual RS systems and pooled data. CV range represents the minimum and 
maximum percentage values obtained at peak maxima for meaningful Raman 
bands. 
Sample System TSV (AU) CV Range 
Vitamin E 
1 1.79 (0.20% - 1.31%) 
2 2.84 (0.38% - 1.89%) 
3 2.23 (0.26% - 1.79%) 
4 2.69 (0.39% - 2.73%) 
Single Skin 
Site 
1 15.34 (1.75% - 10.64%) 
2 17.44 (2.02% - 12.06%) 
3 13.58 (2.05% - 7.39%) 
4 13.04 (1.44% - 9.61%) 
Vitamin E All 10.92 (0.86% - 5.47%) 
Skin Site All 36.58 (5.81% - 26.38%) 
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A1.4.3 Physiological-induced variability 
Raman spectra (n=15) were obtained from each of 5 anatomical 
locations on the upper extremity and face from 5 healthy volunteers. Based on 
the results, substantial intra-patient differences are present between unique 
anatomical locations (Figure A1.3A). Measurements were repeatable across 
days and patients for each location. The peaks with intensity variations have 
previously been correlated with tissue protein and lipid content (1440 cm-1 and 
1750 cm-1) and Amides I (1645-1680 cm-1) and III (1230-1300 cm-1).52, 53 The 
spectra group together into spectral families, each having a unique line shape. 
For example, there are few variations between the spectra acquired from family 
1, the finger and palm, but these variations are not consistent with the few 
variations between family 2, the face and both sides of the arm. As quantified 
in Table A1.4, when all the data from the 5 sites across a single system are 
pooled, the TSV is 59.06 and maximum CV is 38.39%. When separated into 
the two families described above, the values decrease. Combined spectra from 
the arm and cheek result in a TSV and maximum CV of 35.67 and 28.67%, 
respectively. The finger and palm spectra have a TSV of 34.36 and maximum 
CV of 23.26% when combined. When a single location was considered the 
values were lower still, with a maximum TSV and CV of 18.26 and 7.38%, 
respectively. The decrease in TSV indicates consistent spectral families when 
the data is grouped. The CV ranges suggest that the relative dispersion is highly 
variable for even the most uniform comparison and can increase for a peak as 
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groups are combined. The families differ in peak intensities at 1440 cm-1, the 
presence of defined peaks at 1300cm-1 and 1750cm-1, and the full width at half 
maximum (FWHM) intensity of the Amide I band centered at 1658cm-1. 
 
Figure A1.3. (A) Intra-patient location based differences in Raman spectra. (B) 
Raman spectra acquired from healthy skin above and adjacent to a large 
superficial blood vessel. 
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Table A1.4. Quantified RS single system variability for skin sites grouped into 
spectral families and pooled data. Intra-patient variability is representative and 
consistent with data obtained from all systems analyzed. 
Grouping TSV (AU) CV Range 
Single Skin Site 18.26 (2.57% - 7.38%) 
Family 1 34.36 (5.66% - 23.26%) 
Family 2 35.67 (4.76% - 28.67%) 
All skin sites 59.06 (5.36% - 38.39%) 
 
To evaluate the effect of superficial blood vessels beneath the sampling 
volume of a normal measurement, Raman measurements (n=15) were obtained 
from normal tissue directly above a visible vein and adjacent to the same vein. 
As Figure A1.3B shows, there are changes in spectral signatures including 
notable spectral disintegration from 1200-1300 cm-1, decreased intensity at 
1440 cm-1, and a broader 1658 cm-1 peak, which are all reproducible for 
measurements above a vessel. When comparing the normal measurements 
obtained from skin over the vessel in Figure A1.3B to the spectra in Figure 
A1.3A, the measurements over a vessel on the forearm more strongly resemble 
the spectral family from the finger than the forearm itself. Grouping spectra 
from above the vein with those from the adjacent forearm resulted in a TSV of 
62.5, compared to 50.6 when grouping above the vein and finger spectra. 
Representative mean spectra from multiple systems for 2 locations on a 
single patient are presented in Figure A1.4. Each location retains the unique 
spectral signature measured and presented in Figure A1.3A for the finger (site 
1) and the cheek (site 2), but measurements from individual systems contribute 
characteristic variations to the data. With differences in filtering and tissue 
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fluorescence, the spectral response calibration and signal processing for 
background removal was unequal between systems and anatomical locations. 
Despite the systematic effects on data collection by each instrument, the data 
still group consistently into spectral families with similar line shape. 
 
Figure A1.4. Raman spectra from 2 anatomical locations on a single patient 
measured on 4 RS systems. 
 
Figure A1.5 extends the previous analysis to include multiple patients 
and depicts spectral changes associated with locations on multiple patients 
measured with different systems. The results mirror those of multiple locations 
on a single patient, where strong location-specific signals are present and 
repeatable between patients and system-based changes impact each 
measurement similarly. Measurements from a single location resulted in a 
consistent spectral line shape between patients and systems. However, the 
intensity of acquired spectra differed between patients and between systems. 
This is most clearly depicted in Figure A1.5 by grouping site 2 measurements. 
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Also, the intensities for spectra from patient 1 exhibit low dispersion compared 
to the spread of patient 2 spectra. This effect is most obvious at the peak 
intensities for 1440 cm-1 (CH2 bending) and 1300 cm-1 (Amide III CH stretch). 
 
Figure A1.5. Representative Raman spectra of 2 anatomical locations 
reproduced for 2 patients measured on 2 RS systems. 
 
Based on the ANOVA analysis presented in Figure A1.6 for the 
complete block design of measurements made from 5 locations on 5 people with 
4 instruments, the intra-patient variation (“Location”) is the most influential 
factor. The inter-patient differences in the spectra account for less than 7% of 
the variance from the entire dataset. This value was minimized by controlling 
for inter-patient variables prior to the study. The inter-patient differences were 
insignificant compared to 29.7% contribution from system and 48.9% from 
location. The interaction between inter-patient and intra-patient differences is 
consistent with the patient-specific changes presented in Figure A1.5. These 
results are in agreement with both the TSV and CV range values from Table 
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A1.3 and Table A1.4, such that, by controlling parameters, the intra-patient 
variation (location) is more influential than system-induced variation. 
 
Figure A1.6. Percent contribution by source and interaction terms to the 
variance of RS data. The presence of the “Location on Patient” interaction term 
indicates that a location may take a unique intensity level for each patient 
measured. Non-significant interaction terms are combined in “Other” and 
represent less than 4% of total variance. 
 
A1.5 Discussion 
Previous studies have investigated the use of RS to detect changes in 
tissue for numerous applications, but few have addressed the latent sources for 
variability during measurement or the potential issues when comparing 
biological measurements between systems. The initial goal of this study was to 
understand how different sources of variability impact the measured Raman 
spectra of tissue. While this study has focused on skin as the tissue of interest, 
subsequent investigations should consider the influence of variability sources 
on other clinical applications and targets of RS. An obstacle to testing these 
variables in tissue is the inherent inconsistency and sample inhomogeneity. To 
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avoid this innate biological variation, a biological tissue analog, vitamin E, was 
introduced as an ideal tissue that is not subject to variation and presents the 
best-case for measurement reproducibility. In this paper, Raman spectra 
acquired from both normal tissue and vitamin E are evaluated for the effects of 
three broad categories: user-induced, instrumentation-induced, and 
physiologically-based sources of variability. 
A1.5.1 User-induced variability 
As a new and increasingly-used clinical tool, RS users need to 
understand the impact of contact pressure and fiber probe angle on obtaining 
consistent and accurate results regardless of the user. Analysis in this study 
found no significant differences or increased variability introduced when user-
induced factors were properly controlled. Even with high variability in the 
subjectively determined pressure exerted by different probe operators, 
demonstrated in Figure A1.1A, spectra with low variability were obtained. The 
results of applying varying pressure during spectral measurement suggest that 
a range of applied pressures are acceptable for collecting reproducible and 
reliable Raman spectra (Figure A1.1B and Table A1.2). Spectral change was 
observed only in measurements made under extreme pressure, in this case over 
55kPa. Previous studies have shown that increasing pressure can change the 
interactions between light and tissue, for example by decreasing fluorescence 
and increasing optical penetration depth.21-23, 34 Increased probe pressure will 
compress the tissue and more densely pack Raman active molecules, potentially 
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leading to more frequent Raman scattering events. Likewise, increased pressure 
could lead to occlusion under the tip of the probe, altering perfusion and blood 
content within the sample. The acceptable range of applied pressures may 
depend on variable thickness, hydration, elasticity, or other patient, location, or 
age related changes. In general, however, the probe should minimally or 
reversibly displace the tissue surface and remain in contact during the 
measurement. The increased variability introduced by high contact pressure can 
be avoided if users are trained to operate under low pressures. 
By changing the angle of contact between the probe and sample, the 
volume of tissue being measured will change as the light scatters. Despite this 
subtle change in interrogated tissue, few significant spectral differences were 
collected between signals over the range of measured angles. The sampling 
volumes of fiber-optic probes are relatively large compared with tissue 
structures, yielding a low probability that a slight variation in probe angle will 
cause dramatic changes in the spectrum. However, because probe collection 
geometries have many designs, slight variations in probe angle may collect 
signal from a different location than intended. Probe operators should 
understand the importance of using consistent angles between measurements. 
 
A1.5.2 Instrumentation-induced variability 
The common practice of using a single instrument during data collection 
has had both positive and negative consequences for RS. While it has simplified 
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data interpretation for researchers by removing a significant variable, it has also 
hindered both data comparison and spectral database development, which are 
prerequisites for generating reliable diagnostic algorithms. In this study, the 
contribution of instrumentation-induced variability to the acquired spectra was 
validated and quantified for several potential sources. Variability between 
repeated measurements for time points and probe placement was found to be 
insignificant, confirming previous reports.51 During Raman measurements, 
instrumentation-induced variability was considered a system dependent 
response. This is demonstrated in Figure A1.2B, where minimal intensity 
differences between systems were detected within a single location of the skin. 
These small differences were obtained after spectral response calibration, 
processing, and normalization, which are important steps in reducing 
differences between instruments. However, these steps alone may not be 
sufficient to remove the effects of multiple instruments and probes. Spectral 
response calibration accounts for only the detection arm of an RS system and 
requires system isolation for calibration, which is impractical in a clinical 
setting. Other data processing options are currently under investigation. 
Because probe-based RS systems can have variable components, calibration 
methods need to account for the specific and collective responses of the system. 
Several research groups, including ours, have proposed the use of reflective 
standards or other similar calibration techniques that account for both excitation 
and collection branches of the system to address and potentially minimize these 
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responses. When comparing spectra from a single location measured by 
multiple systems, as presented in Figure A1.2, there are no significant 
differences. However, comparing spectra from a different tissue location or 
patient (Figure A1.4 and Figure A1.5), these signals are complicated by other 
factors. 
Isolating system-dependent responses with vitamin E also generated 
negligible differences in spectra acquired by different instruments after 
processing. The narrow range of detected Raman signal for the biological 
analog, depicted in Figure A1.2A, confirm the instrument stability and 
reliability which is needed for cross-validation and spectral library generation. 
As the interrogated sample becomes more heterogeneous, the complex 
interactions of inherent scattering and system-dependent response increase 
spectral variability. This result is demonstrated in Table A1.3, where the sum 
of TSV for vitamin E of individual systems is approximately equal to the pooled 
value for all systems. In contrast, the TSV for skin of separate systems are 
individually half the value for the data pooled for all systems, demonstrating 
that the complexity of skin results in increased variability that differs between 
RS systems. For measurements made with separate RS systems, users must 
understand the implications for cross-system comparison and determine how 
spectral changes introduced by separate instruments will influence the 
diagnostic capability of an algorithm. Using a biological analog can aid in 
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evaluating multiple RS instruments for consistent measurement and comparison 
of tissue spectra. 
A1.5.3 Physiologically-induced variability 
Variability sources based on characteristic tissue differences between 
multiple locations on a single patient and between patients were identified as 
important factors for RS of the skin. The anatomical location analysis yielded 
spectra with visibly and statistically significant differences (Figure A1.3A). 
This result is consistent with knowledge of the heterogeneity of skin anatomy. 
Multiple studies have documented the anatomical location-based changes in 
many skin properties including thickness, presence of hair, tissue hydration, 
pigmentation, sun exposure/damage, subsurface structures, and compositional 
differences of lipids and proteins.9, 54-56 Raman scattering signals from different 
anatomical locations are distinct, so tracking where such measurements are 
made is critical when comparing across locations. Separating the anatomical 
locations into distinct spectral families, based on intensity and line shape as in 
Table A1.4, may be a more thorough comparison of physiologically-induced 
changes that are not directly caused by variations in the measurement location. 
Statistical analysis reveals that the spectral variance and primary source 
of variability depends on peak intensity. TSV is dominated by fluctuations in 
peak intensity of major Raman active bands, with 1440 cm-1 (CH2 bending) 
accounting for nearly 30% of total variability in the data and 1300 cm-1 (Amide 
III CH stretch) for another 10%. Despite accounting for intensity, the maximum 
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CV reported for each group is mediated by fluctuations in peak intensity and 
can be amplified for low peaks and shoulders. Physiologically-induced 
variability, due to measurement location, dominates the dispersion sources 
when comparing multiple anatomical locations for a single system and appears 
at strong Raman peaks. Instrumentation-induced variability dominates regions 
of peak shoulders and background subtraction when comparing a single 
measurement location across different systems. 
Significant spectral differences were also observed between patients 
(Figure A1.5). Studies from our lab and others have reported the sensitivity of 
RS to patient-based variables.51, 57 Some of the potential variables that may 
contribute to the observed inter-patient changes in spectral signature for normal 
healthy skin include hormonal variations, BMI, gender, race/ethnicity, age, 
accumulated photodamage/UV exposure, and skin type. Knudsen et al. reported 
significant peak intensity ratio differences between patients, which agree with 
findings presented here. In that report, a single location across 13 patients 
yielded mean values ranging from 0.94-1.15 for the intensity ratio of Amide I 
(1660 cm-1)/CH2 bending (1440 cm-1). The mean values measured between 
patients here ranged from 0.70-0.76 for this ratio. The differences between the 
reported peak ratios are likely the result of variations in study equipment and 
processing procedures. However, the variation in values is consistent between 
reports, indicating inter-patient changes detected in the skin. Further analysis of 
our data suggests that these ratios are dependent upon location of the 
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measurement. The mean values obtained here range from 0.86 on the hand to 
0.56 on the cheek of a single patient. 
To simplify comparisons between patients, age and skin type were 
controlled. The inter-patient differences detected here demonstrate minor 
spectral changes when controlling for other variability sources. Physiological 
variability between locations within a single patient has been reported in the 
literature and suggests the need to account for anatomical site prior to 
comparison.49 A potential method to overcome these variations would utilize 
paired spectral measures, or the collection of adjacent and contralateral normal 
measurements for each measurement of interest. Difference spectra between the 
variable and paired normal locations would normalize a measurement to its 
inherent location-based signal, which could remove influences of intra-patient 
variation. Selection of the location for a paired measurement is critical due to 
the location-based variability in signal. A further complication is introduced by 
the presence of superficial blood vessels beneath the measurement location. The 
obtained spectrum from atop the vessel neither replicates skin measurements 
nor the reported spectra of blood, suggesting that signal changes are not derived 
from the blood alone.7, 32 While the source of the altered spectrum is currently 
unclear, some potential physiological explanations include the components of 
the vessel wall, muscles lining vessels, increased collagen content and 
microvasculature surrounding these vessels, as well as the blood cells and 
serum proteins in the measurement area. The results in Figure A1.3B suggest 
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that paired measurements should come from adjacent or contralateral locations 
of normal tissue, avoiding hair and visible superficial blood vessels. Adjacent 
measurements from the same small area of tissue were found to be reproducible, 
but the total size of this area is unknown. In general, the closer the paired 
measurement to the original measurement location, the more likely a 
measurement will account for normal variations.  
Statistical comparison indicated that anatomical location most 
significantly impacts collected data, followed by instrumentation-induced 
variability and inter-patient changes (Figure A1.6). These findings mirror 
conclusions drawn from the TSV and CV range values and suggest that when 
patient variables are controlled, the detected inter-patient differences exert less 
influence on the data than alternate sources. The significant interaction term 
(“Location on patient”) is likely the result of inter-patient variation that affects 
intra-patient changes. Each patient will have unique effects on the spectra that 
will cause individual anatomical location to vary in intensity. The presence of 
this interaction complicates the interpretation and impact of multiple patients. 
As all other interaction terms combined have little influence, it is logical to 
conclude that the primary concerns for spectral variability will be the effects 
from anatomical location, system, and patient based differences. These patient 
specific differences may become the dominant source as a more diverse 
population of normal tissues is analyzed. This result further emphasizes the 
need to control for the measurement location. 
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Because the influence of a particular source of variation is not uniform 
across the spectrum, understanding and minimizing variability sources is 
important. Through ANOVA of spectra at each wavenumber, the relative 
impact of each source of variability can be discerned. Spectral libraries and 
algorithms for diagnosis or tissue classification need to perform independently 
of these confounding variability sources. Algorithms may need to account for 
the variances introduced by multiple instruments or compare spectral regions 
that are dominated by a common variability source. For example, the intensity 
of CH2 bending (1440 cm-1) is dominated by physiologically-induced 
variability, while the FWHM of the 1070 cm-1 feature, which is linked in-part 
to silica fiber signal, is dominated by instrumentation-induced variability. A 
ratio of these features would give inconsistent and instrument-dependent 
results. The dispersions of strong Raman active bands are associated with 
differences in anatomical location and should be used for intra- and inter-patient 
comparison. Comparing regions of background subtraction will represent 
variations between multiple instruments.  
The purpose of this paper is to examine different sources of variability 
that can impact in vivo RS measurements of tissue and to suggest steps for 
limiting the influence of these confounding factors. Table A1.5 briefly outlines 
the sources examined and the influences detected. These results indicate that, 
when properly used, contact pressure, probe angle, and probe replacement have 
no significant contribution to spectral variance. The use of multiple RS 
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instruments will undoubtedly introduce some variation into the collected data, 
but options to limit these influences are under investigation. Despite these 
findings, thorough analysis of the potential sources of measurement error 
should be conducted with any system to understand the obtained results, ideally 
prior to the beginning of the study. We suggest that several steps be taken during 
the design and execution of in vivo RS tissue measurements to address potential 
sources of variability. These steps are as a follows: 1) Standardized tissue 
cleaning protocols, such as cleaning with an alcohol swab, should be used to 
minimize error contribution (especially for measurements of the skin due to 
cosmetics and lotions); 2) Measurements with the probe should use low but 
consistent pressure during collection, keeping the probe approximately normal 
to the surface (user should be trained); 3) For normal measurements, a single 
collection per location is sufficient; 4) Paired measurements may provide 
normalization of a spectrum to the inherent signal based on anatomical location 
and person specific signals; 5) The selection of the location for a normal paired 
measurement should be carefully determined, avoiding hair follicles and major 
superficial blood vessels. Furthermore, adjacent and contralateral normal 
measurements at a single location should be investigated for consistency. 
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Table A1.5. Variability sources investigated and determined effects. 
Variable Effect 
Contact pressure 
For low or medium pressure, no detected effect 
High pressure, significant effect detected 
Probe angle No detected effect 
Probe replacement No detected effect 
Instrument stability 
No detected effect for biological analog 
Significant effect detected between tissue measurements 
Multiple instruments 
No detected effect for biological analog 
Significant effect detected for biological samples 
Anatomical location Significant effect detected 
Presence of blood vessel Significant effect detected 
Inter-patient 
Significant effect; 
Minimized by controlling patient variables 
 
A1.6 Conclusions 
In general, these findings apply to probe-based measurements for all 
optical modalities; other collection configurations, such as confocal 
microspectroscopy, will likely contain alternate variability sources to address. 
Practically, normal tissues are not often studied, as they are not the focus of a 
novel diagnosis or treatment. The default assumption is that all normal samples 
are similar; however, complex interrelationships and differences between 
separate normal tissues exist. By expanding our understanding of normal tissues 
and the influence of data collection and instrumentation, the potential exists for 
more accurate and effective analyses to differentiate unique variables of 
interest. The analytic methods for RS should consider the major sources of 
variance contribution prior to the development of classification algorithms. 
Thorough analysis of instrument response, stability, and calibration are 
important to standardize RS as a clinically viable tool. Measurements by 
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separate instruments will likely exhibit unique responses. If these variations are 
understood and accounted for, measurements can be compared across systems 
and spectral libraries can be compiled. Here, practical considerations and results 
are presented that suggest how RS can and should be used in vivo to minimize 
sources of variation prior to processing, comparison, and classification, leading 
to an application that can be used to accurately differentiate disease classes. 
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